Proteomic Profiling of the mdx Animal Model for Duchenne Muscular Dystrophy by Carberry, Steven
 1 
 
 
 
 Proteomic Profiling of the mdx Animal  
 Model for Duchenne Muscular 
Dystrophy 
 
 
 
 
Submitted to National University of Ireland Maynooth for the degree of  
Doctor of Philosophy  
 
 
 
 
 
 
 
 
 
 
 
 
 
Steven Carberry, B. Sc  
 
 
 
 
Head of Department Supervisor 
Professor Paul Maynough, Professor Kay Ohlendieck, 
Department of Biology, Department of Biology, 
NUIM Maynooth, NUIM Maynooth, 
Co. Kildare. Co. Kildare.
   
i 
  
Publications   
 
Carberry, S., M. Zweyer, D. Swandulla, and K. Ohlendieck. 2014. Comparative 
proteomic analysis of the contractile-protein-depleted fraction from normal versus 
dystrophic skeletal muscle. Anal Biochem 446: 108-115. 
 
Carberry, S., M. Zweyer, D. Swandulla, and K. Ohlendieck. 2013. Application of 
Fluorescence Two-Dimensional Difference In-Gel Electrophoresis as a Proteomic 
Biomarker Discovery Tool in Muscular Dystrophy Research. BIOLOGY 2: 1438-1464.  
 
Carberry, S., H. Brinkmeier, Y. Zhang, C. K. Winkler, and K. Ohlendieck. 2013. 
Comparative proteomic profiling of soleus, extensor digitorum longus, flexor digitorum 
brevis and interosseus muscle from the mdx mouse model of Duchenne muscular 
dystrophy. Int J Mol  Med 32: 544–556. 
 
Holland, A., S. Carberry, and K. Ohlendieck. 2013. Proteomics of the dystrophin-
glycoprotein complex and dystrophinopathy. Curr. Protein Pep Sci 14 (8): 680-97. 
 
Carberry, S., M. Zweyer, D. Swandulla, K. Ohlendieck. 2012. Proteomics reveals 
drastic increase of extracellular matrix proteins collagen and dermatopontin in the 
aged mdx diaphragm model of Duchenne muscular dystrophy. Int J Mol Med 30: 
229-234. 
 
Carberry, S., M. Zweyer, D. Swandulla, and K. Ohlendieck. 2012. Profiling of age-
related changes in the tibialis anterior muscle proteome of the mdx mouse model 
of dystrophinopathy. J. Biomed Biotechnol 2012: 691641. 
 
Carberry, S., and K. Ohlendieck. Gel electrophoresis-based proteomics of 
senescent tissues. Methods Mol Biol. 2013; 1048:229-46. 
 
Lewis, C., S. Carberry, and K. Ohlendieck. 2009. Proteomic profiling of x-linked 
muscular dystrophy. J Muscle Res Cell Motil 30(7-8): 267-9. 
 
   
ii 
  
Presentations:  
 
Poster presentations  
Comparative proteomic profiling of soleus, extensor digitorum longus, flexor 
digitorum brevis and interosseus muscle from the mdx mouse model of Duchenne 
muscular dystrophy. Carberry, S., H. Brinkmeier, Y. Zhang, C. K. Winkler, and K. 
Ohlendieck. European Proteomics association 2013, Saint Malo, France.  
Comparative proteomic profiling of soleus, extensor digitorum longus, flexor 
digitorum brevis and interosseus muscle from the mdx mouse model of Duchenne 
muscular dystrophy. Carberry, S., H. Brinkmeier, Y. Zhang, C. K. Winkler, and K. 
Ohlendieck. EMBO life sciences conference 2013, Amsterdam, Netherlands.  
Proteomics reveals drastic increase of extracellular matrix proteins collagen and 
dermatopontin in aged mdx diaphragm muscle. Carberry, S., M. Zweyer, D. 
Swandulla, and K. Ohlendieck. Biology Research Day 2012, NUI Maynooth. 
 
Research Presentations 
Establishment of a protein biomarker signature for x-linked muscular dystrophy: 
Identificant of novel integral muscle proteins by mass spectrometry-based 
proteomics. 2012-14. Muscular Dystrophy Ireland, MDI. 
 
Departmental Seminars  
Proteomic profiling of x-linked muscular dystrophy. 2011-13. National University of 
Ireland, Maynooth. 
 
 
 
 
 
 
 
   
iii 
  
  
Table of contents 
1. Introduction  
1.1 Muscle Biology... ........................................................................................................................................... .1 
1.2 Skeletal muscle structure... ...................................................................................................................... .1 
1.3 Sliding filament and lever-arm theory... ............................................................................................. .1 
1.4 Skeletal muscle excitation-contraction coupling... ......................................................................... .4 
1.5 Skeletal muscle fibers... ............................................................................................................................ ...6 
1.6 Dystrophin and its Isoforms... ............................................................................................................... ...7 
1.7 Dystrophinopathies... ................................................................................................................................. .11 
1.8 Dystroglycan complex... ............................................................................................................................. .14 
1.9 Dystrophic mdx animal model... ............................................................................................................. .16 
1.10 Proteomics... .............................................................................................................................................. ...17 
1.10.1 Sample preparation... ........................................................................................................................... .18 
1.10.2 2-D gel electrophoresis... .................................................................................................................... .19 
1.10.3 Protein visualisation............................................................................................................................. .19 
1.10.4 Protein identification... ........................................................................................................................ .22 
1.10.5 Mass Spectrometry... ............................................................................................................................ .22 
1.11 Aims of proposed project... .................................................................................................................... .22 
 
2. Materials and methods  
2.1 Materials... ....................................................................................................................................................... .24 
2.1.1 Equipment... ................................................................................................................................................ .24 
2.1.2 Reagent solutions... ................................................................................................................................ ...24 
2.1.3 1-D and 2-D electrophoresis ................................................................................................................ .25 
2.1.4 Protein Staining... .................................................................................................................................... ...25 
2.1.5 Mass Spectrometry... ............................................................................................................................... .25 
2.1.6 Western blotting... .................................................................................................................................... .26 
 
   
iv 
  
 
2.2 Methods 
2.2.1 Dystrophic mdx animal model... ....................................................................................................... ..28 
2.2.2 Preparation of crude skeletal muscle extracts... ........................................................................ ..28 
2.2.3 1-D Gel Electrophoresis... ...................................................................................................................... .29 
2.2.4 2-D Gel Electrophoresis... ...................................................................................................................... .29 
2.2.5 Protein Staining... ..................................................................................................................................... ..30 
2.2.5.1 Collodial Coomassie Staining... ....................................................................................................... ..30 
2.2.5.2 RuBPs Stain Preparation... ............................................................................................................... .31 
2.2.5.3 RuBPs Staining... .................................................................................................................................. ...31 
2.2.6 Fluorescence difference in-gel electrophoretic analysis... ...................................................... .32 
2.2.7 Protein visualization and data analysis... ....................................................................................... .32 
2.2.8 In-gel digestion of proteins for Mass spectrometric identification... .................................. .33 
2.2.9 Mass spectrometric identification of skeletal muscle proteins... ......................................... .33 
2.2.10 Immunoblot analysis.......................................................................................................................... ...34 
2.2.11 Statistical Analysis............................................................................................................................... ...35 
 
 
3. Proteomic profiling of age-related changes in the tibialis anterior muscle  
proteome of the mdx mouse model of dystrophinopathy  
 
3.1 Introduction... ............................................................................................................................................. ...36 
3.1.1 Duchenne muscular dystrophy and tibialis anterior skeletal muscle... .......................... ...36 
3.1.2 Experimental design... ......................................................................................................................... ...37 
3.2 Results............................................................................................................................................................ ...37 
3.2.1 Comparative proteomic analysis of mdx tibialis anterior muscle  .................................... ...37 
3.2.2 RuBPs analysis of landmark proteins in normal tibialis anterior muscle... ................. ...38 
3.2.3 Proteomic analysis of dystrophic tibialis anterior muscle during aging ........................ ...42 
3.2.4 RuBPs analysis of dystrophic tibialis anterior muscle... ........................................................ ...44 
3.2.5 Immunoblot analysis of dystrophic tibialis anterior muscle .............................................. ...47 
3.3 Discussion... ................................................................................................................................................. ...51 
3.3.1 Proteomic expression changes of tibialis anterior analysis... ............................................. ...51 
   
v 
  
3.3.2 Elevated metabolic enzymes in mdx tissue ................................................................................ ...52 
3.3.3 Perturbed stress response in mdx tissue... ................................................................................. ...52 
3.3.4 Altered glycolytic and oxidative enzymes in mdx tissue ...................................................... ...53 
3.3.5 Other proteins......................................................................................................................................... ...53 
3.4 Conclusions... ............................................................................................................................................... ...54 
 
 
4. Proteomic profiling of age-related changes in severely dystrophic Diaphragm  
muscle proteome of the mdx mouse model of dystrophinopathy  
 
4.1 Introduction... ............................................................................................................................................. ...55 
4.1.1 Duchenne muscular dystrophy and Diaphragm skeletal muscle... .................................. ...55 
4.1.2 Experimental design... ......................................................................................................................... ...56 
4.2 Results............................................................................................................................................................ ...57 
4.2.1 Comparative proteomic analysis of mdx diaphragm muscle... ......................................... ...57 
4.2.2 Proteomic analysis of dystrophic diaphragm muscle during aging................................. ...57 
4.2.3 RuBPs analysis of dystrophic diaphragm muscle... ................................................................. ...60 
4.2.4 Comparative proteomic analysis of mdx versus wild-type diaphragm muscle... ....... ...63 
4.2.5 DIGE analysis of dystrophic Diaphragm muscle... ................................................................... ...66 
4.2.6 Immunoblot analysis of of altered proteins in aged mdx diaphragm muscle ............. ...76 
4.3 Discussion... ................................................................................................................................................. ...86 
4.3.1 Proteomic expression changes of diaphragm analysis during aging .............................. ...86 
4.3.2 Increased extracellular matrix proteins in aging mdx tissue... ........................................... ...87 
4.3.3 Perturbed stress response and cytoskeletal disruption in aging mdx tissue in  
aging mdx tissue ................................................................................................................................................ ...88 
4.3.4 Other proteins... ...................................................................................................................................... ...88 
4.3.5 Proteomic expression changes of aged diaphragm analysis .............................................. ...88 
4.3.6 Increased extracellular matrix proteins in aged mdx tissue ............................................... ...89 
4.3.7 Perturbed stress response in aged mdx tissue... ....................................................................... ...89 
4.3.8 Increased expression of Iron handling proteins in aged mdx tissue ............................... ...90 
4.3.9 Reduced mitochondrial enzymes in aged mdx tissue... ......................................................... ...90 
4.3.10 Other proteins... ................................................................................................................................... ...91 
   
vi 
  
4.3.11 Predicted interaction patterns of altered proteins in aged mdx diaphragm  
muscle... ................................................................................................................................................................ ...91 
4.4 Conclusions... ............................................................................................................................................... ...94 
5. Comparative proteomic profiling of soleus, extensor digitorum longus, flexor 
digitorum brevis and interosseus muscle from the mdx mouse model of Duchenne  
muscular dystrophy 
 
5.1 Introduction... ............................................................................................................................................. ...95 
5.1.1 Duchenne muscular dystrophy and skeletal muscle subtypes... ....................................... ...95 
5.1.2 Experimental design... ......................................................................................................................... ...96 
5.2 Results............................................................................................................................................................ ...97 
5.2.1 Comparative proteomic analysis of mdx versus normal muscle... .................................. ...97 
5.2.2 Proteomic analysis of dystrophic skeletal muscle subtypes... ............................................ ...97 
5.2.3 RuBPs analysis of dystrophic soleus muscle... ........................................................................... ...100 
5.2.4 RuBPs analysis of dystrophic EDL muscle... ............................................................................... ...104 
5.2.5 RuBPs analysis of dystrophic FDB muscle.................................................................................. ...108 
5.2.6 RuBPs analysis of dystrophic INT muscle... ................................................................................ ...112 
5.2.7 Immunoblot analysis of dystrophic skeletal muscle subtypes .......................................... ...115 
5.2.8 Histological profiling of skeletal muscle tissue from mdx mice  ....................................... ...125 
5.3 Discussion... ................................................................................................................................................. ...127 
5.3.1 Moderate expression changes of RuBPs labelled skeletal muscle proteins ................. ...128 
5.4 Conclusions... ............................................................................................................................................... ...131 
6. Comparative proteomic analysis of the contractile protein-depleted fraction  
of the mdx mouse model of dystrophinopathy 
 
6.1 Introduction... ............................................................................................................................................. ...133 
6.1.1 Duchenne muscular dystrophy and hind limb skeletal muscles... .................................... ...133 
6.1.2 Experimental design... ......................................................................................................................... ...134 
6.2 Results............................................................................................................................................................ ...134 
6.2.1 Comparative proteomic analysis of mdx hind limb skeletal muscle... ........................... ...134 
 
   
vii 
  
6.2.2 RuBPs analysis of landmark proteins in total extract of normal hind limb skeletal  
muscle... ................................................................................................................................................................ ...135 
6.2.3 DIGE analysis of landmark proteins in the contractile protein-depleted fraction  
from mouse skeletal muscle... ..................................................................................................................... ...141 
6.2.4 Proteomic analysis of dystrophic skeletal muscle... ............................................................... ...147 
6.2.5 DIGE analysis of dystrophic muscle proteins... ......................................................................... ...149 
6.2.6 Immunoblot analysis of dystrophic hind limb muscle .......................................................... ...152 
6.3 Discussion... ................................................................................................................................................. ...161 
6.3.1 Proteomic expression changes of skeletal muscle analysis ................................................ ...163 
6.3.2 Increased expression of Iron handling proteins... ................................................................... ...164 
6.3.3 Perturbed stress response in mdx tissue... ................................................................................. ...165 
6.3.4 Other protein... ........................................................................................................................................ ...165 
6.4 Conclusions... ............................................................................................................................................... ...166 
 
7. General Discussion... .............................................................................................................................. ....168 
 
 
Bibliography... ................................................................................................................................................. ….179 
 
List of figures  
 
Figure 1-1 Skeletal muscle structure... .................................................................................................... ...2 
Figure 1-2 Cross-bridge sliding filament theory... ............................................................................. ...3 
Figure 1-3 Voltage-gated action potential... .......................................................................................... ...5 
Figure 1-4 Genomic organisation of the dystrophin gene .............................................................. ...8 
Figure 1-5 Dystrophin and Utrophin domain structures... ............................................................. ...10  
Figure 1-6 Overview of neuromuscular disorders with primary defects in components  
of the dystrophin-glycoprotein complex.... ............................................................................................ ...13 
Figure 1-7 Synopsis of the structure of the DAGC form skeletal muscle and its role in the  
molecular pathogenesis of X-linked muscular dystrophy............................................................... ...15 
Figure 1-8 Overview of the main approaches used in fluorescence difference in-gel  
electrophoresis (DIGE) gel-based proteomics... .................................................................................. ...21 
   
viii 
  
Figure 3-1 Landmark 2D gel of normal mouse tibialis anterior muscle ................................... ...39 
Figure 3-2 Two-dimensional gel electrophoretic analysis of aging mdx mouse tibialis  
anterior muscle... .............................................................................................................................................. ...43 
 
Figure 3-3 Fluorescence two-dimensional gel electrophoretic analysis of mdx tibialis  
anterior muscle... .............................................................................................................................................. ...45 
Figure 3-4 Immunoblotting analysis of dystrophin-associated glycoprotein  
β-dystroglycan... ................................................................................................................................................ ...48 
Figure 3-5 Immunoblotting analysis of carbonic anhydrase enzyme ...................................... ...49 
Figure 3-6 Immunoblotting analysis of the small heat shock protein 27... ............................ ...50 
Figure 4-1 Two-dimensional gel electrophoretic analysis of aging mdx mouse diaphragm  
muscle ................................................................................................................................................................... ...59 
Figure 4-2 Fluorescence gel electrophoretic analysis of aged mdx mouse diaphragm  
muscle... ................................................................................................................................................................ ...61 
Figure 4-3 Shown is the 2-D DIGE analysis of dystrophic mdx versus normal diaphragm  
skeletal muscle... ............................................................................................................................................... ...64 
Figure 4-4 Overview of the standard 2D-DIGE image analysis process used in muscle 
proteomics .......................................................................................................................................................... ...65 
Figure 4-5 Fluorescence 2D-DIGE master gel of aged mdx diaphragm muscle... ................ ...68 
Figure 4-6 Protein interaction map of mdx diaphragm muscle proteins ................................. ...75 
Figure 4-7A Immunoblotting analysis of extracellular matrix protein collagen ................... ...77 
Figure 4-7B Immunoblotting analysis of unchanged extracellular matrix laminin... ........ ...78 
Figure 4-7C Immunoblotting analysis of of dystrophin-associated glycoprotein  
β-dystroglycan... ................................................................................................................................................ ...79 
Figure 4-7D Immunoblotting analysis of small heat shock protein cvHSP ............................. ...80 
Figure 4-7E Immunoblotting analysis of large heat shock protein 70... .................................. ...81 
Figure 4-7F Immunoblotting analysis of prohibitin protein... ..................................................... ...82 
Figure 4-7G Immunoblotting analysis of calcium-binding protein parvalbumin ................. ...83 
Figure 4-7H Immunoblotting analysis of the luminal calcium-binding protein  
calsequestrin... ................................................................................................................................................... ...84 
Figure 4-7I Immunoblotting analysis of mitochondrial enzyme ATP synthase................... ...85 
   
ix 
  
Figure 4-8 Overview of the molecular function of altered diaphragm-associated  
proteins... ............................................................................................................................................................. ...93 
Figure 5-1 Overview of two-dimensional gel electrophoretic analysis of the mdx mice  
skeletal muscles for x-linked muscular dystrophy ........................................................................... ...99 
Figure 5-2 Fluorescence two-dimensional gel electrophoretic analysis of mdx soleus  
muscle... ................................................................................................................................................................ ...101 
Figure 5-3 Fluorescence two-dimensional gel electrophoretic analysis of mdx extensor  
digitorum longus muscle... ............................................................................................................................ ..105 
Figure 5-4 Fluorescence two-dimensional gel electrophoretic analysis of mdx flexor  
digitorum brevis muscle ................................................................................................................................ ...109 
Figure 5-5 Fluorescence two-dimensional gel electrophoretic analysis of mdx  
interosseus muscle... ........................................................................................................................................ ...113 
Figure 5-6A Immunoblotting analysis of the extracellular matrix protein laminin in  
normal versus mdx skeletal muscle subtypes... .................................................................................. ..116 
Figure 5-6B Immunoblotting analysis of myoglobin in soleus muscle... .................................. ..117 
Figure 5-6C Immunoblotting analysis of extracellular matrix protein collagen in  
soleus muscle ...................................................................................................................................................... ...118 
Figure 5-6D Immunoblotting analysis of α-actinin-3 in extensor digitorum longus  
muscle... ................................................................................................................................................................ ...119 
Figure 5-6E Immunoblotting analysis of phosphoglycerate kinase in extensor  
digitorum longus muscle... ............................................................................................................................ ..120 
Figure 5-6F Immunoblotting analysis of calcium-binding protein parvalbumin in  
flexor digitorium brevis muscle... ............................................................................................................... ..121 
Figure 5-6G Immunoblotting analysis of serpina 1d in flexor digitorium brevis muscle... ..122 
Figure 5-6H Immunoblotting analysis of calcium-binding protein parvalbumin in  
interosseus muscle ........................................................................................................................................... ..123 
Figure 5-6I Immunoblotting analysis of αB-crystallin in interosseus muscle... .................... ..124 
Figure 5-7 Histological profiling of skeletal muscles from mdx mice....................................... ..126 
Figure 6-1 landmark 2D gel of total mouse skeletal muscle extracts... .................................... ..137 
Figure 6-2 landmark 2D gel of the subcellular mouse muscle fraction... ................................ ..142 
 
   
x 
  
Figure 6-3 Fluorescence 2D-DIGE analytical gel of normal versus mdx skeletal muscle  
fraction... ............................................................................................................................................................... ..148 
Figure 6-4 Fluorescence 2D-DIGE master gel of the subcellular mouse muscle  
fraction .................................................................................................................................................................. ...150 
Figure 6-5A Immunoblotting analysis of unchanged MLC2... ...................................................... ...153 
Figure 6-5B Immunoblotting analysis of equally loaded extracellular matrix protein  
laminin……………………………………... ........................................................................................................... ..154 
Figure 6-5C  Immunoblotting analysis of dystrophin-associated glycoprotein  
β-dystroglycan... ................................................................................................................................................ ..155 
Figure 6-5D Immunoblotting analysis of extracellular matrix protein collagen... ................ ..156 
Figure 6-5E Immunoblotting analysis of iron transporter protein transferrin... .................. ..157 
Figure 6-5F Immunoblotting analysis of large heat shock protein 70... .................................. ..158 
Figure 6-5G Immunoblotting analysis of unchanged calcium-binding protein 
parvalbumin……………………………………... ................................................................................................. ..159 
Figure 6-5H  Immunoblotting analysis of iron storage protein ferritin... ................................. ..160 
Figure 6-6 Differential centrifugation of muscle homogenates to obtain a contractile  
protein-depleted fraction for comparative subproteomic analysis... ......................................... ..162 
Figure 7-1 MS-based proteomic profiling of the mdx mouse model of Duchenne  
muscular dystrophy... ..................................................................................................................................... ..170 
Figure 7.2 Proteomic survey of the mdx animal model for Duchenne muscular 
dystrophy……………………………………... ...................................................................................................... ..174 
 
List of tables  
Table 2.1 Antibodies... ..................................................................................................................................... ..27 
Table 3.1 List of unchanged landmark 2D protein spots from normal mouse tibialis  
anterior muscle.................................................................................................................................................. ..40 
Table 3.2 List of identified muscle proteins with a significant change of abundance in  
aging mdx tibialis anterior muscle... .......................................................................................................... ..46 
Table 4.1 List of identified muscle proteins with a significant change of abundance in  
aging mdx diaphragm muscle ...................................................................................................................... ..62 
Table 4.2 List of identified proteins from 2D-DIGE analyses that exhibit a drastic change  
   
xi 
  
in abundance in the aged mdx diaphragm... .......................................................................................... ..69 
Table 5.1 List of muscle-associated proteins with changes in abundance in the soleus  
muscle from mdx mice... ................................................................................................................................. .102 
Table 5.2 List of muscle-associated proteins with changes in abundance in the extensor  
digitorum longus muscle from mdx mice ................................................................................................ .106 
Table 5.3 List of muscle-associated proteins with changes in abundance in the flexor  
digitorum brevis muscle from mdx mice ................................................................................................. .110 
Table 5.4 List of muscle-associated proteins with changes in abundance in the  
interosseus muscle from mdx mice ............................................................................................................ .114 
Table 6.1 Mass spectrometry list of 2D-landmark proteins from crude tissue extracts... . .138 
Table 6.2 Mass spectrometry list of 2D-landmark proteins from the subcellular  
fraction .................................................................................................................................................................. .143 
Table 6.3 List of changed proteins in the subcellular fraction from mdx muscle as verified  
by fluorescent 2D-DIGE analysis ............................................................................................................... .151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
xii 
  
Acknowledgements  
Firstly, I would like to thank Prof. Kay Ohlendieck for giving me the opportunity to pursue 
a PhD in his laboratory and for all his guidance and support throughout my studies.  
Thank you to all members of the Muscle Biology laboratory past and present. I would 
especially like to thank Caroline Lewis for getting me settled in the lab and showing me the 
ropes, Lisa for all the chats and teaching me about the countryside and Ashling for the lifts 
from DCU when the Typhoon decided to act up.  
To all the Biology Department staff at NUI Maynooth who keep the department running, 
Prof. Sean Doyle for guidance throughout my undergrad and Michelle for help with the 
most random things.  
To the college for the John Hume scholarship which enabled me to carry out my studies, as 
well as the Ulysses and Endeavour research award for giving me the opportunity to travel 
and study aboard as part of my PhD.   
To Joe and Muscular Dystrophy Ireland for all their support and to all the families I have 
met over the years at the AGMs or at the CRC, who remind me of the importance of the 
research. 
To all my friends for postponing their social life’s so I wouldn’t feel left out and for stop 
saying “so when yeah finished?” and “sure college closes during the summer!”. 
I would especially like to thank my family, my parents Tony and Ann for their constant 
support throughout my education from late nights in the lab to surprise trips to Belfast to 
catch ferries. You both have always been there for me whenever I have needed 
encouragement or an ear, to listen to a random science rant. Thank you for all your support 
and I dedicate this work to you.   
PhD is time consuming, so looking forward to catching up on the latest youtube cat videos. 
 
   
xiii 
  
 
Declaration  
 
 
 
 
 
 
 
This thesis has not been submitted in whole or in part to this or any other university for 
 any degree, and is the original work of the author except where stated. 
 
 
 
 
 
 
 
 
Signed_______________________________  
 
Date__________________________________  
 
 
 
 
 
 
 
   
xiv 
  
Abbreviations  
 
1D One-dimensional 
2D Two-dimensional 
2D-GE Two-dimensional gel electrophoresis 
Ab Antibody 
AB  Abcam 
ACh Acetylcholine 
AChR Acetylcholine receptor 
ADP Adenosine diphosphate 
AK1 Adenylate kinase 
AMC Actin membrane cytoskeleton 
AT Amino terminal 
ATP Adenosine triphosphate 
BIO Affinity Bioreagents 
BMD Becker muscular dystrophy 
Ca2+ Calcium 
CBB Coomassie brilliant blue 
CHAPS 3-[3-chlolamidopropyl- 
 Dimethylammonio-1-propane 
 sulfonate] 
Ck Chicken 
CMD Congential muscular dystrophy 
CR Cysteine-rich 
CSQ Calsequestrin 
CT Carboxyl terminal 
cvHSP Cardiovascular heat shock protein 
CYT Cytosol 
DAGC Dystrophin-associated glycoprotein complex 
DG Dystroglycan 
DGC Dystrophin-glycoprotein complex 
DHPR Dihydropyridine receptor 
   
xv 
  
DIA Diaphragm  
DIGE Difference in-gel electrophoresis 
DMD Duchenne muscular dystrophy 
DMF Dimethlformamide 
DTT Dithiothreitol 
DYB Dystrobrevin 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDL Extensor Digitorum Longus 
EOM Extraocular muscle 
ES Extracellular space 
ESI Electrospray ionization 
FABP Fatty acid binding-protein 
FDB Flexor digitorum brevis 
fmol Femtomole 
g g force 
GAPDH Glyceraldehyde 3-phosphate 
GRMD Golden retriever muscular dystrophy 
h Hours 
HCl Hydrochloric acid 
HPLC High performance liquid 
HRP Horse radish peroxidase 
Hsp Heat shock protein 
ID Identification 
IDH Isocitrate dehydrogenase 
IEF Isoelectric focusing 
IF Intermediate filament 
INT Interosseus 
IPG Immobilized pH gradient 
K+ Potassium Ions 
kDa Kilodaltons 
   
xvi 
  
LAM Laminin 
LC-MS Liquid chromatography mass spectrometry 
LGMD Limb-girdle muscular dystrophy 
M Molar 
m/z Mass/charge 
MDX Murine X chromosome linked 
MHC Myosin heavy chain 
min Minute 
ml Milliliter 
MLC Myosin light chain 
mM Millimolar 
mRNA Messenger ribonucleic acid 
MS Mass spectrometry 
Ms Mouse 
MW Molecular Weight 
µg Microgram 
µL Microlitre 
µM Micromolar 
Na+ Sodium Ions 
NADH Nicotinamide adenine dinucleotide 
NC Novocastra 
ng Nanogram 
NL Non linear 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
pI Isoelectric point 
PTM Post-translational modifications 
Rb Rabbit 
RuBPs Ruthenium (II) tris-bathophenantroline disulfonate 
RyR1 Ryanodine receptor 
SAR Sarcalumenin 
   
xvii 
  
SC Santa Cruz 
SDS Sodium dodecyl sulphate 
SERCA Sarcoplasmic endoplasmic reticulum calcium ATPase 
SG Sarcoglycan 
SGC Sigma Chemicals 
SGN Stressgen 
SL Sarcolemma 
SOL Soleus 
SR Sarcoplasmic reticulum 
SS Sarcospan 
SYN Syntrophin 
TA Tibialis anterior 
TEMED Tetramethylethylenendiamine 
TGF- β Transforming growth factor beta 
Tn Troponin 
TnC Troponin C  
TnI Troponin I  
TnT Troponin T 
TRAMP Tyrosine-rich matrix protein 
T-tubules Transverse tubules 
V Volts 
W Watts 
WB Western blotting 
WGA Wheat germ agglutinin 
WT Wild-type 
XLDCM X-linked dilated cardiomyopathy 
α-DG alpha-Dystroglycan 
β-DG beta-Dystroglycan 
 
 
 
   
xviii 
  
Abstract   
Duchenne Muscular Dystrophy is a lethal childhood disorder which results in 
progressive muscle weakness and wasting due to genetic abnormalities in the 
dystrophin gene. While the primary abnormality lies with the loss of the crucial 
membrane cytoskeletal protein dystrophin and the reduction of its associated 
glycoprotein complex, secondary alterations in cellular signalling, ion homeostasis 
regulation and metabolic pathways lead to fiber degeneration and subsequent 
fibrosis. These changes result in loss of ambulation and sufferers being wheelchair 
bound in early adulthood. Severe diaphragm and cardiac complications in later life 
tend to be fatal. The aim of this project was to create a detailed proteomic profile of 
differentially affected dystrophic tissues using the mdx mouse model; from severely 
dystrophic diaphragm; moderately affected hind limb to naturally protected 
interosseus muscle were used to investigate the pathogenesis of the disease.  
Proteomic analysis of the muscle subtypes indicated that skeletal muscles are 
differentially affected by the absence of dystrophin protein. Naturally protected 
interosseus exhibited very little histological and proteomic changes. In contrast to 
the moderately affected mdx hind limb muscles, the dystrophic diaphragm exhibits 
severe symptoms of skeletal muscle fiber degeneration that more closely 
resembles that of the neuromuscular pathology exhibited in Duchenne patients 
than any other muscle. Novel molecular insights into dystrophic changes suggest 
increased cellular stress, impaired calcium buffering, cytostructural alterations and 
disturbances of mitochondrial metabolism in dystrophin-deficient muscle tissue. 
Thus, the absence of the dystrophin isoform Dp427 and resulting reduction in 
dystrophin-associated glycoproteins in the dystrophic sarcolemma seems to trigger 
a variety of secondary abnormalities in muscular dystrophy. This work has 
successfully established a detailed biomarker signature that maybe used to 
evaluate new treatments, improve understanding of the pathobiochemical process 
and supports the use of mdx mouse as a suitable model for Duchenne muscular 
dystrophy. 
  
1 
 
1 Introduction  
 
1.1 Muscle Biology 
Muscle tissue can be divided into four distinct types: skeletal muscle, smooth muscle, 
cardiac muscle and myoepithelial cells, all differing in location and function. In this thesis, 
we examined multiple subtypes of skeletal muscle from the diaphragm, interosseus and 
flexor digitorum brevis muscle to hind limb muscles such as tibialis anterior, extensor 
digitorum longus and soleus muscle of the murine animal model.  
 
1.2 Skeletal muscle structure  
A muscle is comprised of many skeletal muscle fibers. A muscle fiber consists of  
bundles of myofibrils that are arranged longitudinally along the axis of each muscle 
fibers. Thus results in the striated muscle pattern of skeletal muscle, a myofibril contain 
sarcomeres (see Figure 1-1). The sarcomere structure consists of two main filaments, a 
thick and a thin filament. 
1.3 Sliding filament and lever-arm theory  
Skeletal muscle contraction involves the two types of filaments. Thick filaments are 
made up of myosin (and myosin heads) found in the centre of the sarcomeres. Thin 
filaments are made up of actin, tropomyosin and troponin (Tn) and surround each thick 
filament. It is this alignment that gives muscle cells its striated pattern. Calcium in the 
cytosol released from the sarcoplasmic reticulum (SR) binds to Troponin C (TnC) (see 
Figure 1-2) leading to a conformational change of the Troponin complex. In the presence 
of ATP this allows a myosin head on the thick filaments to bind with actin initiating a cross-
bridge (Holmes, 1997; Huxley, 2000; Huxley, 2004). 
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Figure 1-1 Skeletal muscle structure  
Contractile elements comprise the repeating sarcomeres, which arrange to form the 
myofibrils. The thick filaments of the H band consist of intertwined myosin chains enclosed 
by the thin actin filaments. (image from ucl.ac.uk)  
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Figure 1-2 Cross-bridge sliding filament theory  
A conformational change happens to tropomyosin after the binding of calcium to troponin 
C. An actin binding site becomes exposed and the myosin head forms a cross-bridge. 
Allowing the thin filaments to slide over the thick filament and result in muscle shortening. 
(image from edoc.hu-berlin.de)  
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ATP is broken down and myosin head released and continues to the next actin along the 
thin filaments causing the sarcomere to shorten. This cycle of muscle fiber shortening is 
maintained by the interaction of multiple myosin head and actin cross-bridges (while 
calcium is present). The filaments, thin and thick are not altered in length but the H zone 
and I band which are shortened and the level of shortening is proportional with the degree 
of contraction (Reedy, 2000). 
 
1.4 Skeletal muscle excitation-contraction coupling  
Before skeletal muscle can contract an electrical signal must travel from the motor center 
of the brain along the spinal cord. When an electrical signal meets a motor neuron that 
ends beside a muscle fiber it enters the neuromuscular junction. The electrical signal is 
then converted into a chemical signal at this junction in the form of acetylcholine (ACh) 
(see Figure 1-3) which can then cross the synapse to the muscle fiber. In the muscle 
membrane ACh binds to and activates post-synaptic acetylcholine receptors (AChR) 
causing localised depolarisation (Farley and Miles, 1977). The activation of the voltage 
dependent channels results in sodium channels opening causing sodium ions (Na+) 
to flux out to the cytosol and potassium ions to enter into the sarcoplasm. 
Depolarisation of the sarcolemma results in an action potential and enters down into 
the transverse tubules (T-tubules) (Cooke, 1986). 
 Depolarization of the T-tubules activates the alpha-1 subunit of dihydropyridine receptor 
(DHPR). A conformational change in the protein allows its II - III loop domain to physically 
interact with the ryanodine receptor (RyR1) on the SR (Tanabe et al., 1990). The 
interaction with RyR1 allows calcium channels to open causing a flux of Ca2+ into the 
cytoplasm of the cells (Meissner and Lu, 1995). The increase in cytosolic Ca2+ results in 
the conformational change in the troponin complex, no longer inhibiting the interaction of 
the myosin head with actin (Cooke, 1986).  
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Figure 1-3 Voltage-gated action potential 
An impulse activates voltage-gated ion channels along the sarcolemma and into T-
tubules. The activated dihydropyridine receptor also known as the L-type calcium channel 
interacts with the ryanodine receptor (RyR1) of the sarcoplasmic reticulum. Storage bodies 
release calcium within the sarcoplasmic reticulum, which result in interactions with 
contractile elements of the myofibril. (image from www.sim-bio.org)  
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1.5 Skeletal Muscle Fibers  
Skeletal muscle is an extremely heterogeneous tissue composed of a large variety of 
functionally diverse fiber types and subtypes. The properties of individual muscles largely 
depend on the combination of the individual properties of their different fiber types and 
their proportions. Traditionally, fiber types were classified depending on their varying color, 
type I fibers red (slow-twitch) due to the high levels of myoglobin and type II fibers white 
(fast-twitch). These fibers types can be further subdivided into type IIA or type IIB whereby 
the fast-twitch fibers were more aerobic using oxidative metabolism or anaerobic using 
glycolytic metabolism, respectively. Thus, muscle fibers can be classified by their 
contractile and metabolic properties. There are a number of methods employed to classify 
muscle fibers, histochemical staining for myofibrillar ATPase activity, immunohistochemical 
staining for myosin heavy  chain (MHC) type identification and biochemical identification of 
metabolic enzymes (Pette and Staron 2000).  
Muscle  fibers  are  dynamic  structures  capable  of  change  under  certain conditions 
for example, altered neuromuscular activity, mechanical loading or unloading, changes in 
hormonal profiles,  systemic diseases or during aging. Fiber transitions generally follow a 
pattern of either fast-to-slow or slow-to-fast. These MHC isoform transitions are linked to 
energy cost for force and also differences in the ATP phosphorylation in fast and slow 
muscle fibers production (Bottinelli et al., 1994; Conjard et al., 1998).  During sarcopenia 
the degenerative loss of skeletal muscle mass and strength associated with aging there is 
a decrease in type II fibers with fast-to-slow transitions and glycolytic-to-oxidative shifts in 
aging muscle. 
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1.6 Dystrophin and its Isoforms 
It has been over 20 years since the discovery of the genetic defect causing DMD. 
The DMD gene is a huge 2.5 Mb gene that encodes for the dystrophin protein (see 
Figure 1-4). The massive gene accounts for 1.5% of the X chromosome and also 
represents 0.1% the total human genome (Wells, 2006). Dystrophin is a member of the 
spectrin family of very large actin binding proteins (Menhart, 2006). 
The dystrophin gene has 7 different promoters controlling transcription. Three full-
length dystrophin isoforms that are transcribed by these promoters include Dp427-B, 
Dp427-M and Dp427-P in the brain, skeletal muscle and Purkinje cells respectively, 
differing in the amino terminal end sequence (Boyce et al., 1991; Gorecki et al., 1992; 
Yaffe et al., 1992). 
Shorter isoforms of dystrophin protein are produced by four internal promoters. 
These transcribe Dp260 a 260kDa retina isoform, Dp140 a 140kDa brain/kidney 
isoform, Dp116 a 116Da Schwann cell isoform and Dp71 a 71kDa truncated general 
isoform. Each of these isoforms have an unique amino terminal end and some lack the 
actin binding domain found in full-length dystrophin (Byers et al., 1993; D'Souza et al., 
1995; Lidov et al., 1995). Thus, these shorter isoforms function differently compared to 
that of Dp427 in skeletal/cardiac muscle and nervous system. 
Also a number of dystrophin-related proteins exist, 94kDa α-dystrobrevin in muscle, 
61kDa β-dystrobrevin in muscle and brain (Rentschler et al., 1999), 395kDa full length 
utrophin Up395 in the brain and at neuromuscular junction, 116kDa Up116 in the brain 
and 62kDa N-utrophin in glioma cells. 
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Figure 1-4 Genomic organisation of the dystrophin gene 
Figure 1-4 represents the Genomic organisation of the dystrophin gene which is 
located in Xp21. The 79 exons of the dystrophin gene are represented by the black 
line. The 79 exons are distributed over about 2.5 million bases. The arrows indicate 
the various promoters like are brain (B), muscle (M), and Purkinje (P) promoters are 
indicated by the arrows. The point mutation in exon 23 results in the absence of Dp427 
in mdx mice (image modified from Culligan et al., 2001). 
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Full-length dystrophin is comprised of four major domains, three of which are 
homologous to domains present in several actin binding cytoskeletal proteins (Koenig et 
al., 1988). Dystropins four domains: (i) N-terminal “actin binding” domain with 2 
calponin homology units, (ii) a central “rod domain” consisting of 24 spectrin-like 
repeats and four hinge regions which provide a flexible characteristic, (iii) a cysteine-
rich domain which is vital for binding the integral glycoprotein β-dystroglycan and α-
dystrobrevin, and (Rentschler et al., 1999) (iv) a carboxyl terminal domain, a unique 
sequence that bind dystrophin-associated proteins dystrobrevin and syntrophin through 
its coiled-coil protein-binding motifs (seen in Figure 1-5). Both the cysteine-rich domain 
and C terminus are found in all the dystrophin isoforms (Tinsley et al., 1992). Genetic 
deletions or nonsense mutations that block translation resulting in x-linked muscular 
dystrophy occur in distinct regions in these domains, more frequently in the N-terminal 
area of the rod domain.  
Dystrophin is localised to the cytoplasmic face of the sarcolemma (Zubrzycka-Gaarn 
et al., 1988) and mainly within a cytoskeletal lattice termed costameres, (Campbell, 
1995) where dystrophin interacts through its actin binding domain and cysteine-rich 
domain interacts linking the extracellular dystroglycan complex via β-dystroglycan. 
Without the support of dystrophin, these glycoproteins are quickly lost and thus weaken 
the linkage between the actin membrane cytoskeleton and the extracellular matrix. The 
plasmalemma in turn becomes more susceptible to contraction-induced micro-rupturing. 
Repair mechanisms seem to introduce Ca2+-leak channels in the sarcolemma, which 
result in pathophysiologically elevated Ca2+-levels in the dystrophic cytosol (Alderton and 
Steinhardt 2000). Elevated proteolytic activity triggers then various direct and indirect 
negative effects on ion handling, energy metabolism and the structural integrity of 
dystrophic muscle. Chronic alternations of key pathways and important cellular 
mechanisms cause severe tissue wasting and muscle weakness, eventually leading to 
end-stage contractile failure. Suggesting that dystrophin stabilises the sarcolemma 
against mechanical forces experienced during muscle contraction. 
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Figure 1-5 Dystrophin and Utrophin domain structures 
Shown is a comparative representation of the domain regions of murine dystrophin and 
utrophin.  Utrophin structure lacks the rod domain modules which correspond to the helical 
repeats 15-19 in dystrophin. However, the structures both contain an amino terminal (AT) 
domain,  the four  hinge  regions (H1-H4)  comprising  the  rod  domain (RD)  of  up  to  24  
helical  repeats,  the cysteine-rich (CR) domain and finally the carboxyl terminal (CT) 
domain (image modified from Culligan et al., 2001). 
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1.7 Dystrophinopathies  
Changes in dystrophin and various dystrophin-associated proteins result in a number of 
muscular dystrophies, the effects of which can be seen across multiple muscle types. 
The most common form of muscular dystrophy is Duchenne Muscular dystrophy (DMD) 
(Dellefave and McNally, 2007). DMD is named after Guillaume Benjamin Amand 
Duchenne a French neurologist and was first reported in 1836 (Conte and Gioja, 1836) 
and later described in 1852 by Meryon. DMD is a lethal disorder of childhood believed to 
affect 1 in every 3500 live male births. A recent epidemiology study of DMD reported the 
incidence ranged from 10.71 to 27.78 per 100,000 (Mah et al., 2014). DMD is inherited as 
an X-linked recessive condition only affects males, with women being carriers. 
The reading frame of the dystrophin transcript is changed due to the mutations in the 
dystrophin gene, resulting in a premature stop codon (Dellefave and McNally, 2007). 
Positional cloning was used to identify the DMD defect. Patients with DMD can have 
different types of mutations. Approximately 65% of patients have intragenic out-of-frame 
deletions and approximately 10% have duplications of one or more of the dystrophin 
gene’s exons. The remaining DMD patients have point mutations or smaller gene 
rearrangements (Kinali et al., 2007). The absence of the dystrophin protein is the 
molecular basis for DMD (Rando, 2006). Dystrophin links the cytoskeleton to the 
extracellular matrix (see Figure 1-6). Reduction or absence of dystrophin protein 
compromises this link and leads to muscle fiber degeneration (Kinali et al., 2007). Thus 
DMD is considered a neuromuscular disorder of the membrane cytoskeleton.  
In DMD symptomatic muscle disease onset occurs between three and five years of age. 
The most frequent presenting symptoms are an abnormal gait or motor delays. Affected 
boys may present difficulty in getting up from the ground (Gower’s sign), running and may 
have frequent falls, due to serve impairment of lower extremities (Dellefave and McNally, 
2007). Proximal weakness affects the lower extremities before the upper extremities (Yiu 
and Kornberg, 2008). The weakness is accompanied by muscle pseudohypertrophy, the 
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enlargement of the muscle tissue, typically calf muscles, caused by infiltration of 
connective tissue and adipose into the degenerating muscle. The progression of muscle 
weakness generally leads to DMD patients being wheelchair bound by the age of 12. The 
leading cause of death in individuals is respiratory insufficiency between the late teens or 
early 20s. Respiratory complications account for approximately 80% of deaths, while 20% 
succumb to dilated cardiomyopathy (DCM) (Kinali et al., 2007).  
It depends on the type of mutation, whether a patient shows DMD or it’s more benign 
counter-part Becker muscular dystrophy (BMD) phenotype. DMD results from a severe 
reduction or absence of dystrophin, whereas BMD is associated with expression of a 
partly functional dystrophin protein. BMD is more variable phenotypically with a later 
onset of serve symptoms and normally follows a less progressive form of fiber 
degeneration than DMD (Monaco et al., 1988). An abnormality in DMD gene, which 
results in the promoter on the 5’ end that transcribes for the cardiac specific dystrophin 
protein, causes X-linked dilated cardiomyopathy (XLDCM). This form of 
dystrophinopathy shows little skeletal muscle disease progression however is fatal 
leading to cardiac failure in early 20s (Towbin et al., 1993).  
Absence of dystrophin-associated proteins can lead to other muscular dystrophies. 
Certain limb-girdle muscular dystrophies (LGMD) result from loss of different sarcoglyan 
isoforms and are referred to as sarcoglycanopathies (Lim et al., 1995; Jung et al., 1996). 
These various muscular dystrophies are progressive diseases which affect shoulder and 
pelvic girdle muscles. Congenital muscular dystrophy (CMD) results from a deficiency in 
laminin protein which interacts with the dystrophin-glycoprotein complex (DGC). While 
not a progressive disease, CMD shows muscles weakness and can result in loss of 
ambulation (Minetti et al., 1996). 
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Figure 1-6 Overview of neuromuscular disorders with primary defects in 
components of the dystrophin-glycoprotein complex 
Shown is a diagram representing the dystrophin-associated glycoprotein complex  
and a list of muscle proteins with a genetic abnormality in muscular disorders. Genetic  
changes in laminin (LAM), γ-sarcoglycan (γ-SG), α-SG, β-SG or δ-SG are linked  
with congenital muscular dystrophy (CMD) and limb-girdle muscular dystrophy (LGMD) 
subtypes 2C, 2D, 2E and 2F, respectively. Primary abnormalities in the Dp427 isoform  
of dystrophin located in the actin membrane cytoskeleton (AMC) result in severe 
Duchenne muscular dystrophy (DMD), milder Becker muscular dystrophy (BMD) as well 
as X-linked dilated cardiomyopathy (XLDCM).  
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1.8 Dystroglycan complex  
The plant lectin germ agglutinin chromatography was important for the biochemical 
isolation of dystrophin and led to the dystrophin-associated glycoprotein complex (DAGC) 
idenfication (Campbell and Kahl, 1989). Lectin chromatography established that 
dystrophin was tightly associated to the glycoprotein complex at the muscle periphery. 
The dystrophin-associated proteins can be grouped into three main components (i) the 
sarcolemma, (ii) the membrane cytoskeleton and (iii) the extracellular matrix. The DAGC 
structural overview is shown in Figure 1-7.  
The sarcolemma components of the dystrophin-associated proteins include (i) 50kDa 
sarcoglycan, 43kDa β-sarcoglycan, 35kDa γ-sarcoglycan, 35kDa δ-sarcoglycan and (ii) 
25kDa highly hydrophobic sarcospan protein (Crosbie et al., 1997; Lim and Campbell, 
1998; Barresi et al., 2000) and 43kDa β-dystroglycan trans-sarcolemmal linker 
glycoprotein (Rentschler et al., 1999). The membrane cytoskeletal components include (i) 
43kDa cortical actin, (ii) 94kDa β-dystrobrevin (Wagner et al., 1993) and (iii) 58, 59 and 
60 kDa syntrophins comprised of a protein family, the α, β1 and β2 isoforms respectively 
(Adams et al., 1993; Ahn et al., 1994; Ahn et al., 1996; Piluso et al., 2000). 
Many other proteins are indirectly linked to muscle Dp427 like the extracellular matrix 
component 156kDa α-dystroglycan and ~400 kDa laminin (Ibraghimov-Beskrovnaya et 
al., 1992; Hohenester et al., 1999). In addition to the main components a large number of 
signalling proteins and ion channels are linked to the dystrophin network of proteins. In 
dystrophic muscle tissue the levels of many of these dystrophin-associated proteins are 
dramatically decreased at the sarcolemma. Interestingly it is the absence of Dp427 that 
leads to the disintegration of the DAGC and subsequent separation of actin membrane 
cytoskeleton and laminin with progression of the disorder.  
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Figure 1-7 Synopsis of the structure of the DAGC form skeletal muscle and its role 
in the molecular pathogenesis of X-linked muscular dystrophy 
Shown is a diagrammatic presentation of the supramolecular dystrophin-associated  
complex of the sarcolemma (SL) that  connects  the  actin  membrane  cytoskeleton 
(AMC)  of  the  cytosol (CYT)  with  the extracellular matrix (ECM) protein laminin (LAM). 
The Dp427 dystrophin isoform interacts with dystrobrevins (DYB), syntrophins (SYN) and 
the integral β-dystroglycan  (β−DG) protein, which in turn binds directly to the extracellular 
laminin-binding protein α-dystroglycan (α-DG). Additional Dp427-associated proteins are 
shown as sarcospan (SS) and the sarcoglycans (α-SG, β-SG, γ-SG and δ-SG). 
Dystrophin-deficiency in muscle fibres from DMD patients and its dystrophic mdx animal 
model, result in a drastic decrease in the DAGC. Loss of the linkage between the ECM 
and AMC leads to the weakening of the SL membrane system, causing various cellular 
disturbances and finally severe muscular degeneration. 
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1.9 Dystrophic mdx animal model  
In biochemical and biomedical research animal models play a crucial role for 
investigating molecular and cellular pathogenesis as well as preclinical evaluation of new 
treatment strategies for neuromuscular disorders they mimic (Vainzof et al., 2008). 
Ideally, an animal model for a genetic disorder should: (i) show similar primary defects 
and secondary downstream changes as seen in the equivalent human disease; (ii) 
closely resemble the pathogenesis of the human disorder in onset, progression and 
severity; (iii) develop majority of the multifactorial features seen in complex human 
pathologies; (iv) exhibit sufficient similarities to human physiology, metabolism and 
immune responses so that there no major differentiating influence of these biological 
factors on disease progression in animal models vs. patients; (v) be suitable for the 
facilitation of physiological and surgical procedures and for genetic manipulations; (vi) be 
easy to breed and house at a practical cost; and (vii) be large enough to yield adequate 
amounts of tissue samples for extended biological analyses (Guenet, 2011). 
The murine X chromosome-linked (mdx) mouse animal model is an established model 
for the study of x-linked muscular dystrophies. The naturally occurring mouse model has a 
point mutation on exon 23 of the dystrophin gene. This results in the almost complete 
absence of the Dp427 protein isoform of the membrane cytoskeleton protein dystrophin. A 
single base pair change from cysteine to thymine on the exon creates a premature 
termination codon. This results in an 115kDa truncated protein product with limited 
function offering some of membrane stability but with over half the rod and terminal 
domain missing there is no interaction with the intracellular actin cytoskeleton. Four 
shorter isoforms of dystrophin are also expressed by mdx mouse in non-muscle tissues. 
These contain the C-terminal end and result in less severe pathologies of the dystrophy 
in these various tissues. This may account for the milder pathology observed in the mdx 
mouse compared with DMD patients (Sicinski et al., 1989). 
The absence of dystrophin at the muscle sarcolemma causes many of the 
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pathological consequences observed in both mdx and human dystrophic muscle such 
as muscle damage shown by elevated creatine kinase levels in serum, an increased 
susceptibility to osmotic shock and vulnerability to contraction and stretch induced 
injury. Interestingly, the same primary abnormality appears to be subtype specific 
affecting mdx muscles differently. Form mildly affected extraocular (Porter et al., 1998) 
and interosseus muscle to moderately hind limb muscles and dystrophic diaphragm 
muscle with severe fiber degeneration. 
 While limb muscle of the mdx model is less severely affected than the human 
condition due to possible support of the truncated form of dystrophin and its non-muscle 
isoforms as well as homologous utrophin protein in the muscle (Blake et al., 2002; 
Deconinck et al., 1997; Rafael et al., 1999). Aged mdx muscle exhibit severe 
symptoms showing plasmalemma weakening, myofibre replacement by extensive 
connective tissue and exhausted structural and functional recovery of cells after injury. 
Proteomic profiling of senescent muscle is of particular interest to determine age 
related changes in dystrophin-deficient fibers, as the mdx senescent phenotype more 
closely resembles that of the human pathology (Lefaucheur et al., 1995). 
 
1.10 Proteomics  
Proteomics is the large-scale study of proteins expressed by a cell. The entire protein 
complement expressed by a cell is known as the proteome. It is important to note that the 
proteins produced in the cell do not fully match up with the translation of the nucleotide 
sequence. This is due to post-translational modification (PTM), when the proteome is 
subjected to environmental influences this process can be applied to adapt to changing 
situations (Anderson and Seilhamer, 1997). Classic proteomic techniques such as 1D 
and 2D polyacrylamide gel electrophoresis have been employed as standard methods to 
investigate the proteome. However, other recently developed in-gel techniques such as  
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DIGE and gel-free protein labelling methods have empowered proteomic quantitative 
analysis. 
Thus, the rapid advancements in protein biochemical techniques and MS-based 
proteomics have allowed for the establishment of global protein expression patterns, 
molecular interactions and PTMs of muscle proteins in samples. In the case of sports 
physiology a recent study (Egan et al., 2011) employed a number of these novel tools 
following physical exercise and this is a successful example of applied proteomics and 
future exercise intervention in muscle and metabolic diseases can build on these kinds of 
studies. Regular exercise has been shown to be effective in the prevention of chronic 
diseases and increased knowledge of the molecular responses to exercise offers an 
important contrast for interpreting studies of disease and can highlight potential novel 
therapeutic targets (Burniston and Hoffman, 2011). Thus, proteomics is an important tool 
in profiling and characterising changes in protein expression in diseased organisms. 
Skeletal muscle proteomics is concerned with identification and cataloguing of the 
proteins constituents involved in voluntary contractile fibers in normal and disease 
muscle.  
 
1.10.1 Sample preparation 
This first step in proteomic study is solubilisation of the sample proteins. Denaturing 
buffers are used containing a pre-optimised and tailored combination of chemicals to 
both solubilise the maximum amount and variety of proteins depending on the sample. 
Usually consisting of chaotropic agents like urea to disrupt hydrogen and hydrophic 
bonds (Rabilloud, 1998), reducing agents such as dithiothreitol DTT to break disulphide 
bridges and detergents such as CHAPS.  
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1.10.2 2-D gel electrophoresis  
Two-dimensional electrophoresis is a powerful technique which allows for the 
separation and subsequent analyse of proteins in a sample. The technique separates 
proteins in two dimensions and was established by Klose, O’Farrell and many others by 
1975. In the first dimension proteins are separated according to their pH by isoelectric 
focusing (IEF) using polyacrylamide gel strips with immobilised pH gradient (IPG). The 
protein sample must enter the gel strip before they are separated. This can be achieved 
through a number of methods; firstly rehydration buffer is used to rehydrate the IPG 
strips. With in-gel rehydration the protein sample is added to the rehydration buffer and 
enters the gel, or sample can be added post rehydration during IEF by cup/wick 
loading. When an electric field is applied, proteins travel along IPG strips till the protein 
has no net charge. 
In the second dimension the focused strips are positioned running along the top of the 
polyacrylamide gels. An electric current is applied through the gels which move the 
proteins through the pores in the gel. The smaller proteins are capable of moving faster 
through the gel, therefore allowing the proteins to be separated based on their 
molecular weight. Gels are then fixed and stained to visualise the proteins.  
 
1.10.3 Protein visualisation  
There are a number of post separation visualisation methods. A method may be  
chosen a variety of reasons be it sensitivity, downstream processing or simply 
because it is cheap and convenient. Commonly used stains in proteomic studies are 
staining with anionic dyes. These include coomassie, silver and fluorescence staining. 
Coomassie brilliant blue (CBB) provides a low cost and mass spectrometry-compatible 
staining method. CBB binds to basic amino acids in a hydrophobic manner Neuhoff and 
colleagues (1985).  
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Silver staining while more sensitive than CBB, has a very limited dynamic range 
and is not reproducible thus, not suitable for quantitative analysis. Silver nitrate binds 
to proteins and then with the addition of formaldehyde the silver ions become reduced to 
metallic silver (Rabilloud et al., 1994). This method of staining is also mass spectrometry 
compatible however requires a destaining step to remove gluteraldehyde from the excised 
proteins. 
Fluorescent compounds offer a better approach for protein detection with high 
sensitivity and large linear dynamic range but usually at more expense and require 
fluorescent scanners. Fluorescent detection of proteins can be performed in two ways. 
Firstly, post-electrophoretic fluorescent labelling such as Ruthenium (II) tris 
bathophenantroline disulfonate (RuBPs) dye developed Rabilloud and co-workers is 
cost-efficient, simple, sensitive and mass spectrometry compatible.  
Secondly, pre-electrophoretic protein staining such as difference in-gel electrophoresis 
(DIGE), were protein samples are fluorescently labelled with cyanine dyes (CyDyes) that 
react to proteins lysyl residues. CyDyes are the most sensitive dyes available capable 
of detecting nanogram of protein (Minden et al., 2009). CyDyes fluoresce at different 
wavelengths with Cy2 at 520 nanometres (nm), Cy3 at 550nm and Cy5 650nm. This 
allows for comparisons of samples to be analysed together on a single gel. Two protein 
samples are labelled with CyDyes, combined, separated, scanned and analysed with 
fluorescence software (see Figure 1-8). 
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Figure 1-8 Overview of the main approaches used in fluorescence difference in-
gel electrophoresis (DIGE) gel-based proteomics  
The 2-dye or 3-dye DIGE system is most commonly applied method of labelling for 
studying global changes in complex protein populations. Specimens (A) and (B) are 
labelled with CyDyes pre-electrophoresis, samples then separated based by their 
isoeletric point and molecular masses. The gels scanned and image analysis of 
differential expression pattern of fluorescently labelled proteins. 
 
.  
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1.10.4 Protein identification  
Quantitative comparative proteomic analysis of the 2-D gel images highlight changes 
between samples. The identification of these protein changes is achieved using 
mass spectrometry. Firstly, sample is cleaned up to remove contaminants by desalting 
and destaining the protein plug. This is then followed by enzymatic digestion using trypsin 
to cleave the proteins at lysine and arginine amino acid residues. With mass spectrometry 
following ionisation, analysis and detection steps the amino acid sequences of the 
peptides are provided and used to identify the protein from a database.  
 
1.10.5 Mass Spectrometry 
An ion trap liquid chromatography mass spectrometry LC/MS with an electrospray 
ionisation (ESI) has been used for protein identification in this study.  Whereby the peptide 
samples are dissolved in a polar solution tube upon existing tubes tip an electric field is 
applied which charges the solvent. Thus results in the emerging sample drop to divide into 
fine spray of droplets which are directed towards the mass spectrometer by nitrogen gas. 
The warm nitrogen gas flowing through the chamber causes the droplets to evaporate till 
the droplets are small enough allowing free ions to enter the mass spectrometer and be 
analysed (Yamashita and Fenn, 1984; Fenn et al., 1989).  
 
1.11 Aims of proposed project  
Duchenne muscular dystrophy represents one of the most frequently inherited 
childhood diseases affecting 1 in 3,500 live male births, due to genetic abnormalities in 
the dystrophin gene. Absence of dystrophin protein compromises the link between the 
cytoskeleton to the extracellular matrix and leads to muscle degeneration. 
Degeneration of muscle fibers and sequent fibrosis leads to DMD patients being 
  
23 
 
wheelchair bound in early childhood and severe cardiorespiratory complications in 
older children, the leading cause of death in individuals. Although DMD is progressive, 
interestingly different subtypes of skeletal muscles are not all affected to the same 
degree. While mdx diaphragm and cardiac muscle are severely dystrophic and hind 
limb moderately affected, there also appear to be spared phenotypes such as the 
interosseus and extraocular muscle.  
The purpose of this research was to perform a detailed proteomic profile on 
differentially distressed dystrophic muscles, to determine potential muscle subtype-
specific changes in secondary alterations and potential age-related changes in the 
dystrophic phenotype. Therefore, we carried out fluorescence labelling such as DIGE 
and RuBPs, mass spectrometry, histology and immunoblotting of dystrophic and 
normal tissue to establish the global proteomic expression patterns for a number of 
skeletal muscles from aged diaphragm, interosseus and flexor digitorum brevis muscle to 
hind limb muscles such as tibialis anterior, extensor digitorum longus and soleus muscle 
using the mdx animal model. 
However, since the main proteins of the actomyosin apparatus and its supporting 
sarcomeric components frequently negate weak signals from minor muscle protein 
species during proteomic analyses, we also employed a pre-fractionation step to 
remove certain parts of this analytical problem. In order to eliminate a large portion of 
highly abundant contractile proteins, differential centrifugation of the crude skeletal 
muscle extracts were performed to reduce the samples complexity. 
Mass spectrometry-based proteomics has been important in determining the global 
protein expression pattern and effects of the disintegration of the dystroglycan complex 
DAGC as well as the identification of compensatory mechanisms and establishment of 
novel biomarkers in dystrophic tissue.   
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2 Materials & Methods  
 
2.1 Materials  
 
2.1.1 Equipment 
Gel electrophoresis equipment and gel imaging systems used for the proteomic analysis 
of muscle proteins were from Amersham Biosciences/GE Healthcare, Little Chalfont, 
Buckinghamshire, UK, including immobilized pH gradient IPG DryStrip rehydration tray, 
IPGphor IEF unit, manifold, 6 gel casting box, cassette racks, Ettan DALT twelve multiple 
vertical slab gel electrophoresis system, fluorescent glass plates for gel electrophoretic 
analysis and a Typhoon Trio variable mode scanner.  
A Vortex Genie-2 from Scientific Industries, New York, NY, a SSL4 Stuart shaker from 
Lennox Laboratory Supplies Ltd., Dublin, Ireland, a model 5417R centrifuge from 
Eppendorf, Cambridge, UK and a Heto speedvac concentrator Medical Supply Company, 
Dublin, Ireland were used for routine mixing, shaking, centrifugation and concentrating 
steps, respectively. Identification of protein species was performed on an electrospray 
ionization Agilent 6340 Ion Trap LC mass spectrometer from Agilent Technologies, Santa 
Clara, CA, USA. With a nanoflow Agilent 1200 series system, fitted with a Zorbax 300SB 
C18 µm and 4mm 40nl pre-column was equipped for the separation of peptides. 
 
2.1.2 Reagent solutions  
All reagent solutions were prepared with ultrapure water using a Millipore Mill-Q 
apparatus, to reduce contamination of protein samples to a minimum. General solutions 
and chemicals were purchased from Sigma Chemical Company in Dorset, UK and were of 
proteomic/analytical grade, unless stated otherwise. Protease inhibitors were from Roche 
Diagnostics in Mannheim, Germany. 
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2.1.3 1-D and 2-D gel electrophoresis  
For gel electrophoretic protein separation, ultrapure Protogel acrylamide stock 
solution and 4X Protogel Resolving Buffer stock solutions were purchased from 
National Diagnostics (Atlanta, GA, USA). Isoelectric focusing immobilized pH gradient 
(IPG) strips of pH 3-10 24cm and pH 3-11 non-linear (NL) 24cm for 2-D 
electrophoresis, IPG buffer  and ampholytes were   purchased   from   Amersham   
Biosciences/GE   Healthcare (Little   Chalfont, Buckinghamshire, UK), and protein 
molecular weight markers and laemmli buffer were obtained from Biorad  
Laboratories (Hemel-Hempstead,  Hertfordshire,  UK).   
 
2.1.4 Protein staining  
Ruthenium batho-phenanthrolinedisulfonate chelate for the production of RuBPs dye 
was from Reagecon Diagnostic Limited (Shannon, Ireland). Sodium Ascorbate for 
RuBPs dye was purchased from Sigma Chemical Company (Dorset, U.K). Coomassie 
Brilliant Blue G-250 was purchased from Bio-Rad Labs, (Herts, UK). DIGE fluor minimal 
dyes Cy3 and Cy5 were purchased from GE Healthcare (Little Chalfont, Bucks., UK).  
 
2.1.5 Mass spectrometry  
Mass Spectrometry grade solvents were purchased for mass spectrometry analysis from 
Sigma Chemical Company (Dorset, UK). LC-MS Chromaslv water and formic acid were 
obtained from Fluka (Dorset, UK). Acetonitrile was from Amersham Biosciences/GE  
Healthcare  (Little  Chalfont,  Bucks.,  UK)  For protein digestion sequencing grade modified 
trypsin was purchased from Promega  (Madison, WI, USA). Model 6340 Ion Trap LC/MS, 
LC/MS vials and ProtlD-Chip-150 II 300A C18 150nm column were from Agilent 
Technologies Ireland Ltd. (Santa Clara, CA, USA). 
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2.1.6 Western blotting  
Chemiluminescence substrate was purchased from Roche Diagnostics (Mannheim,  
Germany).  Nitrocellulose transfer membrane was obtained from Millipore (Bedford, 
MA, USA). X-ray film was from Fuji Photo Film Co.Ltd. (Tokyo, Japan). 
Developer/Fixer was purchased from Sigma Chemical Company (Dorset, UK). 
Ponceau S-Red Staining Solution were purchased from Sigma Chemical Company 
(Dorset, UK). All secondary antibodies used were purchased from Chemicon 
International (Temecula, CA., USA). All antibodies used in this research are shown in 
Table 2-1 with company details and dilutions.  
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Table 2.1 Antibodies  
List of antibodies used for immunoblotting this project including the dilutions used 
for both primary and secondary antibodies, host species (species), company and 
ordering information. Species= Host species; mouse (Ms), rabbit (Rb), chicken (Ck), 10= 
primary; 20= secondary; AB= abcam; NC= Novocastra; SC= Santa Cruz; SGN= Enzo 
Stressgen; SGC= Sigma Chemicals and BIO= Affinity Bioreagents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody 10 Ab 
Dilutions 
Species 20 Ab 
Dilutions 
10 Order No. Company 
αB-crystallin 1:500 Ms 1:1000 ab13496 AB 
Actinin 1:1000 Ms 1:2000 ab9465 AB 
ATP synthase 1:500 Ck 1:1000 ab43176 AB 
βDystroglycan 1:100 Ms 1:500 NCL-b-DG NC 
βDystroglycan 1:100 Ms 1:500 ab sc-33701 SC 
Calsequestrin 1:500 Ms 1:1000 VIIID12 BIO 
Carbonic anhydrase 1:1000 Rb 1:2000 ab54913 AB 
Collagen 1:1000 Rb 1:2000 ab6588 AB 
cvHSP 1:500 Rb 1:1000 ab111233 AB 
Ferritin light chain 1:500 Rb 1:1000 ab69090 AB 
Hsp27 1:500 Rb 1:1000 ab12351 AB 
Hsp70/72 1:250 Rb 1:1000 ab ADI-SPA-811 SG 
Laminin 1:500 Rb 1:1000 ab L-9393 SGC 
MLC-2 1:500 Rb 1:1000 ab92721 AB 
Myoglobin 1:500 Rb 1:1000 ab77232 AB 
Parvalbumin 1:1000 Rb 1:2000 ab11427 AB 
Phosphoglycerate 
kinase 
1:1000 Rb 1:2000 ab75223 AB 
Prohibitin 1:500 Rb 1:1000 ab28172 AB 
Serpina 1:1000 Ck 1:2000 ab14226 AB 
Transferrin 1:500 Rb 1:1000 ab9033-1 AB 
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2.2 Methods  
 
2.2.1 Dystrophic mdx animal model  
Proteomic analysis was carried out using dystrophic mdx and aged matched C57 control 
mice. All tissue samples were obtained from the Animal House in the University of 
Greifswald in Karlsburg, Germany. The mice were maintained under standard living 
conditions and in accordance to all German and Irish procedures relating to the use of 
animals for scientific experiments. Mice were sacrificed by cervical dislocation and freeze 
frozen in liquid nitrogen.  
 
2.2.2 Preparation of crude skeletal muscle extracts  
The various skeletal muscle extracts for each study were prepared separately. For the 
proteomic profiling control C57 and age matched mdx muscles were taken. The 
diaphragm (DIA), tibialis anterior (TA), soleus (SOL), extensor digitorum longus (EDL), 
interosseus (INT), flexor digitorum brevis (FDB) and crude hind limb muscle extracts 
were washed in distilled water to remove any skin, bone, hair and blood. 
For the initial break-up of the tough contractile fibres the tissue was dissected with a 
blade. Using appropriate safety equipment and protective clothing liquid nitrogen was 
added to freeze the tissue followed by grinding of the tissue into a fine powder with 
mortar and pestle. Each of the ground up muscle powder was solubilised in lysis buffer 
at a ratio of 1:10 (w/v) respectively. With lysis buffer containing 7M urea, 2M thiourea, 4% 
(w/v) (3-[3-Cholamidopropyl)-Dimethylammonio]-1-Propane sulfonate) CHAPS, 2% (v/v) 
IPG buffer pH3-10, 2% (w/v) (dithiothretiol) DTT and protease inhibitors. Samples 
undergoing DIGE analyses were limited to buffer consisting 9.5M urea, 2% (w/v) CHAPS 
and a protease inhibitor cocktail (Doran et al., 2006a). 
The suspension was vortexed and gently left rocking for 1 hour at room temperature 
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followed by centrifugation at 4 0C for 20 min at 20,000g. The protein containing middle layer 
was retained. In the case of further subcellular fractionation an extra differential 
centrifugation step was performed at 100,000g for 1 hour at 4 0C. With sucrose buffer 
containing 20mM sodium pyrophosphate, 20mM sodium phosphate, 1mM MgCl2, 0.303M 
sucrose, 0.5mM EDTA, pH 7.0 and protease inhibitors. Pellets were resuspended in lysis 
buffer and the protein concentration determined using the Bradford assay system 
(Bradford, 1976). 
 
2.2.3 1-D Gel Electrophoresis  
One dimensional SDS polyacrylamide gel electrophoresis was carried out using a 
Bio-Rad Mini-Protean III gel system from Bio-Rad Laboratories (Hemel-Hempstead, 
Herts., UK) and performed according to Laemmli (1970). Ten percent resolving gel were 
used containing 10% (w/v) acrylamide from protogel acrylamide stock, 4X Protogel 
resolving buffer, 0.69M APS, 0.438M SDS and 0.1% (v/v) TEMED (N, N, N’, 
N’-tetramethylethylenendiamine). The stacking gel consisted of 5% (w/v) acrylamide, 
0.69M APS, 0.5M Tris-PO4 at pH 6.7, 0.438M SDS and 0.1% (v/v) TEMED. When 
casting the resolving gel was poured first and stacking gel poured over the resolving gel 
once it had time to polymerise. Samples were heated for 10 min at 960C in a 1:1 dilution 
of Laemmli buffer with 350mM DTT before loading onto the gel. 10mg of protein was 
loaded per lane. Electrophoresis was carried out using running buffer (125mM Tris, 
0.96M glycine, 0.1% (w/v) SDS) and run at 60 volts till sample passed the stacking gel 
were increased to 120 volts until the tracking dye ran off the bottom of the gel.  
 
2.2.4 2-D Gel Electrophoresis  
For isoelectric focusing IPG strips were in-gel rehydrated with sample (and equal 
volume 2x lysis buffer for DIGE analysis) and made up with rehydration buffer (7M urea, 
2M thiourea, 4% (w/v) CHAPS, 2% (v/v) IPG buffer pH3-10, 2% (w/v) DTT, protease 
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inhibitors and 1.2% (v/v) DeStreak rehydration solution from Amersham  
Biosciences/GE   Healthcare. ).  Different volumes were used according to the length of 
the IPG strip and amount of sample required depending on the staining  
technique. For the IPG 24cm strips a total volume (rehydration buffer and sample) of 
450ml is required. 
Rehydrated strips were run on an IPGphor IEF instrument and isoelectric focusing was 
carried as followed:  80V for 4h, 100V for 2h, 500V for 1.5h, 1000V for 1h, 2000V for 1h, 
4000V for 1h, 6000V for 2h and finally 8000V for 2.5h. After completion of isoelectric 
focusing, the IPG strips were initially incubated in equilibration buffer (6M urea, 30% (v/v) 
glycerol, 2% (w/v) SDS, 100mM Tris-HCl, pH 8.8) with addition of 100mM DTT for 20 min 
followed by  an additional equilibration step with 0.25M (iodoacetamide) IAA for 20 min 
(Lewis et al., 2009).  
Strips were then washed briefly in (sodium dodecyl sulphate) SDS  
containing running buffer (125mM Tris, 0.96M glycine, 0.1% (w/v) SDS) and placed 
onto a 12.5% (v/v) resolving slab gel. Sealing solution containing 1x SDS running 
buffer plus 1% (w/v) agarose and Bromophenol Blue was heated to seal the strip gels. Gel 
slabs were then loaded into an Ettan DALT-twelve tank system from GE Healthcare (Little 
Chalfont, Bucks., UK) and electrophoresis carried out at 0.5W/gel for 1 hour followed by 
15W/gel until the Bromophenol Blue dye front ran off the gel.  
 
2.2.5 Protein Staining  
2.2.5.1 Collodial Coomassie Staining  
Colloidal Coomassie staining is a post electrophoretic staining method and was 
performed according to Neuhoff and co-workers (1988). The gels were washed in dH2O 
and placed into the Colloidal Coomassie staining solution, 1part Stock Solution A (5% (w/v) 
Coomassie Brilliant Blue G250), 40 parts Stock Solution B (10% (w/v) ammonium  sulfate, 
2%  (v/v)  phosphoric  acid) and 10 parts methanol and left rocking overnight. The gels were 
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then washed with neutralisation buffer (0.1M Tris-PO4 pH 6.5) for 3 min. Followed by 25% 
methanol wash step for 1 min to help reduce the background and gels fixed overnight in  
fixation solution (20% (w/v) ammonium sulphate). The Collodial Coomassie Staining 
method was repeated until sufficient protein pattern is visualised.  
 
2.2.5.2 RuBPs Stain Preparation 
Ruthenium II Bathophenathroline Disulfonate Chelate (RuBPs) 20mM stock solution was 
synthesised as outlined by Rabilloud and colleagues (2001). Potassium pentachloroaquo 
ruthenate (0.2g) was dissolved into 20ml of boiling dH2O and kept under reflux, resulting in 
a deep red-brown colour solution. Bathophenanthroline disulfonate (3M) was then added 
and kept under reflux for 20 min, resulting in a greenish-brown colour solution. 500mM 
sodium ascorbate solution made up to 5mls was then added and kept under reflux for 20 
min, resulting in a deep orange-brown colour solution. The solution was then cooled and 
adjusted to pH 7 with sodium hydroxide. The RuBPs stain was then adjusted with dH2O to 
give a final volume of 26ml and stored at 4oC till use. 
 
2.2.5.3 RuBPs staining  
Following electrophoresis gels were placed in fixation solution (30% ethanol, 10% acetic 
acid) for 1 hour. The gels were then washed in 20% ethanol for 30 min and repeated three 
times. The gels were then incubated for 6 hours in 20% (v/v) ethanol containing 200nM of 
ruthenium chelate staining dye. Following ruthenium staining the gels were destained for 
overnight in 40% ethanol, 10% acetic acid. Gels were then equilibrated in dH2O twice for 10 
min. RuBPs gels were scanned using variable mode imager from Amersham 
Biosciences/GE Healthcare Typhoon Trio apparatus. The RuBPs labelled muscle proteins 
were scanned at wavelength of λ=532nm. The Photomultiplier tube PMT-values for gels 
analysed were between 500V and 600V and the maximum pixel volume was between 
80,000 and 99,000.  The RuBPs stained gels were scanned at 100 µm resolution. 
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2.2.6 Fluorescence difference in-gel electrophoretic analysis  
Similar to RuBP’s staining DIGE labelling was used to determine potential differences in 
expression patterns of the skeletal muscle soluble proteome (Viswanathan  et  al.,  2006),  
as  recommended  by  Karp  and  Lilley (2005). Prior to use the CyDye’s were taken from 
-200C and left at room temperature. Cy3 and Cy5 dyes were reconstituted in freshly 
prepared (dimethylformamide) DMF to give a working solution of 400pmol/ul. Samples 
were labelled with 400pmols of Cy3 fluor dye per 50µg protein. The internal pooled 
standard for each sample were labelled with Cy5 fluor dye containing 25µg control and 
25µg mdx. The labelled samples were mixed and centrifuged briefly and left on ice for 
30 min in the dark. The reaction was stopped with 10mM lysine for 10 min in the dark. 
The labelled samples and pooled internal standards were combined according to the 
experimental design. Equal amounts of 2x lysis buffer was added and left for 10 min 
prior to electrophoresis separation.  
 
2.2.7 Protein visualization and data analysis  
Fluorescent CyDye and RuBPs labelled proteins were visualised using an Amersham 
Biosciences/GE Healthcare Typhoon Trio variable mode. For image acquisition, RuBPs 
labelled proteins were scanned at a wavelength of λ=532nm. While Cy3 and Cy5 labelled 
proteins were scanned at a wavelength of λ=550nm and λ=650nm, respectively. The 
photomultiplier tube PMT values were adjusted so that the volume of the most abundant 
spot on the gel images was between 80,000 and 99,000 when scanned at 100µm 
resolution. Allowing for an accurate analysis of the gel images as no spot would be 
saturated. The RuBPs and DIGE CyDye gel images were then analysed using an 
alignment based approach with Samespots Progenesis software version 3.2.3 from 
NonLinear Dynamics (Newcastle upon Tyne, UK). RuBPs based experiments were 
normalised against their biological replicates while Cy3 images in the DIGE experiments 
used their corresponding Cy5 image. All the gels in an experiment were then aligned to a 
reference gel. Spots were then detected and filtered.  
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Following filtering, gel images were then placed into groups (control versus disease) and 
analysed to determine significant differences in the abundance of distinct protein spots. A 
list was generated of spots with changed abundance. Each spot was given a power score 
or principal component analysis PCA and any below <0.8 were excluded from analysis. 
Similarly, spots with a P value <0.05 were included with those >0.05 being excluded from 
the experiment. An anova score was established using the one way anova test, an 
ANOVA score above >0.5 was required for consideration. Any spots that met the 
significance criteria were subsequently identified by LC-MS/MS analysis. 
 
2.2.8 In-gel digestion of proteins for Mass spectrometric identification  
Preparative gels containing 800µg of protein (1:1 disease to control) were labelled with 
RuBPs stain and scanned at a wavelength of λ=532nm as previously discussed above. 
These images were attached to the Progenesis Samespots report and aligned to the 
experiments reference gel, highlighting the key protein spots of interest. Prior to 
identification via LC-MS/MS these key protein spots were excised, washed and digested 
according to Shevchenko and colleagues (2006). The gel pieces were destained and 
treated with 400ng of trypsin per gel plug and left at 40C for 30 min before being digested at 
370C overnight. 100µl of extraction buffer (1:2 v/v of 5% (v/v) formic acid/acetonitrile) was 
added to the digested plugs and incubated at 370C for 15min. Resulting supernantant 
fractions were transferred into fresh tubes and the peptides were dried down in a vacuum 
centrifuge.  
 
2.2.9 Mass spectrometric identification of skeletal muscle proteins 
Peptides were reconstituted in 16µl of 0.1% (v/v) formic acid. Followed by brief vortex, 
sonication and centrifugation for 20min in cellulose spin filter tubes at 14,000g. Samples 
were then transferred into individually labelled LC-MS vials and analysed on a 6340 Model 
Ion Trap LC mass spectrometer apparatus using electrospray ionization from Agilent  
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Technologies (Santa Clara, CA, USA). Samples were injected and followed previously 
optimised (Lewis et al., 2010b) running conditions of 10min gradient of 5-100% 
acetonitrile/0.1% formic acid and with a post run of 1min. Peptide separation was 
achieved with a nanoflow Agilent 1200 series system from Agilent Technologies, equipped 
with Zorbax 300SB C18 5µm, 4mm 40nl pre column and a Zorbax 300SB C18 5µm, 43mm 
x 75µm analytical reversed phase column with HPLC-Chip technology.  
Mobile phases were (A): 0.1% (v/v) formic acid, (B): 90% (v/v) acetonitrile and 0.1% (v/v) 
formic acid. Samples (6µl) were loaded into the enrichment column at a capillary flow rate 
of 4µl/min with a mix of A and B at a ratio of 19:1. Elution of the tryptic peptides was 
carried out on a linear gradient with a constant nano pump flow rate of 0.6µl/min. To 
eliminate any sample carryover a 5 min post time of solvent A was carried out. Capillary 
voltage maintained at 2,000V with temperature and flow rate of the drying gas at 3000C 
and 41/min, respectively. 
Distinct protein species were identified using database search engine, Mascot MS/MS 
Ion search from Matrix Science London, UK.  Each search performed followed the same 
criteria (i) two missed cleavages by trypsin, (ii) species Mus “musculus” as taxonomic 
category, (iii) oxidation of methionine as variable modification, (iv) mass tolerance of 
precursor ions ±2.5Da and product ions ±1Da and (v) carboxymethylated cysteine fixed  
modification. Identification of protein of interest were accepted once a Mascot score >49 
was confirmed with >2 peptides matched and pI and molecular weight matched the 
reference gel. Mascot score of >49 (corresponding to <p 0.05) offers a 95% confidence the 
match is correct.  
 
2.2.10 Immunoblot analysis  
Key proteins of interest were selected and antibodies purchased. Samples (10µg) were 
loaded onto 1D gel according to the experimental design with a molecular weight marker. 
Gel electrophoretic separation of 1D gel was carried out with a Mini-Protean II 
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electrophoresis rig from Bio-Rad Laboratories (Hemel-Hempstead, Herts., UK) and 
transferred onto nitrocellulose membrane using transfer system from Bio-Rad. Muscle 
proteins were run at 100V for 70min at 40C. Ponsceau S-Red staining was carried out on 
the nitrocellulose membrane and labelled appropriately.  
Prior to immune decoration, nitrocellulose sheets were blocked with milk solution (5% 
(w/v) fat-free milk powder in phosphate-buffered saline PBS) for 1 hour. Membranes 
were then incubated overnight with sufficiently diluted primary antibody solution with 
gentle agitation. Membranes were washed and incubated with secondary 
peroxidase-conjugated antibodies in blocking solution for 1 hour at room temperature. 
Following another wash step the immune-decorated protein bands were visualised 
with enhanced chemiluminescene (ECL) method from Roche Diagnostics (Mannheim, 
Germany) in a darkroom. Immunoblots were then analysed, densitometric scanning was 
performed with Image J software (NIH, Bethesda, Maryland, USA) and Graphpad prism 
statistical software (Graphpad software Inc.) 
 
2.2.11 Statistical Analysis 
Densitometric scanning of Immunoblots was performed with Image J software (NIH, 
Bethesda, Maryland, USA) and Graphpad prism statistical software (Graphpad software 
Inc.). Throughout this project a probability (p) value of 0.05 was used within a Student’s 
t-test, providing a 95% confidence our data is significant. 
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3 Proteomic profiling of age-related changes in the tibialis 
anterior muscle proteome of the mdx mouse model of 
dystrophinopathy  
 
3.1 Introduction  
X-linked Duchenne muscular dystrophy is an extremely progressive childhood 
neuromuscular disorder and can be characterised by primary genetic abnormalities in the 
dystrophin gene. The established mdx mouse model of dystrophinopathy exhibits 
progressive muscle tissue deterioration with age as a result aged mdx muscle specimens 
were analysed on a large-scale survey of potential age-related changes in the dystrophic 
phenotype. Since the mdx mouse tibialis anterior muscle is a commonly used model 
system in muscular dystrophy research, we investigated this particular tissue to determine 
the global changes in the dystrophic skeletal muscle proteome.  
 
3.1.1 Duchenne muscular dystrophy and tibialis anterior skeletal muscle  
The tibialis anterior is one of the most active muscles in the lower leg (Mesin et al., 
2010), displaying a relatively high level of resistance to fatigue or weakness during 
periods of intense exercise (Jones et al., 2009). This level of resistance makes the 
muscle particularly interesting to study with respect to the secondary effects of 
dystrophinopathy. Senescent mdx muscle has been studied as the dystrophic mouse 
muscle progressively deteriorates with age and as a result more closely resembles that of 
the neuromuscular pathology exhibited in Duchenne patients (Lefaucheur et al., 1995). 
Hence, aged mdx muscle represents an appropriate dystrophic phenotype for determining 
and identifying potential global alterations in the protein complement during aging.  
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3.1.2 Experimental design  
Comparative gel-based proteomic analysis of aged mdx tibialis anterior muscle. Muscle 
protein extracts were separated by two-dimensional gel electrophoresis and labelled with 
the fluorescent dye ruthenium II tris bathophenanthroline disulfonate. Then proteins with a 
significant change in their concentration were identified by mass spectrometry. Key 
proteomic findings were verified by immunoblot analysis. This report describes the 
analysis of RuBPs labelled aged dystrophic tibialis anterior tissue across 8 week, 12 
month and 22 month-old dystrophin-deficient mice along 3-10 pH range. Proteomic 
profiling established a change in abundance of 8 protein species across the tibialis 
anterior muscle age groups. Identified proteins were involved in various processes form 
cytosolic cycle, muscle metabolism and the cellular stress response. 
 
3.2 Results  
3.2.1 Comparative proteomic analysis of mdx tibialis anterior muscle  
High-resolution two-dimensional gel electrophoresis was carried out to separate 
the proteome from aged dystrophic mdx tibialis anterior muscle tissues. A pH-range 
of 3-10 in the first dimension was employed to establish a global proteomic pattern. 
Followed by post-electrophoretic labelling of the protein spots with fluorescent dye 
RuBPs. With the help of a Typhoon Trio variable imager and Progenesis 2-D 
analysis software, mdx skeletal muscle proteomes were compared. An altered 
concentration was revealed for 8 protein species, with 4 proteins being increased 
and 4 proteins showing decreased expression in aged mdx tissue. Mass 
spectrometry was then used to identify a number of unchanged landmark proteins 
and the significant muscle-associated proteins of interest from the tibialis anterior 
muscle and listed in Tables 3-1 and 3-2, respectively.  
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3.2.2 RuBPs analysis of landmark proteins in normal tibialis anterior 
muscle  
A list of unchanged landmark 2D protein spots from the tibialis anterior muscle are 
numbered 1 to 20 and marked by circles in the landmark master gel shown in figure 
3-1. The mass spectrometric identification of these unchanged landmark muscle 
proteins is listed in Table 3-1. This table contains the identified muscle-associated 
proteins names, international accession number, relative molecular masses, pI-
values, number of matched peptide sequences, Mascot scores, and percentage 
sequence coverage of major individual muscle protein species in aged dystrophic 
mdx tibialis anterior. 
Identified protein species ranged from a molecular mass of 17 kDa (myoglobin) to 
71 kDa (spot 2 unknown protein product) and with a pI-range from 4.6 pI (myosin 
light chain MLC3) to 8.7 pI (troponin TnI). Spots 1 to 22 represent major muscle-
associated protein species from ATP synthase (spot 1), unnamed protein product 
(spot 2), pyruvate kinase  (spot 3), enolase (spot 4), creatine kinase (spot 5) , actin 
(spot 6), tropomyosin (spots 7 and 8), malate dehydrogenase (spot 9), aldolase (spot 
10), phosphate dehydrogenase (spot 11), carbonic anhydrase (spot 12),
 triosephosphate (spots 13 and 14), troponin TnI (spot 15), adenylate kinase (spot 
16), various myosin light chains consisting of MLC1/3, MLC2, MLC3 (spots 17-20), 
parvalbumin (spot 21) and myoglobin (spot 22). A significant number of the landmark 
proteins identified are part of the contractile apparatus. 
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Figure 3-1 landmark 2D gel of normal mouse tibialis anterior muscle 
Figure 3-1 Two-dimensional gel electrophoretic analysis of normal tibialis anterior 
mouse muscle. Shown is a RuBPs-stained gel with 8 weeks old tibialis anterior 
muscle extracts. Major protein spots are numbered 1 to 22 and marked by circles. 
See Table 3-1 for the mass spectrometric identification of the 2D landmark proteins 
with no change during aging of the mdx model of Duchenne muscular dystrophy. 
The pH-values of the first dimension and molecular mass standards of the second 
dimension are shown on the top and on the left of the panels, respectively  
 
 
 
 
 
 40 
 
Table 3.1 List of unchanged landmark 2D protein spots from normal mouse tibialis 
anterior muscle 
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1 Mitochondrial ATP 
synthase  
AAH37127   5.24 56,632 23 64 456 
2 Unnamed protein 
[Mus musculus]  
BAC34145 5.75  70,730 12 21 230 
3 Pyruvate kinase, 
isozymes M1/M2 
NP_001240812 6.69  58,461 25 51 1149 
4 Enolase, beta, 
isoform 1   
NP_031959 6.73 47,337 21 56 450 
5 Creatine Kinase, 
 M-type 
NP_031736   6.58 43,250 23 47 509 
6 Actin, beta  CAA27396 5.78 39,446 12 41 103 
7 Tropomyosin, beta 
chain  
NP_033442 4.66 32,931 22 59 395 
8 Tropomyosin, beta 
chain  
NP_033442 4.66 32,933 15 32 241 
9 Malate 
dehydrogenase, 
cytosolic  
AAA37423  6.16  36,625 9 36 190 
10 Aldolase A, isoform 
2  
NP_031464   8.31 39,795 24 75 498 
11 Glyceraldehyde- 3-
phosphate 
dehydrogenase  
NP_032110    8.44 36,072 14 57 238 
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12 Carbonicanhydrase  
 CA3  
 NP_031632
  
6.89  29,638 12 43 431 
13 Triosephosphate  
isomerase   
AAB48543 5.62  22,720 11 62 248 
14 Triosephosphate  
isomerase   
AAB48543 5.62  22,720 11 68 638 
15 Troponin TnI, fast 
skeletal muscle 
NP_033431 8.65 21,515 5 20 150 
16 Adenylate kinase, 
isoenzyme 1  
NP_067490  5.7   23,330 14 70 184 
17 Myosin light  
chain MLC1/3  
NP_067260  4.98  
 
20,697 17 79  426 
18 Myosin light chain 
MLC2 
NP_058034  4.82  
 
19,057 
 
15 61 
 
216 
19 Myosin light chain 
MLC2 
NP_058034 4.82  19,059 19 81 391 
20 Myosin light  
chain MLC3 
AAH59087  
    
4.63 18,968 11 60 222 
21 Parvalbumin, alpha NP_038673 5.02 11,923 12 89 622 
22 Myoglobin NP_038621 7.07 17,116 5 37 98 
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3.2.3 Proteomic analysis of dystrophic tibialis anterior muscle during 
aging 
Following the optimisation and initial mass spectrometric identification of landmark 
muscle proteins in normal tibialis anterior mouse muscle, fluorescence high-
resolution two-dimensional gel electrophoresis  was  performed  to  determine  
potential  differences  in  aging-related  protein expression patterns in mdx tibialis 
anterior mouse muscle proteome. Figure 3-2 shows the analytical gels with 4 
biological repeats of 8 week, 12 month and 22 month old total mdx mouse muscle 
extracts. Panels labelled TA MDX 1-4, TA MDX 5-8 and TA MDX 9-12 represent 8 
week, 12 month and 22 month old tibialis anterior muscle preparations, respectively.  
A detailed denitometric analysis was performed on the 2D spot patterns of normal 
versus dystrophic mouse tibialis anterior muscle in order to determine potential 
differences in individual protein species. Densitometric analysis was carried out 
using a Typhoon Trio variable imager scanner and Samespot Progenesis 2-D 
analysis software was performed to establish differential expression patterns during 
the muscle aging. The detailed proteomic profiling of dystrophic tibialis anterior 
showed distinct age-related changes in 8 muscle protein species between 8 week 
and 22 month old total mdx mouse muscle preparations.  
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Figure 3-2 Two-dimensional gel electrophoretic analysis of aging mdx 
mouse tibialis anterior muscle 
Shown are RuBPs-stained gels from 8 weeks (TA MDX 1-4), 12 months (TA MDX 
5-8) and 22 months (TA MDX 9-12) old tibialis anterior muscle extracts. Fluorescent 
images are shown along the pH 3-10 range.  
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3.2.4 RuBPs analysis of dystrophic tibialis anterior muscle  
A list of the tibialis anterior proteins with significantly altered expression level in 
age-related dystrophic mdx tissue is shown in Table 3-2. Proteins with significant 
changes in expression levels are numbered 1 to 8 and marked by circles in the 
master gel Fig 3-3. The mass spectrometric identification of these altered muscle 
proteins is listed in Table 3-2. This table contains the identified muscle-associated 
proteins names, international accession number, relative molecular masses, pI-
values, number of matched peptide sequences, Mascot scores, percentage 
sequence coverage, and fold-change of individual muscle proteins affected in aged 
dystrophic mdx tibialis anterior.  
Protein species with an altered concentration in aged mdx tibialis anterior muscle 
ranged from a molecular mass of 23 kDa (heat shock protein Hsp27) to 224 kDa 
(myosin 3) and with a  pI-range  from  4.7 pI (tropomyosin)  to  8.5 pI (electron  
transferring flavoprotein). The expression levels showed an increased abundance for 
the carbonic anhydrase CA3 isoform (spots 1 and 4), the glycolytic enzyme aldolase 
protein (spot 2) and electron transferring flavoprotein (spot 3). While the expression 
levels of key cytosolic enzyme pyruvate kinase (spot 5), myosin 3 (spot 6), 
tropomyosin beta chain (spot 7) and the molecular chaperone Hsp27 (spot 8) were 
shown to be decreased in mdx aged tissue.  
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 Figure 3-3 Fluorescence two-dimensional gel electrophoretic analysis of mdx 
tibialis anterior muscle 
Figure 3-3 Fluorescence gel electrophoretic analysis of aged mdx mouse tibialis 
anterior muscle. Shown is a representative RuBPs-stained master gel with crude 
tissue extracts from mdx tibialis anterior muscle. Proteins with an age-related 
change in expression levels are numbered 1 to 8 and marked by circles. See Table 
3-2 for the mass spectrometric identification of the individual muscle-associated 
proteins. The pH-values of the first dimension and molecular mass standards of the 
second dimension are shown on the top and on the left of the panels, respectively. 
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 Table 3.2 List of identified muscle proteins with a significant change of 
abundance in aging mdx tibialis anterior muscle 
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1 Carbonic anhydrase 
CA3  
 NP031632 6.89  29,638 4 
 
26  
 
181 2.9 
 
2 Aldolase A 
isoform 2  
NP031464 8.31  39,795 2  14  85  2.3 
3 Electron transferring 
flavoprotein, beta 
EDL22660 
 
8.50  29,177 13 42  190 1.9 
4 Carbonic  anhydrase 
CA3 
NP031632  6.89 29,638 12 53 182 1.7 
5 Pyruvate kinase NP035229  7.18 58,388 7 18 440 -1.4 
6 Myosin 3 NP001078
847 
5.62 224,75
5 
9 5 141 -1.4 
7 Tropomyosin, beta 
chain  
NP033442 
 
4.66 32,933 3 14 126 -1.6 
8 Heat shock protein 
Hsp27 
AAA18335 6.45 22,945 2  15 550 -1.9 
 47 
 
3.2.5 Immunoblot analysis of dystrophic tibialis anterior muscle 
In order to further characterise the tibialis anterior phenotype, comparative 
immunoblotting was carried out following the mass spectrometric establishment of the 
age-related changes in the urea-soluble mdx muscle proteome. Immunoblotting was 
performed to investigate the concentration of the two most extensively altered new 
biomarkers, carbonic anhydrase CA3 and heat shock protein Hsp27 in normal versus 
dystrophic muscle preparations.  
Antibodies to β-dystroglycan (β-DG), a dystrophin-associated glycoprotein which 
forms the main trans-sarcolemmal linker among the extracellular matrix and the 
cytoskeleton in the fibre periphery, were used to confirm the dystrophic status of mdx 
muscle samples during aging. Immunoblotting of the glycoprotein (Figure 3-4) clearly 
shows the drastic reduction of β-DG in both 8 week and 22 month old mdx mouse 
tibialis anterior muscle, which is characteristic of dystrophinopathy.  
Immunoblotting of young versus old muscle samples with the CA3 isoform of 
carbonic anhydrase antibody (Figure 3-5) showed an increased abundance of the 
metabolic enzyme. While immunoblotting with the molecular chaperone Hsp27 
antibody (Figure 3-6) showed a decreased concentration of the small heat shock 
protein in dystrophin-deficient mdx muscle. Thus, both the CA3 fibre type-specific 
protein and the Hsp27 molecular stress protein represent suitable biomarker 
candidates of the dystrophic phenotype.  
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Figure 3-4 Immunoblotting analysis of dystrophin-associated glycoprotein β-
dystroglycan 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblots were labelled with the β-dystroglycan (β-DG) antibody. Lanes 1, 
2 and 3, 4 represent 8 week vs 22 month-old normal wild type vs dystrophic mdx tibialis 
anterior muscle, respectively. The comparative  blotting  was  statistically  verified  using  
an  unpaired  Student’s  t-test (n=4 replicates). Standard deviation represented by Error 
bars, (*p<0.05). 
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Figure 3-5 Immunoblotting analysis of carbonic anhydrase enzyme 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblots were labelled with the fiber type-specific enzyme carbonic 
anhydrase (CA3) antibody. Lanes 1, 2 and 3, 4 represent 8 week vs 22 month-old 
normal wild type vs dystrophic mdx tibialis anterior muscle, respectively. The 
comparative  blotting  was  statistically  verified  using  an  unpaired  Student’s  t-test (n=4 
replicates). Standard deviation represented by Error bars, (*p<0.05). 
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Figure 3-6 Immunoblotting analysis of the small heat shock protein 27 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblots were labelled with the molecular chaperone heat shock protein 
27 (Hsp27) antibody. Lanes 1, 2 and 3, 4 represent 8 week vs 22 month-old normal wild 
type vs dystrophic mdx tibialis anterior muscle, respectively. The comparative  blotting  
was  statistically  verified  using  an  unpaired  Student’s  t-test (n=4 replicates). Standard 
deviation represented by Error bars, (**p<0.005). 
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3.3 Discussion  
Duchenne muscular dystrophy is one of the most crippling childhood neuromuscular 
disorders (Emer, 2002), therefore meriting comprehensive large-scale studies into the 
establishment of detailed biomarker signatures of dystrophinopathy (Lewis et al., 2009; 
Griffin and Rosiers, 2009). In dystrophinopathy, the loss or almost complete absence 
of the crucial 427kDa cytoskeletal membrane protein dystrophin result in a drastic 
reduction of a large number of surface glycoproteins which leads to a loss of 
sarcolemmal integrity.   
In this chapter, proteomic profiling revealed that during the natural aging of  
the moderately dystrophic mouse tibialis anterior muscles a key number of skeletal 
muscle proteins change in abundance. Senescent mdx muscle has been studied as 
the dystrophic mouse muscle progressively deteriorates with age and as a result 
more closely resembles that of the neuromuscular pathology exhibited in Duchenne 
patients (Lefaucheur et al., 1995). Hence, aged mdx muscle represents an 
appropriate dystrophic phenotype for determining and identifying potential global 
alterations in the protein complement during aging.    
 
3.3.1 Proteomic expression changes of tibialis anterior analysis  
This chapter has summarised the results of a comparative proteomic analysis of 
moderately affected mdx tibialis anterior muscle from 8 week, 12 month and 22 month 
old mice. The identification of carbonic anhydrase, aldolase, electron transferring 
flavoprotein, tropomyosin, myosin, pyruvate kinase, and Hsp27 small heat shock 
protein as new markers of progressive muscular dystrophy might be helpful for the 
establishment of a detailed biomarker signature of Duchenne muscular dystrophy. 
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3.3.2 Elevated metabolic enzymes in mdx tissue 
The protein spot with the highest age-related increase was carbonic anhydrase 
isoform CA3 (Fremont et al., 1988). In general, carbonic anhydrases are involved in 
catalysing the reversible hydration of CO2 and are commonly distributed throughout the 
body (Geers, 2000). Several isoforms of this key metabolic enzyme are expressed by 
skeletal muscles in a fiber type-specific manner. The principal CA3 isoform is mostly 
located in the cytosolic fraction of type I and IIa fibers (Fremont et al., 1988). 
Interestingly, altered neuromuscular activity patterns, disuse atrophy, stretch-induced 
hypertrophy and metabolic adaptations significantly influence the expression of muscle 
carbonic anhydrases (Brownson et al., 1988; Brownson and Loughna, 1996; Cote et 
al., 1999). 
The increased concentration of the carbonic anhydrase CA3 isoform in aged mdx 
muscle, as revealed in this survey by mass spectrometry-based proteomics, could 
suggest an increased demand for effective CO2-removal during mdx fibre aging. That 
or perhaps since the CA3 isoform is mainly located in slower-twitching fibre 
populations, its change in density could also be contributed to age-related fibre type 
shifting in the mdx mouse tibialis anterior muscle. 
 
3.3.3 Perturbed stress response in mdx tissue 
The muscle-associated protein spot with the greatest reduction during aging of the 
mdx mouse tibialis anterior muscle was shown to be anti-apoptotic small heat shock 
protein, Hsp27. This suggests a potentially diminished anti-oxidative stress response in 
the dystrophic tibialis anterior muscle fibers and establishes that clear differences exist 
with respect to expression levels of small cellular heat shock proteins in moderately 
affected hind limb muscles compared to severely dystrophic diaphragm muscle in the 
mdx mouse model of dystrophinopathy, shown in chapter 4 (Doran et al., 2006a; Doran 
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et al., 2009a).  
 
3.3.4 Altered glycolytic and oxidative enzymes in mdx tissue 
The enzyme aldolase and pyruvate kinase catalyses the reversible cleavage of 
fructose-1,6-bisphosphate into glyceraldehyde-3-phosphate and dihydroxyacetone 
phosphate and  the  important oxidoreduction-phosphorylation  step  that transforms  
ADP  and  phosphoenolpyruvate  to yield  ATP  and  pyruvate,  respectively 
(Ohlendieck, 2001). These changes in glycolytic enzymes and mitochondrial proteins in 
mdx mouse tibialis anterior muscle suggest altered flux rates through the key metabolic 
pathway. With regards to the glycolytic pathway, pyruvate kinase is central for the 
regulation an enzymatic level (Ohlendieck, 2001). This vital role of pyruvate kinase in 
muscle metabolism makes its altered abundance in the mdx mouse tibialis anterior 
muscle a key finding. Mass spectrometry-based proteomics has clearly confirmed a 
glycolytic-to-oxidative metabolic shift during mdx skeletal muscle aging. 
Previously published surveys have shown pyruvate kinase as a potential biomarker 
for the overall aging process in skeletal muscle tissues (Doran et al., 2008; Doran et 
al., 2009a). The altered metabolic enzymes in the aged mdx mouse tibialis anterior 
muscle agree with the proteomic profiling of the golden retriever muscular dystrophy 
GRMD. In the dog model of dystrophinopathy various glycolytic and oxidative enzymes, 
were found to reduced, such as the aldolase and pyruvate kinase enzymes (Guevel et 
al., 2011).  
 
3.3.5 Other proteins 
While alterations of the contractile apparatus elements indicate down-stream effects 
of dystrophin deficiency on myosin and tropomyosin organisation, changed expression 
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levels in electron transferring flavoprotein suggest perturbed mdx muscle metabolism. 
The electron transferring flavoprotein beta polypeptide chain plays an important role in 
amino acid and mitochondrial fatty acid catabolism, and facilitates the transporting of 
electrons between flavoprotein dehydrogenases (Toogood and Scrutton, 2007). 
 
3.4 Conclusion  
In conclusion, the comparative proteomic profiling of dystrophic tibialis anterior  
muscle from 8 week versus 22 month-old mdx mice has revealed changes in expression 
levels in a number of key proteins during skeletal muscle aging. However, the level  
of  concentrations  altered  was  less  evident  in  the  moderately  dystrophic  tibialis  
anterior mouse muscle as compared to previously analysed aged mdx mouse diaphragm 
(Carberry et al., 2012a). These differing proteomic results agree with the 
pathophysiological notion that the aged mdx mouse diaphragm muscle is more severely 
dystrophic as compared to moderately affected mdx hind limb muscle.   
In the long-term, the continued proteomic identification of novel biomarkers of 
dystrophinopathy may potentially be useful for the establishment of a detailed and 
muscle subtype-specific biomarker signature of Duchenne muscular dystrophy. This 
would be important for monitoring disease progression, identifying novel therapeutic 
targets, improving diagnostic procedures and aid in the evaluation of new treatments, 
such as stem cell therapy or exon-skipping therapy. 
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4 Proteomic profiling of age-related changes in severely 
dystrophic Diaphragm muscle proteome of the mdx mouse 
model of dystrophinopathy  
 
4.1 Introduction  
Aging is a complex and fundamental biological process. The established mdx mouse 
model of dystrophinopathy exhibits progressive muscle tissue deterioration with age and 
more closely resembles the human pathology as a result aged mdx muscle specimens 
were analysed on a large-scale survey of potential age-related changes in the dystrophic 
phenotype. Thus, since senescent mdx mouse diaphragm muscle appears to represent a 
more suitable dystrophic phenotype, we investigated this particular tissue to determine the 
global changes in the protein complement during the natural aging process of the mdx 
muscle. 
4.1.1 Duchenne muscular dystrophy and Diaphragm skeletal muscle  
In contrast to the mdx hind limb muscles, the dystrophic mdx diaphragm exhibits severe 
symptoms of skeletal muscle fibre degeneration that more closely resembles that of the 
neuromuscular pathology exhibited in Duchenne patients than any other muscle 
(Lefaucheur et al., 1995). The Diaphragm is one of the most severely affected muscles in 
Duchenne patients and is the primary cause of death leading from respiratory problems in 
late twenties. Senescent mdx muscle has been studied as the severely dystrophic 
diaphragm mouse muscle progressively deteriorates with age making it more comparable 
to Duchenne muscular dystrophy.  
The  age-related pathogenesis  of  mdx  mouse muscle  is  characterised  by  
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progressive motor weakness (Lynch et al., 2001), a shortened life span with increased 
susceptibility to spontaneous rhabdomyosarcoma (Chamberlain et al., 2007), muscle 
periphery weakening triggered by the presence of branched fibres (Mouisel et al.,2010), 
severe loss  of  myofibres with concomitant replacement by connective tissue (Wineinger 
et al., 1998; Pastoret and  Sebille, 1995a; Pastoret and  Sebille, 1995b), a reduction in 
regenerative potential and changes in the crucial mTOR signaling pathway (Mouisel et 
al.,2010), and impaired structural and functional recovery after injury (Irintchev et al., 
1997). Hence, aged mdx muscle represents an appropriate dystrophic phenotype for 
determining and identifying potential global alterations in the protein complement during 
aging.  
 
4.1.2 Experimental design  
Comparative gel-based proteomic analysis of mdx Diaphragm muscle. Muscle protein 
extracts were separated by two-dimensional gel electrophoresis and labelled with the 
fluorescent dyes. Then proteins with a significant change in their concentration were 
identified by mass spectrometry. Key proteomic findings were verified by immunoblot 
analysis. This report describes both the analysis of RuBPs labelled aged dystrophic 
Diaphragm muscle across 8 week, 12 month and 22 month-old dystrophin-deficient mice 
along 3-10 pH range. Proteomic findings established an age-related change in 
abundance of 11 protein species across the aged mdx Diaphragm muscle.  
This was followed by a detailed comparative DIGE analysis of 22 month-old dystrophin-
deficient mice versus age-matched control mice across 3-11 NL pH range. Proteomic 
profiling established a significant change in abundance of 84 protein species in the aged 
mdx Diaphragm muscle. Identified proteins were involved in various processes form the 
extracellular matrix, contractile apparatus, metabolite transport, mitochondrial energy 
metabolism and the cellular stress response. 
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4.2 Results  
4.2.1 Comparative proteomic analysis of mdx diaphragm muscle  
High-resolution two-dimensional gel electrophoresis was carried out to separate 
the proteome from aged dystrophic mdx diaphragm muscle tissues. A pH-range of 
3-10 in the first dimension was employed to establish a global proteomic pattern. 
Followed by post-electrophoretic labelling of the protein spots with fluorescent dye 
RuBPs. With the help of a Typhoon Trio variable imager and Progenesis 2-D 
analysis software, mdx skeletal muscle proteomes were compared. An altered 
concentration was revealed for 11 protein species, with 10 proteins being increased 
and 1 protein showing decreased expression in senescent mdx tissue. Mass 
spectrometry was then used to identify these significant muscle-associated proteins 
of interest and listed in Table 4-1. 
 
4.2.2 Proteomic analysis of dystrophic diaphragm muscle during aging 
Fluorescence high-resolution two-dimensional electrophoresis in combination with MS 
analysis was performed to determine potential differences in aging-related protein 
expression patterns in mdx diaphragm muscle proteome. Figure 4-1 shows the analytical 
gels with 4 biological repeats of 8 week, 12 month and 22 month-old total mdx mouse 
muscle extracts. Panels labelled DIA MDX 1-4, DIA MDX 5-8 and DIA MDX 9-12 
represent 8 week, 12 month and 22 month-old dystrophic diaphragm muscle 
preparations, respectively.  
The overall 2D protein spot patterns of differently aged dystrophic muscle preparations 
were relatively comparable as a result a detailed denitometric analysis was performed in 
order to determine potential differences in individual protein species. Densitometric 
analysis was carried out using a Typhoon Trio variable imager scanner and Samespot 
Progenesis 2-D analysis software was performed to establish differential expression 
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patterns during the muscle aging. The detailed proteomic profiling of dystrophic 
diaphragm showed distinct age-related changes in 8 muscle protein species between 8 
week and 22 month old total mdx mouse muscle preparations.  
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Figure 4-1 Two-dimensional gel electrophoretic analysis of aging mdx mouse 
diaphragm muscle  
Shown are RuBPs-stained gels from 8 week (DIA MDX 1-4), 12 month (DIA MDX 
5-8) and 22 month (DIA MDX 9-12) old diaphragm muscle extracts. Fluorescent 
images are shown along the pH 3-10 range. 
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4.2.3 RuBPs analysis of dystrophic diaphragm muscle  
The overall degree of diaphragm proteins with significantly altered expression 
levels in age-related dystrophic mdx tissue was striking. Proteins with significant 
changes in expression levels are numbered 1 to 11 and marked by circles in the 
master gel Figure 4-2. The mass spectrometric identification of these altered muscle 
proteins is listed in Table 4-1. This table contains the identified muscle-associated 
proteins names, international accession number, relative molecular masses, pI-
values, number of matched peptide sequences, Mascot scores, percentage 
sequence coverage, and fold-change of individual muscle proteins affected in aged 
dystrophic mdx diaphragm.  
Protein species with an altered concentration in aged mdx diaphragm muscle 
ranged from a molecular mass of 20 kDa (αB-crystallin) to 110 kDa (collagen) and 
with a pI-range from 4.7 pI (dermatopontin) to 8.6 pI (myozenin). The expression 
levels showed an increased abundance for the collagen α-1(VI) chain (spot 1), the 
dermatopontin extracellular matrix protein (spot 2), the ubiquitin carboxyl-terminal 
hydrolase enzyme (spot 3), the αB-crystallin small heat shock protein (spot 4), α-2 
actinin (spot 5), the ferritin heavy chain (spot 6), vimentin (spot 7), the fibrinogen γ 
chain (spot 8) mimecan (spot 9) and apolipoprotein E (spot 10). While the 
expression level of myozenin (spot 11) was shown to be decreased in mdx aged 
diaphragm muscle. 
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Figure 4-2 Fluorescence gel electrophoretic analysis of aged mdx mouse 
diaphragm muscle 
Shown is a representative RuBPs-stained master gel with crude tissue extracts 
from mdx diaphragm muscle. Proteins with an age-related change in expression 
levels are numbered 1 to 11 and marked by circles. See Table 4-1 for the mass 
spectrometric identification of the individual muscle-associated proteins. The pH-
values of the first dimension and molecular mass standards of the second dimension 
are shown on the top and on the left of the panels, respectively. 
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 Table 4.1 List of identified muscle proteins with a significant change of 
abundance in aging mdx diaphragm muscle 
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1 Collagen α-1(VI) 
chain 
NP034063 5.20 109,582  12 15  259 3.6 6.3 
2 Dermatopontin  NP062733 4.70  24,559 4  21 122 5.4 6.1 
3 Ubiquitin carboxyl-
terminal hydrolase 
enzyme 
AAD51029 5.33  25,170 4  30 83 3.5 4.1 
4 αB-crystallin  NP034094  6.76 20,056 7 38 113 3.7 4 
5 α-2 actinin AAK64510  5.34 104,447 4 5 196 4.3 3.6 
6 Ferritin heavy 
chain  
NP034369 5.53 21,227 3 18 50 2.6 2.6 
7 Vimentin CAA39807 5.06 53,747 14 37 140 2.5 2.5 
8 Fibrinogen γ chain NP598623 5.54 50,056  4 12 65 1.9 2.5 
9 Mimecan NP032786 5.52 34,339 5 19 293 1.8 2.2 
10 Apolipoprotein E AAA37252 5.82 33,206 8 32 169 2 1.5 
11 Myozenin-1 NP067483 8.57 31,438 9 54 174 3 -3.6 
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4.2.4 Comparative proteomic analysis of mdx versus wild-type 
diaphragm muscle  
In order to establish the extent of secondary changes in the senescent mdx mouse 
diaphragm proteome due to absence in the membrane cytoskeletal dystrophin 
protein, the urea-soluble protein complement from 22 month-old wild type versus 
age-matched dystrophic diaphragm mouse muscle was investigated. Following 
fluorescent labelling of wild type or mdx samples with the CyDyes Cy3, as well as 
fluor tagging of the pooled standard using the CyDye Cy5, high-resolution two-
dimensional gel electrophoresis was carried out to separate the proteome from aged 
dystrophic mdx diaphragm muscle.  
A pH-range of 3-11NL in the first dimension was employed to establish a global 
proteomic pattern. Detailed densitometric analysis was carried out using a Typhoon 
Trio variable imager scanner and Samespot Progenesis 2-D analysis software was 
performed to establish differential expression patterns of the aged muscle. Figure 4-
3 shows the 2-D DIGE analysis of 22 month-old dystrophic mdx versus aged-
matched normal diaphragm skeletal muscle with 4 biological repeats. 
Panels labelled (MDX 1-4) and (WT 1-4) represent the Cy3-labelled gels of total 
muscle extracts from mdx versus normal wild type mice as well as pooled standard 
Cy5-labelled gels, respectively. DIGE images are shown for the pH 3-11NL range. 
The detailed proteomic profiling of dystrophic diaphragm revealed distinct changes in 
concentration for 84 protein species, with 27 proteins being increased and 57 
proteins showing decreased expression in the total mdx mouse muscle preparations 
(Fig 4-4). Mass spectrometry was then used to identify these significant muscle-
associated proteins of interest and listed in Table 4-2. 
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Figure 4-3 Shown is the 2-D DIGE analysis of dystrophic mdx versus normal 
diaphragm skeletal muscle 
Shown are Cy3-labelled gels of total muscle extracts from mdx (MDX1 to MDX4) 
versus normal wild type (WT1 to WT4) mice, as well as pooled standard Cy5-labelled 
gels. DIGE images are shown for the pH 3-11NL range.  
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Figure 4-4 Overview of the standard 2D-DIGE image analysis process used in 
muscle proteomics 
Shown are a 2D-DIGE master gel of the analysis of normal versus dystrophic aged 
diaphragm muscle (A), the visualization of the altered levels of parvalbumin (B, D, E) and 
cvHsp (C, F, G), the range of detected alterations between normal and dystrophic samples 
(H, I) and the graphical 3D montage of the drastic reduction in parvalbumin (J, K) and 
increase in expression of cvHsp (L, M) in dystrophic muscle. 
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4.2.5 DIGE analysis of dystrophic Diaphragm muscle  
The overall number and degree of diaphragm proteins with significantly altered 
expression levels in aged dystrophic mdx tissue was drastic with 84 changes. 
Showing a significant increase in 27 and decrease in 57 proteins in dystrophin-
deficient and aged diaphragm. Proteins with significant changes in expression levels 
are numbered 1 to 84 and marked by circles in the master gel Fig 4-5. The mass 
spectrometric identification of these altered muscle proteins is listed in Table 4-2. 
This table contains the identified muscle-associated proteins names, international 
accession number, relative molecular masses, pI-values, number of matched 
peptide sequences, Mascot scores, percentage sequence coverage, and fold-
change of individual muscle proteins affected in aged dystrophic mdx diaphragm. 
Protein species with an altered concentration in aged mdx diaphragm muscle ranged 
from a molecular mass of 11.9 kDa (Parvalbumin) to 87.7 kDa (Nebulin fragment) 
and with a pI-range from 4.07 pI (Troponin C) to 9.19 pI (Nebulin fragment). 
Identified proteins were involved in various processes form the extracellular matrix, 
contractile apparatus, ion homeostasis, mitochondrial energy metabolism and the 
cellular stress response. 
The expression levels showed an increased abundance for the extracellular matrix 
protein dermatopontin (spot 1, 2, 3), the HspB7/cvHsp small heat shock protein (spot 
4), the myosin light chain 6B (spot 5), unnamed protein product (spots 7, 17, 26), 
beta actin (spot 10), Hsp70 heat shock protein cognate (spots 11, 21, 22), 
mitochondrial stress 70 protein (spots 12, 24), gamma actin smooth muscle (spot 
13), nebulin fragment (spot 14), lumican (spot 15), prohibitin protein (spot 16), 
transferrin (spot 18), annexin A5 (spot 19), Hsp8 heat shock protein (spot 23), Fmod 
protein (spot 25) and glucose regulated 78 kDa protein (spot 27). 
In contrast, a decreased expression level was shown for alpha parvalbumin (spots 
29, 80, 84), for various isoforms of malate dehydrogenase (spots 30, 39, 41, 46, 49, 
57, 77), ATP-synthase (spots 31, 43, 59, 63), isocitrate dehydrogenase (spot 35), 
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alpha actin (spot 36), coiled-coil-helix-coiled-coil-helix domain-containing 
mitochondrial protein 3 (spot 37), Cu/Zn superoxide dismutase (spot 38), 
peroxiredoxin (spot 40), cytochrome c oxidase (spot 42), Hsp beta-6 heat shock 
protein (spot 44), creatine kinase (spots 45, 52, 74), troponin C (spots 47, 48), 
myoglobin (spots 50, 71, 72, 76, 79, 81), FABP3 fatty acid-binding protein (spots 53, 
78, 82, 83), NCS-1 calcium-binding protein (spot 54), electron transferring 
flavoprotein (spots 55, 60), isocitrate dehydrogenase (spot 56), cofilin-2 (spot 61), 
AK1adenylate kinase (spot 62), MLC2 myosin light chain (spots 65, 73), fumarate 
hydratase (spot 66), ubiquinone biosynthesis COQ9 protein (spot 68) and 
calsequestrin (spot 69). 
A number of proteins with differential expression patterns were identified as 
tropomyosin beta chain, myosin light chain 1/3 and the alpha-fetoprotein. Individual 
2D protein spots representing the tropomyosin beta chain isoforms exhibited both 
increased (spots 6, 9) and decreased (spots 32, 64) levels. In the case of the myosin 
light chain 1/3 1f muscle isoform, both increased (spot 8) and decreased (spots 28, 
51, 67, 75) concentrations were determined. The alpha-fetoprotein was shown to be 
increased (spot 20) and decreased (spot 33) in concentration. Although spots 12, 50, 
54, 72 were only had 1 matched peptide, they were included in Table 4-2 based on 
their mascot scores of 57, 61, 48, 59, respectively. All other proteins species were 
identified by at least 2 peptides or more. 
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Figure 4-5 Fluorescence 2D-DIGE master gel of aged mdx diaphragm muscle 
Shown is a representative DIGE master gel of aged mdx diaphragm muscle. 
Proteins with a significant change in expression levels are numbered 1 to 84 and 
marked by circles. See Table 4-2 for the mass spectrometric identification of the 
individual muscle-associated proteins. The pH-values of the first dimension and 
molecular mass standards of the second dimension are shown on the top and on the 
left of the panels, respectively. 
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Table 4.2 List of identified proteins from 2D-DIGE analyses that exhibit a 
drastic change in abundance in the aged mdx diaphragm 
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1 Dermatopontin NP_062733 4.7 24,559 5 28 73 5.9 
2 Dermatopontin NP_062733 4.7 24,559 7 37 111 4.4 
3 Dermatopontin NP_062733 4.7 24,559 6 26 100 3.4 
4 
Heat shock protein 
HspB7 (beta7, cvHsp) 
NP_038896 5.95 18,681 5 38 87 3.3 
5 Myosin light chain 6B  NP_758463 5.41 22,851 14 74 181 3.1 
6 
Tropomyosin, beta 
chain isoform 1 
NP_033442 4.66 32,933 22 61 319 2.9 
7 
Unnamed protein 
product 
BAE35818 5.78 70,776 15 30 286 2.8 
8 
Myosin light chain 1/3, 
isoform 1f, muscle 
NP_067260 4.98 20,697 2 12 97 2.7 
9 
Tropomyosin, beta 
chain isoform 1 
NP_033442 4.66 32,933 11 35 107 2.7 
10 
Actin, beta (aa 27–
375) 
CAA27396 5.78 39,451 9 21 124 2.6 
11 
Heat shock protein 
Hsp70 cognate 
AAA37869 5.37 71,025 11 23 110 2.6 
12 
Mitochondrial stress-
70 protein  
BAA04493 5.91 73,773 1 1 57 2.6 
13 
Actin, gamma, 
smooth muscle  
AAC52237 5.36 43,258 5 16 81 2.6 
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14 Nebulin (fragment) AAF59979 9.19 87,694 4 7 53 2.5 
15 Lumican  AAB35361 5.84 38,733 2 5 103 2.4 
16 Prohibitin  NP_032857 5.57 29,860 15 69 350 2.4 
17 
Unnamed protein 
product 
BAC34145 5.75 70,766 8 14 129 2.4 
18 Transferrin AAL34533 6.92 78,832 19 24 168 2.3 
19 Annexin A5 NP_033803 4.83 35,788 16 45 249 2.3 
20 Alpha-fetoprotein AAA37190 5.47 48,819 2 6 112 2.2 
21 
Heat shock protein 
Hsp70 cognate  
AAA37869 5.37 71,025 11 23 110 2.2 
22 
Heat shock protein 
Hsp70 cognate  
AAA37869 5.37 71,025 4 6 77 2.2 
23 Heat shock protein 8 AAH66191 5.28 71,060 11 23 110 2.2 
24 
Mitochondrial stress-
70 protein  
BAA04493 5.91 73,773 5 9 71 2.1 
25 Fmod protein AAH52673 5.56 46,637 2 4 92 2.1 
26 
Unnamed protein 
product  
BAC34145 5.75 70,766 8 17 254 2.1 
27 
78 kDa glucose-
regulated protein  
BAA11462 5.09 72,528 7 15 112 2.0 
28 
Myosin light chain 1/3, 
isoform 1f, muscle 
NP_067260 4.98 20,697 15 63 222 −2.0 
29 Parvalbumin, alpha  NP_038673 5.02 11,923 6 57 156 −2.0 
30 
Malate 
dehydrogenase  
AAA39509 8.93 36,052 3 11 90 −2.1 
32 
Tropomyosin, beta 
chain 
gi|11875203 4.66 32,933 11 32 180 −2.1 
33 Alpha-fetoprotein AAA37190 5.47 48,819 2 5 95 −2.1 
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34 
Isocitrate 
dehydrogenase 
subunit alpha 
NP_083849 6.27 40,077 6 20 242 −2.1 
35 
L-lactate 
dehydrogenase B 
chain  
NP_032518 5.7 36,839 5 12 54 −2.1 
36 Actin, alpha, cardiac gi|387090 5.23 42,048 2 7 51 −2.1 
37 
Coiled-coil-helix-
coiled-coil-helix  
domain-containing 
protein 3, 
mitochondrial 
NP_079612 8.56 26,550 5 24 80 −2.1 
38 
Cu/Zn superoxide 
dismutase 
1513495A 6.03 15,926 5 41 147 −2.1 
39 
Malate 
dehydrogenase 
mitochondrial  
NP_032643 8.93 36,053 12 45 256 −2.1 
40 Peroxiredoxin Prdx1 NP_035164 8.26 22,394 11 47 97 −2.1 
41 
Malate 
dehydrogenase 
mitochondrial 
NP_032643 8.93 36,053 15 56 343 −2.1 
42 
Cytochrome c 
oxidase, subunit Va 
CAA34085 6.08 16,252 8 48 125 −2.2 
43 
ATP synthase, 
mitochondrial F0 
complex 
AAH16547 5.52 18,810 5 47 148 −2.2 
44 
Heat shock protein 
Hsp beta-6 
NP_0010124
01 
5.64 17,568 6 51 130 −2.2 
45 
Creatine kinase, M-
type 
NP_031736 6.58 43,250 9 27 276 −2.2 
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46 
Malate 
dehydrogenasemitoch
ondrial 
NP_032643 8.93 36,053 9 36 243 −2.2 
47 
Troponin C, skeletal 
muscle 
NP_033420 4.07 18,156 3 28 238 −2.2 
48 
Troponin C, skeletal 
muscle 
NP_033420 4.07 18,156 8 53 774 −2.3 
49 
Malate 
dehydrogenase 2, 
mitochondrial 
ABD77283 7.7 32,121 7 28 365 −2.3 
50 Myoglobin NP_038621 7.07 17,117 1 9 61 −2.3 
51 
Myosin light chain 1/3, 
isoform 1f, muscle 
NP_067260 4.98 20,697 4 17 93 −2.3 
52 
Creatine kinase, M-
type 
NP_031736 6.58 43,250 10 28 297 −2.3 
53 
Fatty acid-binding 
protein FABP3 
NP_034304 6.11 14,810 6 48 157 −2.3 
54 
Calcium-binding 
protein NCS-1-like 
XP_0039459
63 
6.49 12,957 1 17 48 −2.4 
55 
Electron transferring 
flavoprotein,alpha 
AAH03432 8.62 35,366 11 44 449 −2.4 
56 
Isocitrate 
dehydrogenase 
subunit alpha 
NP_083849 6.27 40,077 6 19 167 −2.4 
57 
Malate 
dehydrogenase 2, 
mitochondrial 
ABD77283 7.7 32,121 2 8 85 −2.4 
58 
Creatine kinase, M-
type 
NP_031736 6.58 43,250 11 33 404 −2.4 
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59 
ATP synthase, 
subunit d, 
mitochondrial 
NP_082138 5.52 18,796 11 70 168 −2.4 
60 
Electron transfer 
flavoprotein, subunit 
alpha 
NP_663590 8.62 35,336 8 39 195 −2.5 
61 Cofilin-2 NP_031714 7.66 18,814 5 36 158 −2.5 
62 
Adenylate kinase, 
isoenzyme AK1 
NP_067490 5.7 23,334 6 36 104 −2.5 
63 
ATP synthase, beta-
subunit 
AAB86421 5.14 56,344 6 16 301 −2.6 
64 
Tropomyosin, beta 
chain 
gi|11875203 4.66 32,920 10 25 129 −2.6 
65 
Myosin light chain 
MLC2, skeletal 
muscle 
NP_058034 4.82 19,059 2 8 93 −2.7 
66 Fumarate hydratase 1 AAH06048 9.12 54,568 6 17 173 −2.8 
67 
Myosin light chain 1/3, 
isoform 1f, muscle 
NP_067260 4.98 20,697 11 53 201 −2.9 
68 
Ubiquinone 
biosynthesis protein 
COQ9 
NP_080728 5.6 35,235 5 21 150 −3.0 
69 
Calsequestrin, 
skeletal muscle 
AAC63616 3.93 45,619 8 22 143 −3.1 
70 
Creatine kinase, M-
type 
NP_031736 6.58 43,250 10 31 505 −3.1 
71 Myoglobin NP_038621 7.07 17,117 6 48 124 −3.1 
72 Myoglobin NP_038621 7.07 17,117 1 11 59 −3.2 
73 
Myosin light chain 
MLC2, skeletal 
muscle 
NP_058034 4.82 19,059 15 68 267 −3.4 
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74 
Creatine kinase, M-
type 
NP_031736 6.58 43,250 11 31 266 −3.5 
75 
Myosin light chain 1/3, 
isoform 1f, muscle 
NP_067260 4.98 20,697 2 12 87 −3.6 
76 Myoglobin NP_038621 7.07 17,117 2 21 91 −3.7 
77 
Malate 
dehydrogenase  
AAA39509 8.93 36,052 5 20 126 −3.7 
78 
Fatty acid-binding 
protein FABP3 
NP_034304 6.11 14,810 11 77 426 −3.7 
79 Myoglobin NP_038621 7.07 17,117 6 46 129 −4.0 
80 Parvalbumin, alpha  NP_038673 5.02 11,923 6 57 285 −4.0 
81 Myoglobin NP_038621 7.07 17,117 6 41 89 −4.3 
82 
Fatty acid-binding 
protein FABP3 
NP_034304 6.11 14,810 7 63 188 −5.3 
83 
Fatty acid-binding 
protein FABP3 
NP_034304 6.11 14,810 9 71 532 −5.3 
84 Parvalbumin alpha  NP_038673 5.02 11,923 8 57 431 −10.5 
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Figure 4-6 Protein interaction map of mdx diaphragm muscle proteins 
The STRING database of known and predicted protein associations (version 9.1) was 
used to generate a protein interaction map that includes direct physical and indirect 
functional protein linkages. This analysis was performed with proteins that exhibited a 
changed abundance in aged mdx diaphragm (Table 4.2).  
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4.2.6 Immunoblot analysis of of altered proteins in aged mdx diaphragm 
muscle 
In order to further characterise the most drastic changes in aged mdx diaphragm as 
shown by proteomics, comparative immunoblotting was carried out. While laminin 
expression was shown not to be affected in muscular dystrophy (Fig 4-7B), the dystrophin-
associated glycoprotein b-dystroglycan showed a drastic reduction in dystrophic muscle 
(Fig 4-7C) confirming the mutant status of the mdx tissue used in this study. In contrast, 
the extracellular matrix protein collagen was shown to be increased during the aging 
process (Fig 4-7A), which agrees with the previous senescent and dystrophic aged mdx 
diaphragm muscle study. This exhibited a general increase of collagen in 12 month and 22 
month-old muscle. However, aged dystrophic mdx diaphragm muscle showed a 
significantly higher increase in collagen expression as compared to aged normal muscle.  
FigureS 4-7(D-I) shows immunoblot labelling of key proteins with an increased or 
decreased expression in aged mdx diaphragm muscle. Increased markers of the 
senescent mdx diaphragm were verified to be the small heat shock protein cvHsp, the 
molecular chaperone Hsp70 and the mitochondrial protein prohibitin figures 4-7D, E and F, 
respectively. In contrast the cytosolic Ca2+- binding alpha parvalbumin protein, the luminal 
Ca2+- binding calsequestrin protein of the sarcoplasmic reticulum and mitochondrial ATP 
synthase figures 4-7G, H and I, respectively were shown to be decreased markers of 
senescent mdx diaphragm. The immunoblot of calsequestrin showed besides the major 
60kDa band of its monomer there are also several high molecular mass bands that 
represent calsequestrin-like proteins. All bands labelled by antibodies to calsequestrin 
showed a reduced abundance in the dystrophic diaphragm.  
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Figure 4-7A Immunoblotting analysis of extracellular matrix protein collagen  
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowheads, with graphical presentation of the statistical 
evaluation. Immunoblots were labelled with the collagen antibody. Lanes 1-3 and 4-
6 represent 8 week, 12 month and 22 month-old normal wild type vs dystrophic mdx 
diaphragm muscle, respectively.  The comparative blotting was statistically verified 
using an unpaired Student’s t-test (n=4 replicates). Standard deviation represented 
by Error bars, (***p<0.001). 
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Figure 4-7B Immunoblotting analysis of unchanged extracellular matrix laminin 
Shown are representative blots with expanded views of immuno-decorated protein bands 
indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the laminin antibody. Lanes 1, 2 represent 22 month-old 
normal wild type vs dystrophic mdx diaphragm muscle, respectively. The comparative 
blotting  was  statistically  verified  using  an  unpaired  Student’s t-test (n=4 replicates).  
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Figure 4-7C Immunoblotting analysis of of dystrophin-associated glycoprotein β-
dystroglycan 
Shown are representative blots with expanded views of immuno-decorated protein bands 
indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the dystrophin-associated glycoprotein β-dystroglycan 
antibody. Lanes 1, 2 represent 22 month-old normal wild type vs dystrophic mdx diaphragm 
muscle, respectively. The comparative blotting was statistically verified using an unpaired 
Student’s t-test (n=4 replicates). Standard deviation represented by Error bars, (**p<0.005). 
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Figure 4-7D Immunoblotting analysis of small heat shock protein cvHSP 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in normal versus aged mdx 
diaphragm muscle. Immunoblots were labelled with the cvHSP antibody. Lanes 1, 2 
represent 22 month-old normal wild type vs dystrophic mdx diaphragm muscle, 
respectively.  The comparative blotting was statistically verified using an unpaired 
Student’s t-test (n=4 replicates). Standard deviation represented by Error bars, 
(***p<0.001). 
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Figure 4-7E Immunoblotting analysis of large heat shock protein 70 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in normal versus aged mdx 
diaphragm muscle. Immunoblots were labelled with the Hsp70 antibody. Lanes 1, 2 
represent 22 month-old normal wild type vs dystrophic mdx diaphragm muscle, 
respectively. The comparative blotting was statistically verified using an unpaired  
Student’s t-test (n=4 replicates). Standard deviation represented by Error bars, 
(*p<0.05). 
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Figure 4-7F Immunoblotting analysis of prohibitin protein  
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in normal versus aged mdx 
diaphragm muscle. Immunoblots were labelled with the prohibitin antibody. Lanes 1, 2 
represent 22 month-old normal wild type vs dystrophic mdx diaphragm muscle, 
respectively. The comparative blotting was statistically verified using an unpaired 
Student’s t-test (n=4 replicates). Standard deviation represented by Error bars, 
(**p<0.005). 
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Figure 4-7G Immunoblotting analysis of calcium-binding protein parvalbumin 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in normal versus aged mdx 
diaphragm muscle. Immunoblots were labelled with the parvalbumin antibody. Lanes 1, 2 
represent 22 month-old normal wild type vs dystrophic mdx diaphragm muscle, 
respectively. The comparative blotting was statistically verified using an unpaired 
Student’s t-test (n=4 replicates). Standard deviation represented by Error bars, 
(***p<0.001). 
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Figure 4-7H Immunoblotting analysis of the luminal Ca2+-binding protein 
calsequestrin  
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in normal versus aged mdx 
diaphragm muscle. Immunoblots were labelled with the calsequestrin antibody. Lanes 1, 
2 represent 22 month-old normal wild type vs dystrophic mdx diaphragm muscle, 
respectively. The comparative blotting was statistically verified using an unpaired 
Student’s t-test (n=4 replicates). Standard deviation represented by Error bars, 
(*p<0.05). 
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Figure 4-7I Immunoblotting analysis of mitochondrial enzyme ATP synthase 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in normal versus aged mdx 
diaphragm muscle. Immunoblots were labelled with the mitochondrial ATP synthase 
antibody. Lanes 1, 2 represent 22 month-old normal wild type vs dystrophic mdx 
diaphragm muscle, respectively. The comparative  blotting  was  statistically  verified  
using  an  unpaired  Student’s  t-test (n=4 replicates). Standard deviation represented by 
Error bars, (*p<0.05). 
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4.3 Discussion  
In this chapter, proteomic profiling revealed that during the natural aging of the 
severely dystrophic mdx diaphragm muscles a key number of skeletal muscle 
proteins change in abundance. Senescent mdx muscle has been studied as the 
dystrophic muscle progressively deteriorates with age and as a result more closely 
resembles that of the neuromuscular pathology exhibited in Duchenne patients 
(Lefaucheur et al., 1995).   
The  age-related pathogenesis  of  mdx  mouse muscle  is  characterised  by  
progressive motor weakness (Lynch et al., 2001), a shortened life span with 
increased susceptibility to spontaneous rhabdomyosarcoma (Chamberlain et al., 
2007), muscle periphery weakening triggered by the presence of branched fibres 
(Head, 2010), severe loss  of  myofibres with concomitant replacement by 
connective tissue (Wineinger et al., 1998; Pastoret and  Sebille, 1995a; Pastoret 
and  Sebille, 1995b), a reduction in regenerative potential and changes in the 
crucial mTOR signaling pathway (Mouisel et al.,2010), and impaired structural and 
functional recovery after injury (Irintchev et al., 1997). Hence, aged mdx muscle 
represents an appropriate dystrophic phenotype for determining and identifying 
potential global alterations in the protein complement during aging. This chapter 
has summarised the results of a comparative proteomic analysis of severely 
affected mdx diaphragm muscle from aging 8 week versus 22 month-old mice as 
well as a comprehensive aged-matched 22 month-old dystrophic diaphragm versus 
22 month-old control mice. 
 
4.3.1 Proteomic expression changes of diaphragm analysis during 
aging 
Dystrophic mdx diaphragm muscle exhibited changed expression levels in 11 
protein species during skeletal muscle aging. Alterations in the aging mdx 
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diaphragm proteome indicate elevated levels of fibrosis, an increased stress 
response and an escalation in cytoskeletal elements perhaps compensating the 
lack of dystrophin. These proteomic results support the idea of more extensively 
perturbed protein concentrations in dystrophin-deficient mdx diaphragm tissue as 
compared to other mdx muscle subtypes (Lewis et al., 2009). 
 
4.3.2 Increased extracellular matrix proteins in aging mdx tissue 
The approximately 6-fold increase of collagen and dermatopontin in aging mdx 
diaphragm muscle are key proteomic findings and reveal the dystrophic status of 
this muscle type. Immunoblotting analysis clearly shows the dramatic increase of 
collagen in the mdx diaphragm supporting the mass spectrometric results in table 
4-1 and 4-2. While it is known that collagen levels are elevated in the extracellular 
matrix of the skeletal muscle during the natural aging process (Kragstrup et al., 
2011), the mdx dystrophic phenotype demonstrates an intensified age-related 
increase of collagen α-1(VI) chain. Collagen is the key protein component of 
connective tissue and is particularly enriched in the endomysium of the skeletal 
muscles. Previous studies have highlighted increase amounts of mRNA in the mdx 
diaphragm (Goldspink et al., 1994), which agrees with the elevated collagen protein 
levels and supports the notion of severe fibrosis in the mdx tissue (Graham et al., 
2010; Trensz et al., 2010)   
Dermatopontin the non-collagenous extracellular matrix protein plays a role in 
matrix assembly and cell-matrix interactions (Okamoto and Fujiwara, 2006) and 
also known as tyrosine-rich acidic matrix protein (TRAMP) (Forbes et al., 1994)). 
TRAMP seems to regulate interactions of transforming growth factor beta (TGF-β), 
fibronectin and decorin (Kato et al., 2011). Its increased abundance in mdx 
diaphragm is possibly due to greater demands for collagen matrix organisation 
within the dystrophic muscle tissues.  
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4.3.3 Perturbed stress response and cytoskeletal disruption in aging 
mdx tissue 
The increased levels of αB-crystallin and vimentin suggests an intensified cellular 
stress response and an up-regulation of cytoskeletal elements in mdx dystrophic 
muscle, respectively, which supports previous proteomic reports (Doran et al., 
2006a). 
 
4.3.4 Other proteins  
Increased concentrations of fibrinogen protein in aged mdx diaphragm, as 
indicated by proteomics, agree with a previous report (Vidal et al., 2008). 
Fibrinogen appears to play a crucial role in fibrosis through a TGF-β or alternative 
macrophage activation pathway in dystrophinopathy.  
 
4.3.5 Proteomic expression changes of aged diaphragm analysis   
The comparative proteomic analysis of the naturally aged diaphragm versus 
dystrophin-deficient mdx diaphragm shown here establishes that the fluorescence 
difference in-gel electrophoresis with optimised animal model proteomics can be 
important for the identification of new protein biomarkers candidates involved in the 
molecular pathogenesis of dystrophinopathy. Figure 14 illustrates an overview of 
the proteomic results from the senescent mdx mouse model survey for Duchenne 
muscular dystrophy.  
Global changes in structural proteins, extracellular proteins, contractile proteins, 
molecular chaperones, calcium-binding proteins, glycolytic enzymes, mitochondrial 
enzymes and metabolite transporters suggest changes in the cytoskeletal complex 
and its indirect linkage to the extracellular matrix, reorganisations within the 
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actomyosin apparatus, an intensified cellular stress response, compromised ion 
handling and metabolic disturbances. Overall, this analysis revealed that protein 
expression patterns are severely changed in the dystrophin-deficient mdx 
diaphragm muscle and that these pathobiochemical alterations are more intense as 
compared to that of the mdx hind limb muscles examined in this thesis 
(Rayavarapu  et al., 2013; Ge et al., 2003; Carberry et al., 2012b).  
 
4.3.6 Increased extracellular matrix proteins in aged mdx tissue 
Elevated levels of dermatopontin and the resulting increase in collagen, as 
indicated here by proteomics and immunoblotting, respectively, supports the initial 
RuBPs aging survey of increased connective tissue in the dystrophic mdx 
diaphragm (Carberry et al., 2012a). 
 
4.3.7 Perturbed stress response in aged mdx tissue 
Increased levels of fibrosis appear to be accompanied by an intensified cellular 
stress response with the up-regulation of various heat shock proteins. In the form of 
several isoforms of Hsp70 and the muscle-specific molecular chaperone cvHsp, 
this supports the general principle of severe cellular stress in dystrophinopathy 
(Carberry et al., 2013a). The various isoforms of Hsp70 play a main role in skeletal 
muscle stress in response to injury, oxidative conditions, reperfusion-induced ischemia, 
excessive exercise and neuromuscular disorders (Liu et al., 2006). 
During periods of muscle stress molecular chaperone regulation has been shown to 
be crucial in protecting muscle from damage (Maglara et al., 2003). In general, stress 
proteins facilitate in protein-protein interactions by helping to stabilise misfolded 
proteins or peptide clusters as well as regulating there degradation and elimination in 
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order to prevent harmful unwanted accumulation of non-functional protein  aggregates 
(Boluyt  et  al., 2006). Hence, the observed increase in expression of mitochondrial 
Hsp70 isoforms can be seen as a compensatory mechanism to protect dystrophic 
fibres from excessive oxidative stress and supporting previous reports on elevated 
levels of the small heat shock protein cvHsp in dystrophic skeletal muscle (Doran et 
al., 2006a).  
 
4.3.8 Increased expression of Iron handling proteins in aged mdx tissue 
The 2-fold increase in transferrin concentration suggests fluctuations in iron 
absorption and use in muscular dystrophy. Since circulating transferrin acts as an 
iron transporter delivering needed iron to tissue proteins (Wang and Pantopoulos, 
2011), the elevated abundance suggests impaired iron homeostasis in the 
degenerating mdx diaphragm muscle. During the aging dystrophic diaphragm study 
which investigated 8-week to 22-month range (Carberry et al., 2012a), we also 
examined the 8-week to 12-month range and recorded a drastic increase in ferritin 
light chain levels in mdx muscle. Deficiency in dystrophin seems to impair iron 
homeostasis and the elevated iron transporter and binding-protein concentrations 
possibly suggest a compensatory mechanism to help prevent harmful iron 
overloading in muscle tissues. 
 
4.3.9 Reduced mitochondrial enzymes in aged mdx tissue 
Previous reports have shown that skeletal muscles from the dystrophin-deficient 
mdx mouse exhibit disturbed mitochondrial metabolism leading to decreased 
intramuscular ATP concentrations. Mitochondrial abnormalities consist of the 
pathophysiological uncoupling of oxidative phosphorylation and the resulting 
reduction in maximal ATP synthesis capacity (Kuznetsov et al., 1998) and a 
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disturbance of the subsarcolemmal localisation of mitochondria which leads to 
metabolic inefficiency and thus limits the maximal generation of ATP (Percival et 
al., 2013). This bioenergetic dysfunction of mitochondria in the senescent mdx 
diaphragm indicates that aged mitochondria are incapable of meeting the ATP 
demand of the dystrophic muscle fibres, which agrees with recent proteomic study 
in aged mdx heart (Holland et al., 2013a). 
A reduced concentration was shown for essential mitochondrial enzymes, 
including cytochrome c oxidase, electron transferring flavoprotein, isocitrate 
dehydrogenase, malate dehydrogenase and ATP synthase. In addition, the 
proteomic findings of a decreased concentration of the vital and rate-limiting 
metabolite transporters for the utilisation of oxygen and fatty acids, intracellular 
oxygen transporter myoglobin and the fatty acid binging protein FABP3, suggest 
the idea of impaired mitochondrial metabolism. 
 
4.3.10 Other proteins 
The contractile apparatus degeneration and/or remodeling, as indicated here with 
actin, troponins, tropomyosin and myosin light chains, and interestingly, possible 
compensatory mechanism to stabilise the deteriorated sarcomeric structure was 
observed with elevated levels of a nebulin fragment perhaps strengthening the 
nebulin-associated thin filament in dystrophic tissue fibres (Holland and 
Ohlendieck, 2013).  
 
4.3.11 Predicted interaction patterns of altered proteins in aged mdx 
diaphragm muscle 
The STRING database of direct physical and indirect functional protein interactions 
(Franceschini et al., 2013) was employed to evaluate potential protein networks within the 
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proteomic data set generated by this study of the aged mdx diaphragm. Figure 4-6 shows 
the result of this bioinformatics analysis, which revealed a relatively complex interaction 
map. Two large clusters were shown to exist that are linked via adenylate kinase and 
creatine kinase interactions. Since both proteins were shown to be reduced in dystrophin-
deficient fibers, this indicates that more severe downstream effects on various proteins 
may occur within these apparent protein clusters. The upper protein network consists 
especially of enzymes involved in mitochondrial metabolism, such as ATP synthase, 
isocitrate dehydrogenase, aconitase and malate dehydrogenase. The lower protein cluster 
contains several major contractile elements, including tropomyosin, troponin and myosins. 
Important ion handling proteins and metabolite transporters are also proposed to interact 
with these protein complexes. 
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Figure 4-8 Overview of the molecular function of altered diaphragm-associated 
proteins  
Shown is the application of the bioinformatics software program PANTHER (database; 
version 8.1) to identify the clustering of molecular functions of the mass spectrometrically 
identified proteins with a changed abundance in aged mdx diaphragm (Table 4.2). The 
molecular functions of the identified muscle proteins have been catalogued as being 
involved in ion homeostasis, the cellular stress response, cytoskeletal stabilization, 
extracellular matrix organization, structural integrity, metabolic transportation and 
metabolism. The largest groups of proteins were represented by calcium-binding proteins, 
cytoskeletal proteins and oxidoreductase. Frequent changes were also observed in 
molecular chaperones, kinases, structural proteins, transferases and carrier proteins. 
Relatively small alterations were shown to occur in extracellular matrix proteins. 
 94 
 
4.4 Conclusion  
In recent years, comparative proteomic studies with mdx muscle tissue extracts 
have shown significant alterations in the enzyme adenylate kinase AK1(Marouga et 
al., 2005; Ng et al., 2012; Theodoridis et al., 2012), the actin binding protein profilin, 
the fatty acid binding protein FABP3 (Okamoto and Fujiwara, 2006), the cytosolic 
Ca2+-binding protein parvalbumin (Stastna and van Eyk, 2012), the Ca2+-binding 
protein calsequestrin CSQf (Cox and Mann, 2011), the enzyme carbonic anhydrase 
CA3 (Carberry et al., 2012b), the molecular chaperone cvHsp/HspB7 (Marouga et 
al., 2005; Kato et al., 2011), the oxygen carrier myoglobin (Stastna and van Eyk, 
2012), different isoforms of annexin (Okamoto and Fujiwara, 2006), the ion 
transporter transferrin (Forbes et al., 1994; Graham et al., 2010), the mitochondrial 
enzyme isocitrate dehydrogenase (Kornegay et al., 2012; Stastna and van Eyk, 
2012; Mallick and Kuster 2010) and the extracellular matrix protein dermatopontin 
(Mouisel  et al., 2010).  
These proteomic profiles of the mdx mouse were performed with multiple muscle 
subtypes, variety of tissue extracts or subcellular fractions, various protein 
separation techniques, opposing labelling methods and different mass 
spectrometric techniques. The proteomic results in this chapter has established 
that the abundance of annexin, carbonic anhydrase CA3, cvHsp, prohibitin, 
transferrin and dermatopontin is significantly increased and that the concentration 
of adenylate kinase, calsequestrin, isocitrate dehydrogenase, myoglobin, and 
parvalbumin is drastically reduced in the aged mdx diaphragm model of DMD.  
This makes these proteins suitable biomarker candidates of dystrophinopathy, 
which might be helpful to evaluate diagnostic, prognostic or therapeutic 
approaches. In conclusion, the proteomic results presented here indicate that the 
aged mdx diaphragm, which shows severe respiratory impairment following fibrosis 
(Ishizaki et al., 2008), is a suitable model system to study the molecular 
pathogenesis of Duchenne muscular dystrophy.  
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5 Comparative proteomic profiling of soleus, extensor 
digitorum longus, flexor digitorum brevis and interosseus 
muscle from the mdx mouse model of Duchenne muscular 
dystrophy  
 
5.1 Introduction  
In the mdx animal model of dystrophinopathy, different skeletal muscle subtypes are 
affected to varying degrees resulting from the same single base substitution of the dystrophin 
gene. Thus, to establish potential muscle subtype-specific alterations in secondary changes 
due to dystrophin-deficiency, we have performed a comparative proteomic survey of multiple 
mdx muscles. We included those specific skeletal muscles that are frequently used for 
studying the muscular dystrophy pathomechanism, soleus, extensor digitorum longus, flexor 
digitorum brevis and interosseus muscle. 
 
5.1.1 Duchenne muscular dystrophy and skeletal muscle subtypes 
In humans, the corresponding mouse muscle tissue subtypes examined relate to (i) soleus 
(SOL), a muscle of the lower back part of the leg located just below the gastrocnemius that 
contains predominantly oxidative type 1 fibers, (ii) extensor digitorum longus (EDL), a 
muscle lying in the lateral front part of the leg that contains a high number of glycolytic type 
2B and 2X fibers, (iii) flexor digitorum brevis (FDB), muscles of the foot located in the middle 
part of the sole and contains a large portion of oxidative-glycolytic type 2A fibers, and (iv) 
interosseus (INT), a muscle of the hand positioned near the metacarpal bones that contains 
almost exclusively type 2 fibers (Jarmey, 2006; Lieber, 2010; Stal et al., 1987; Staron et al., 
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1997). All four muscles have been extensively used to investigate changes of mdx muscle 
structure, physiology, function and biochemistry. 
However, each of these different muscle subtypes has strengths and weaknesses with 
respect to routine biological analyses. While SOL and EDL are ideal to study the 
biochemistry, force and fatigue in muscle, FDB and INT are suited to study muscles on the 
single fiber level, as they can be readily enzymatically dissociated into single fibers. Thus, 
numerous observations on subsarcolemmal Ca2+ levels, Ca2+ influx and the function of 
cation channels have been made with FDB (Boittin et al., 2010; Mallouk et al., 2000; 
Teichmann et al., 2008) and INT (Mallouk et al., 2000; Pritschow et al., 2011; Tutdibi et al., 
1999) without knowing whether these results can be generalised. Thus, we included FDB 
and INT muscle preparations in this proteomic analyses to evaluate whether they exhibit 
similar abnormalities as compared to other mdx mice limb muscles. While different skeletal 
muscle subtypes are affected to varying degrees resulting from the same single base 
substitution of the dystrophin gene these distinct differences in the level of protein 
perturbation of different muscle subtypes from mdx mice are perhaps a result of 
dissimilar secondary processes in the molecular pathogenesis.  
 
5.1.2 Experimental design  
Comparative gel-based proteomic analysis of normal versus mdx soleus, extensor 
digitorum longus, flexor digitorum brevis and interosseus muscle, the urea-soluble protein 
complement was prepared from these four muscles from control and dystrophic mice. 
Muscle protein extracts were separated by two-dimensional gel electrophoresis and labelled 
with the fluorescent dye ruthenium II tris bathophenanthroline disulfonate. Then proteins 
with a significant change in their abundance were identified by mass spectrometry. Key 
proteomic findings were verified by immunoblot analysis. This report describes the analysis 
of RuBPs labelled normal and dystrophic SOL, EDL, FDB and INT tissue of 3-month-old 
dystrophin-deficient versus aged-matched wild type (WT) mice across 3-10 pH range. 
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Proteomic profiling established a change in abundance of 24, 17, 19 and 5 protein species 
in SOL, EDL FDB and INT muscle, respectively. Identified proteins were involved in various 
processes form the contraction-relaxation cycle, muscle metabolism, metabolite transport 
and the cellular stress response. 
 
5.2 Results  
5.2.1 Comparative proteomic analysis of mdx versus normal  muscle  
High-resolution two-dimensional gel electrophoresis was carried out to separate the 
proteome from normal versus dystrophic mdx SOL, EDL, FDB and INT muscle 
tissues. A pH-range of 3-10 in the first dimension was employed to establish a global 
proteomic pattern. Followed by post-electrophoretic labelling of the protein spots with 
fluorescent dye RuBPs, a Typhoon Trio variable imager and Progenesis 2-D analysis 
software were used to analyse the mdx skeletal muscle proteomes. An altered 
concentration was revealed for 24, 17, 19 and 5 protein species, with 19, 15, 8 and 1 
proteins being increased and 5, 2, 9 and 4 proteins showing decreased expression in 
SOL, EDL, FDB and INT mdx tissue, respectively. Mass spectrometry was then used 
to identify these significant muscle-associated proteins of interest and listed in Tables 
(5-1 to 5-4). 
 
5.2.2 Proteomic analysis of dystrophic skeletal muscle subtypes 
Following optimisation, fluorescence high-resolution two-dimensional gel 
electrophoresis was performed to determine potential differences in protein 
expression patterns in mdx skeletal muscle proteomes. Figure 5-1 shows the total 
extracts from 3 month old normal wild-type vs dystrophic mdx (A) SOL, (B) EDL, (C) 
FDB and (D) INT muscles. The 32 RuBPs-stained gel images contain four biological 
repeats of each group of normal wild-type (WT 1-4) versus dystrophic (MDX 1-4) 
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muscle. Fluorescent images are shown along a pH 3-10 range. The overall 2D spot 
patterns of normal versus dystrophic skeletal muscle subtypes were relatively 
comparable as a result a detailed denitometric analysis was performed in order to 
determine potential differences in individual protein species. Densitometric analysis 
was carried out using a Typhoon Trio variable imager scanner and Samespot 
Progenesis 2-D analysis software was performed to establish differential expression 
patterns with the dystrophic muscles. The detailed proteomic profiling of dystrophic 
subtypes showed distinct changes in 24, 17, 19 and 5 muscle protein species in SOL, 
EDL FDB and INT tissue respectively, suggesting the INT to be a much milder affected 
phenotype. 
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Figure 5-1 Overview of two-dimensional gel electrophoretic analysis of the mdx 
mice skeletal muscles for x-linked muscular dystrophy 
Shown are RuBPs stained gels from 3-month-old normal wild type (WT) vs dystrophic 
(MDX) (A) soleus (SOL), (B) extensor digitorum longus (EDL), (C) flexor digitorum brevis 
(FDB) and (D) interosseus (INT) muscle extracts. The 32 gel images comprise of four 
biological repeats of each set of normal (wild-type; WT 1-4) vs diseased (MDX 1-4) muscles. 
Fluorescent images are shown across the pH 3-10 range. 
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5.2.3 RuBPs analysis of dystrophic soleus muscle  
Proteins with significant changes in expression levels are numbered 1 to 24 and 
marked by circles in the master gel Fig 5-2. The mass spectrometric identification of 
these altered muscle proteins is listed in Table 5-1. This table contains the identified 
muscle-associated proteins names, international accession number, relative 
molecular masses, pI-values, number of matched peptide sequences, Mascot scores, 
percentage sequence coverage, and fold-change of individual muscle proteins 
affected in the dystrophic mdx SOL tissue. 
Protein species with an altered concentration in mdx SOL muscle ranged from a 
molecular mass of 17 kDa (myoglobin) to 127 kDa (myosin binding protein) and with a 
pI-range from 4.7 pI (myosin light chain) to 8.9 pI (malate dehydrogenase). The 
expression levels showed an increased abundance for various myosin light chains 
consisting of MLC1/3, MLC2 and MLC3 (spots 1, 5, 11,17 and 19), cadherin 13 (spot 
2), aldolase (spot 3), the molecular chaperone αB-crystallin (spots 4, 9 and 14), 
troponin TnC (spot 6), glutathione transferase (spot 7), different subunits of 14-3-3 
protein (spots 8 and 15), collagen (spot 10) phosphatase (spot 12), iron transporter 
ferritin (spot 13), myosin binding slow protein MyBP-C (spot 16) and peroxiredoxin 
(spot 18). A decreased abundance was established in the tumor metastatic 
process-associated protein NM23 (spot 20), oxygen carrier myoglobin (spot 21), ATP 
synthase Atp5b protein (spot 22), creatine kinase (spot 23) and for malate 
dehydrogenase (spot 24). 
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Figure 5-2 Fluorescence two-dimensional gel electrophoretic analysis of mdx 
soleus muscle 
Shown is a representative RuBPs-stained master gel of crude muscle extracts from 
mdx soleus muscle. Protein spots with age-related alterations in abundance are 
numbered 1 to 24 and marked by circles. See Table 5-1 for the mass spectrometric 
identification of individual muscle-associated protein spots. The pH-values of the first 
dimension and molecular mass standards of the second dimension are shown on the 
top and on the left of the panels, respectively.  
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Table 5.1 List of muscle-associated proteins with changes in abundance in the 
soleus muscle from mdx mice 
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1 Myosin light chain 2 
(MLC2) 
AAA39796 4.71 18870 9 60 401 5.0 
2 Cadherin 13 AAH21628 4.9 78474 2 4 104 4.4 
3 Aldolase A, isoform 2 NP031464 8.31 39795 17 40 136 4.3 
4 αB-crystallin NP034094 6.76 20056 3 28 121 4.2 
5 Myosin light chain 3 
(MLC3) 
EDL09001 5.03 22523 6 38 268 3.3 
6 Troponin C, skeletal 
muscle 
NP033420 4.07 18156 2 20 190 3.1 
7 Glutathione 
S-transferase 
NP034488 7.71 26069 9 42 415 2.8 
8 14-3-3 Protein γ NP036611 4.8 28519 4 9 145 2.8 
9 αB-crystallin NP034094 6.76 20056 1 14 58 2.8 
10 Collagen α-1 (VI) chain NP034063 5.2 109582 13 16 224 2.6 
11 Myosin light chain 2 
(MLC2) 
NP058034 4.82 19059 4 31 272 2.5 
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12 Mg-dependent 
phosphatase 1 
NP075886 6.29 18629 3 29 98 2.4 
13 Ferritin light chain 1 P29391 5.66 20848 6 44 372 2.3 
14 αB-crystallin NP034094 6.76 20056 13 60 141 2.3 
15 14-3-3 Protein ζ BAA13421 4.7 27911 4 18 258 2.2 
16 Myosin binding protein 
C, slow 
HQ848554 5.74 127046 9 10 411 2.1 
17 Myosin light chain 2 
(MLC2) 
NP058034.1 4.82 19059 5 44 161 2.1 
18 Peroxiredoxin-1 NP035164 8.26 22394 5 24 170 2.0 
19 Myosin light chain 1/3 
(MLC1/3) 
NP067260 5 4.98 20697 11 53 514 2.0 
20 Tumor metastatic 
process-associated 
protein NM23 
AAA39826 8.44 18846 4 40 141 -2.0 
21 Myoglobin NP038621 7.07 17117 2 21 161 -2.1 
22 Atp5b protein BC037127 5.24 56632 7 20 488 -2.2 
23 Creatine kinase 
M-type 
NP031736 6.58 43250 2 7 97 -2.3 
24 Malate dehydrogenase AAA39509 8.93 36052 5 22 132 -4.2 
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5.2.4 RuBPs analysis of dystrophic EDL muscle  
Proteins with significant changes in expression levels are numbered 1 to 17 and 
marked by circles in the master gel Fig 5-3. The mass spectrometric identification of 
these altered muscle proteins is listed in Table 5-2. This table contains the identified 
muscle-associated proteins names, international accession number, relative 
molecular masses, pI-values, number of matched peptide sequences, Mascot 
scores, percentage sequence coverage, and fold-change of individual muscle 
proteins affected in the dystrophic mdx EDL tissue. 
Protein species with an altered concentration in mdx EDL muscle ranged from a 
molecular mass of 17 kDa (myoglobin) to 224 kDa (myosin) and with a pI-range from 
5.2 pI (actin) to 9.0 pI (Troponin TnT). Mass spectrometric analyses revealed an 
increased concentration in fast troponin TnT (spots 1 and 9), oxygen carrier 
myoglobin (spot 2), phosphoglycerate mutase 2 (spots 3 and 15), 
glyceraldehyde-3-phosphate dehydrogenase (spot 4), triosephosphate isomerase 
(spot 5), myosin protein (spot 6), lactate dehydrogenase B chain (spot 7), 
phosphoglycerate kinase (spot 8), creatine kinase (spot 10), the malate 
dehydrogenase (spot 11), , actin (spot 12), glycogen phosphorylase (spot 13) and for 
phosphoglycerate kinase (spot 14). In contrast, decreased concentrations were found 
for glycogen phosphorylase (spot 16) and actinin (spot 17). 
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Figure 5-3 Fluorescence two-dimensional gel electrophoretic analysis of mdx 
extensor digitorum longus muscle 
Shown is a representative RuBPs-stained master gel of crude muscle extracts from 
mdx extensor digitorum longus muscle. Protein spots with age-related alterations in 
abundance are numbered 1 to 17 and marked by circles. See Table 5-2 for the mass 
spectrometric identification of individual muscle-associated protein spots. The 
pH-values of the first dimension and molecular mass standards of the second 
dimension are shown on the top and on the left of the panels, respectively.  
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Table 5.2 List of muscle-associated proteins with changes in abundance in the 
extensor digitorum longus muscle from mdx mice 
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1 Troponin T, fast skeletal 
muscle 
AAB39743 9.01 29358 2 11 66 3.8 
2 Myoglobin NP038621 7.07 17117 11 68 547 3.7 
3 Phosphoglycerate 
mutase 2 
NP061358 8.65 28983 11 49 484 3.4 
4 
 
Glyceraldehyde-3-phosph
ate dehydrogenase 
AAH85315 7.59 36099 7 30 347 3.0 
5 Triosephosphate 
isomerase 
AAB48543 5.62 22724 4 22 90 2.6 
6 Myosin-1 NP109604 5.60 224131 19 11 774 2.6 
7 Lactate dehydrogmenase 
B chain 
NP032518 5.70 36839 15 49 775 2.5 
8 Phosphoglycerate kinase AAA70267 7.53 44914 6 21 299 2.3 
9 Troponin T, fast skeletal 
muscle 
AAB39743 9.01 29358 6 31 131 2.3 
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10 Creatine kinase M-type NP031736 6.58 43250 5 16 114 2.2 
11 Malate dehydrogenase AAA39509 8.93 36052 11 41 313 2.1 
12 Actin, α skeletal muscle NP001091 5.23 42372 10 31 136 2.1 
13 Glycogen phosphorylase NP035354 6.65 97689 25 35 1047 2.0 
14 Phosphoglycerate kinase AAA70267 7.53 44914 7 22 109 2.0 
15 Phosphoglycerate 
mutase 2 
NP061358 8.65 28983 14 51 637 2.0 
16 Glycogen phosphorylase NP035354 6.65 97689 2 4 54 -2.6 
17 α-actinin-3 NP038484 5.31 103616 7 9 374 -2.8 
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5.2.5 RuBPs analysis of dystrophic FDB muscle  
Proteins with significant changes in expression levels are numbered 1 to 19 and 
marked by circles in the master gel Fig 5-4. The mass spectrometric identification of 
these altered muscle proteins is listed in Table 5-3. This table contains the identified 
muscle-associated proteins names, international accession number, relative 
molecular masses, pI-values, number of matched peptide sequences, Mascot 
scores, percentage sequence coverage, and fold-change of individual muscle 
proteins affected in the dystrophic mdx FDB tissue. 
Protein species with an altered concentration in mdx FDB muscle ranged from a 
molecular mass of 12 kDa (parvalbumin) to 130 kDa (collagen) and with a pI-range 
from 4.9 pI (vimentin) to 9.2 pI (collagen). MS-based proteomics revealed an 
 increase in expression levels for fast troponin I (spot 1), serpina 1d protein (spots 2, 6 
and 9), the molecular chaperone αB-crystallin (spot 3), vimentin (spot 4), 
phosphoglycerate mutase 2 (spot 5), desmin (spot 7), the leukocyte elastase inhibitor 
A (spot 8) and tropomyosin (spot 10). Decreased protein abundance was established 
in FBD muscle for the glycolytic enzyme aldolase (spots 11, 12, 15, 17 and 18), 
cytosolic Ca2+-binding protein parvalbumin (spots 13 and 16), the 14-3-3 protein (spot 
14) and for collagen (spot 19). 
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Figure 5-4 Fluorescence two-dimensional gel electrophoretic analysis of mdx 
flexor digitorum brevis muscle 
Shown is a representative RuBPs-stained master gel of crude muscle extracts from 
mdx flexor digitorum brevis muscle. Protein spots with age-related alterations in 
abundance are numbered 1 to 19 and marked by circles. See Table 5-3 for the mass 
spectrometric identification of individual muscle-associated protein spots. The 
pH-values of the first dimension and molecular mass standards of the second 
dimension are shown on the top and on the left of the panels, respectively.  
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Table 5.3 List of muscle-associated proteins with changes in abundance in the 
flexor digitorum brevis muscle from mdx mice 
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1 Troponin I, fast 
skeletal muscle 
NP033431 8.65 21518 5 30 57 3.1 
2 Serpina 1d protein AAH21850 5.18 46140 9 24 104 2.7 
3 αB-crystallin NP034094 6.76 20056 8 45 324 2.4 
4 Vimentin CAA69019 4.96 51591 21 50 261 2.4 
5 Phosphoglycerate 
mutase 2 
NP061358 8.65 28983 2 8 75 2.3 
6 Serpina 1d protein AAH21850 5.18 46140 5 11 136 2.3 
7 Desmin NP034173 5.21 53523 10 32 206 2.2 
8 Leukocyte elastase 
inhibitor A 
NP079705 5.85 42722 9 30 178 2.1 
9 Serpina 1d protein AAH21850 5.18 46140 7 17 131 2.0 
10 Tropomyosin, β 
chain 
NP033442 4.66 32933 17 47 176 2.0 
11 Aldolase A, isoform 2 NP001170778 8.31 39795 15 48 202 -2.2 
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12 Aldolase A, isoform 2 NP001170778 8.31 39795 13 40 249 -2.2 
13 Parvalbumin α NP038673 5.02 11923 8 65 228 -2.3 
14 14-3-3 Protein γ AAC14345 4.80 28519 8 38 116 -2.3 
15 Aldolase A, isoform 2 NP001170778 8.31 39795 13 40 163 -2.7 
16 Parvalbumin α NP038673 5.02 11923 8 65 219 -3.0 
17 Aldolase A, isoform 2 NP001170778 8.31 39795 9 27 139 -3.1 
18 Aldolase A, isoform 2 NP001170778 8.31 39795 20 55 215 -3.3 
19 Pro-α-2(I) collagen CAA41205 9.23 130046 2 2 51 -3.4 
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5.2.6 RuBPs analysis of dystrophic INT muscle  
In contrast to the above listed results of extensive alterations in the  
proteomes from the mdx dystrophic SOL, EDL and FDB muscle, the  
MS-based proteomic analyse of INT muscle exhibited only a limited number of 
changed proteins. Proteins with significant changes in expression levels are 
numbered 1 to 5 and marked by circles in the master gel Fig 5-5. The mass 
spectrometric identification of these altered muscle proteins is listed in Table 5-4. This 
table contains the identified muscle-associated proteins names, international 
accession number, relative molecular masses, pI-values, number of matched peptide 
sequences, Mascot scores, percentage sequence coverage, and fold-change of 
individual muscle proteins affected in the dystrophic mdx INT tissue. 
Protein species with an altered concentration in mdx INT muscle ranged from a 
molecular mass of 12 kDa (parvalbumin) to 33 kDa (40 kDa protein) and with a 
pI-range from 4.8 pI (40 kDa protein) to 8.65 pI (Toponin I). MS-based proteomics 
revealed an increase in expression levels for fast Toponin I (spots 1 and 2), the heat 
shock protein αB-crystallin (spot 3) and the 40 kDa protein (spot 4). In contrast, 
decreased protein abundance was found in the cytosolic Ca2+-binding protein 
parvalbumin in the INT muscle. 
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Figure 5-5 Fluorescence two-dimensional gel electrophoretic analysis of mdx 
interosseus muscle 
Shown is a representative RuBPs-stained master gel of crude muscle extracts from 
mdx interosseus muscle. Protein spots with age-related alterations in abundance are 
numbered 1 to 5 and marked by circles. See Table 5-4 for the mass spectrometric 
identification of individual muscle-associated protein spots. The pH-values of the first 
dimension and molecular mass standards of the second dimension are shown on the 
top and on the left of the panels, respectively.  
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Table 5.4 List of muscle-associated proteins with changes in abundance in the 
interosseus muscle from mdx mice 
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1 Troponin I, fast skeletal 
muscle 
NP033431 8.65 21518 8 29 301 4.1 
2 Troponin I, fast skeletal 
muscle 
NP033431 8.65 21518 5 21 245 3.4 
3 αB-crystallin NP034094 6.76 20056 9 56 421 2.2 
4 40 kDa Protein 1405340A 4.80 32848 3 15 164 2.1 
5 Parvalbumin, α NP038673 5.02 11923 7 63 400 -2.2 
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5.2.7 Immunoblot analysis of dystrophic skeletal muscle subtypes 
In order to further characterise the various skeletal muscles, comparative immunoblotting 
was carried out following the mass spectrometric establishment of the subtype specific 
changes in the urea-soluble mdx muscle proteomes. Lanes 1 and 2, 3 and 4, 5 and 6 
and 7 and 8 shown in figure 5-6A were labelled with a laminin antibody for control 
purposes. The extracellular matrix protein presented relatively comparable quantities in 
normal versus dystrophic samples, with the exception of SOL muscle which exhibited an 
increased concentration in mdx preparations.  
As shown in Figure 5-6B to 5-6I, antibody labelling was performed to verify the altered 
abundance of 2 marker proteins from each of the mdx muscle subtypes analysed. The 
reduced expression of myoglobin and increased concentration of collagen in the SOL 
muscle in figure 5-6B and 5-6C, respectively. The lower levels of actinin and higher levels 
of phosphoglycerate kinase in the EDL muscle in figure 5-6D and 5-6E, respectively. The 
reduced expression of parvalbumin and increased concentration of serpina in the FDB 
muscle in figure 5-6F and 5-6G, respectively and the reduced levels of parvalbumin and 
higher levels of αB-crystallin in the INT muscle in figure 5-6H and 5-6I, respectively were 
all confirmed by immunoblot analysis. 
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Figure 5-6A Immunoblotting analysis of the extracellular matrix protein laminin in 
normal versus mdx skeletal muscle subtypes 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the Laminin antibody. Lanes 1 and 2, 3 and 4, 5 and 6 
and 7 and 8 represent 3-month-old normal wild-type vs dystrophic mdx preparations 
from soleus (SOL), extensor digitorum longus (EDL), flexor digitorium brevis (FDB) and 
interosseus (INT) muscles, respectively. The comparative  blotting  was  statistically  
verified  using  an  unpaired  Student’s  t-test (n=4 replicates). Standard deviation 
represented by Error bars, (*p<0.05). 
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Figure 5-6B Immunoblotting analysis of myoglobin in soleus muscle 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the myoglobin antibody. Lanes 1 and 2 represent 
3-month-old normal wild type vs dystrophic mdx soleus (SOL), respectively. The 
comparative  blotting  was  statistically  verified  using  an  unpaired  Student’s  t-test (n=4 
replicates). Standard deviation represented by Error bars, (*p<0.05). 
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Figure 5-6C Immunoblotting analysis of extracellular matrix protein collagen in 
soleus muscle 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the collagen antibody. Lanes 1 and 2 represent 
3-month-old normal wild type vs dystrophic mdx soleus (SOL), respectively. The 
comparative  blotting  was  statistically  verified  using  an  unpaired  Student’s  t-test (n=4 
replicates). Standard deviation represented by Error bars, (**p<0.005). 
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Figure 5-6D Immunoblotting analysis of α-actinin-3 in extensor digitorum longus 
muscle 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the α-actinin-3 antibody. Lanes 1 and 2 represent 
3-month-old normal wild type vs dystrophic mdx extensor digitorum longus (EDL), 
respectively. The comparative  blotting  was  statistically  verified  using  an  unpaired  
Student’s  t-test (n=4 replicates). Standard deviation represented by Error bars, (*p<0.05). 
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Figure 5-6E Immunoblotting analysis of phosphoglycerate kinase in extensor 
digitorum longus muscle 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the phosphoglycerate kinase antibody. Lanes 1 and 2 
represent 3-month-old normal wild type vs dystrophic mdx extensor digitorum longus 
(EDL), respectively. The comparative  blotting  was  statistically  verified  using  an  
unpaired  Student’s  t-test (n=4 replicates). Standard deviation represented by Error bars, 
(*p<0.05). 
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Figure 5-6F Immunoblotting analysis of calcium-binding protein parvalbumin in 
flexor digitorium brevis muscle 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the parvalbumin antibody. Lanes 1 and 2 represent 
3-month-old normal wild type vs dystrophic mdx flexor digitorium brevis (FDB), 
respectively. The comparative  blotting  was  statistically  verified  using  an  unpaired  
Student’s  t-test (n=4 replicates). Standard deviation represented by Error bars, 
(**p<0.005). 
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Figure 5-6G Immunoblotting analysis of serpina 1d in flexor digitorium brevis 
muscle 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the serpina antibody. Lanes 1 and 2 represent 
3-month-old normal wild type vs dystrophic mdx flexor digitorium brevis (FDB), 
respectively. The comparative  blotting  was  statistically  verified  using  an  unpaired  
Student’s  t-test (n=4 replicates). Standard deviation represented by Error bars, (*p<0.05). 
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Figure 5-6H Immunoblotting analysis of calcium-binding protein parvalbumin in 
interosseus muscle 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the parvalbumin antibody. Lanes 1 and 2 represent 
3-month-old normal wild type vs dystrophic mdx interosseus (INT), respectively. The 
comparative  blotting  was  statistically  verified  using  an  unpaired  Student’s  t-test (n=4 
replicates). Standard deviation represented by Error bars, (*p<0.05). 
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Figure 5-6I Immunoblotting analysis of αB-crystallin in interosseus muscle 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical evaluation. 
Immunoblots were labelled with the αB-crystallin antibody. Lanes 1 and 2 represent 
3-month-old normal wild type vs dystrophic mdx interosseus (INT), respectively. The 
comparative  blotting  was  statistically  verified  using  an  unpaired  Student’s  t-test (n=4 
replicates). Standard deviation represented by Error bars, (*p<0.05). 
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5.2.8 Histological profiling of skeletal muscle tissue from mdx mice   
In order to further characterise the various skeletal muscles, histological examination 
was performed using hematoxylin and eosin-stained muscle cross-sections from 
wild-type (WT; A, C, E and G) and mdx mice (B, D, F and H) seen in figure 5-7. The 
histological analysis of cross sections from the SOL, EDL, FDB and INT muscles 
observed central nucleation in all examined types of skeletal muscle from mdx mice 
(Fig 5-7B, D, F and H). In addition, the muscles exhibited variations in fiber size and 
the occurrence of small, rounded fibers. As expected, central nuclei were rarely 
detected in the muscle fibers from WT mice (Fig 5-7A, C, E and G). Quantitative 
evaluation of central nucleation showed a significantly lower degree of nucleation in 
the FDB and INT compared with the SOL and EDL muscles.  
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Figure 5-7 Histological profiling of skeletal muscles from mdx mice 
Shown is a representative hematoxylin and eosin-stained muscle cross-sections 
from wild-type (WT; A, C, E and G) and dystrophic mdx mice (B, D, F and H). Note the 
lower degree of central nuclei in the flexor digitorum brevis (FDB; E and F) and 
interosseus (INT; G and H) muscles, compared with the soleus (SOL; B) and extensor 
digitorum longus (EDL; D) muscles from mdx mice. Muscles were prepared from 
3-month-old dystrophin-deficient versus aged-matched wild type mice. Scale bar, 20 
μm. 
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5.3 Discussion  
In this chapter, proteomic profiling of 4 skeletal muscle subtypes, SOL, EDL, FDB and 
INT muscle, has revealed considerable changes in the extent of protein perturbations 
in different muscles of the mdx dystrophic mouse model of Duchenne muscular 
dystrophy. While we observed 24, 17 and 19 altered protein species in mdx SOL, EDL 
and FDB muscles, respectively, dystrophin-deficient INT muscle preparations 
revealed only changes in fast troponin I, αB-crystallin, the 40 kDa protein and the 
cytosolic Ca2+-binding protein parvalbumin.  
This is an interesting discovery from a global profile of protein expression patterns in 
dystrophinopathy and supports the idea that the loss of dystrophin and resulting 
reduction of associated glycoproteins leads in considerably different secondary 
alterations and cellular adaptations in specific skeletal muscles, even though all 
contractile mdx muscle tissues exhibit the same primary genetic defect. Previous 
proteomic reports of mdx muscle tissues agree that the deficiency in the membrane 
cytoskeletal protein dystrophin leads to impaired protein expression patterns in 
contractile tissues (Lewis et al., 2009). While past studies on mdx muscle proteomics 
vary significantly on the listing of distinct proteins involved in the molecular 
pathogenesis of muscular dystrophy, the disintegration of sarcolemmal integrity 
clearly has severe impact for the overall function of the affected muscle fibers.  
Interestingly, as shown in the previous chapter severely dystrophic mdx diaphragm 
muscle displays extensive alterations in a large number of muscle proteins (Doran et 
al., 2006a; Doran et al., 2006b; Doran et al., 2009b; Carberry., et al 2012a),  while 
mildly affected phenotypes such as mdx extraocular muscle which exhibit much less 
changes in its proteome (Lewis and Ohlendieck, 2010). This establishes a link 
between the pathophysiological phenotype of individual mdx muscle tissues and the 
level of proteome-wide changes.  
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5.3.1 Moderate expression changes of RuBPs labelled skeletal muscle 
proteins 
Muscle-associated proteins with an altered abundance in mdx muscle tissues are 
predominantly involved in the contraction-relaxation cycle, muscle metabolism, 
metabolite transportation, and the cellular stress response. While in the mildly affected 
mdx INT muscle phenotype, the most significantly increased protein was fast troponin I 
(Swartz et al., 2006) suggesting a certain level of remodeling of the regulatory elements 
in the contractile apparatus (Gordon et al., 2000). Other protein alterations in mdx INT 
muscle were minimal, as compared to the other skeletal muscles examined.  
Two additional observations on the mdx INT muscle support the proteomic analyses. 
Firstly, the occurrence of central nucleation in the muscle fibers was lower in the INT 
and FDB compared with the SOL and EDL hind limb muscles (Fig 5-7). This is key, as 
central nucleation is considered as a reliable sign of recent muscle fiber regeneration. 
Secondly, there was no observed increase in muscle mass in INT and FDB, in contrast 
to that of the SOL and EDL muscles. Hypertrophy has been reported in 
dystrophin-deficient muscles in a number of models of DMD, including the mdx mouse 
(Kornegay et al., 2012) though the signaling pathways resulting in muscle growth have 
not yet been fully revealed (Andres-Mateos et al., 2013) (Gundersen, 2011). However, 
both central nucleation and the level of hypertrophy are in agreement with a less 
severe impairment of the mdx INT and FDB, compared with the SOL and EDL 
muscles (Carberry et al., 2013b). 
In mdx SOL muscle, various myosin light chains consisting of MLC1/3, MLC2 and 
MLC3 isoforms (Gonzalez et al., 2002), were revealed to be increased in expression in 
the dystrophin-deficient fibers. The highly complex myosin molecule forms a hexameric 
structure containing 2 MHC heavy chains and various MLC light chains in the contractile 
apparatus (Bozzo et al., 2005; Clark et al., 2002). Various arrangements of myosin heavy 
and light chains form a wide array of fiber type-specific isoforms and the myosin 
complement of contractile fibers is very flexible (Pette and Staron, 2000; Holland and 
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Ohlendieck, 2013).  
Previous proteomic studies have established that neuromuscular activity has an 
intense effect on the myosin isoform expression patterns (Donoghue et al., 2005; 
Donoghue et al., 2007). The drastic alterations in mdx SOL muscle suggest that the 
dystrophic phenotype is concomitant with considerable remodeling of the contractile 
apparatus, together with myosin, myosin binding proteins and troponin. Interestingly, the 
unique GPI-anchored cadherin-13 protein is elevated in mdx SOL muscle and may 
promote angiogenesis the process of new blood vessel formation form existing vessels 
(Philippova et al., 2006). Altered expression levels of the molecular chaperone 
αB-crystallin, ferritin, glutathione S-transferase and peroxiredoxin indicate intensified 
demands for cellular stress response, iron storage, detoxification and anti-oxidant 
activity in dystrophic fibers, respectively.  
Interestingly, specific isoforms of 14-3-3 proteins are altered in muscular dystrophy, 
which has been reported for various neurodegeneration processes (Steinacker et al., 
2011). This indicates that interactions of 14-3-3 proteins with signaling receptors, 
phosphatases and kinases are disturbed in mdx SOL muscle. Reduced concentrations 
of ATP synthase, malate dehydrogenase and myoglobin suggest metabolic disturbances 
in mdx SOL muscle.    
In the mdx EDL muscle, altered protein expression levels were shown for contractile 
elements such as myosin, troponin, actin and actinin, and in the actomyosin apparatus. 
Proteomic analysis also revealed a striking increase in levels of key glycolytic enzymes. 
The affected cytosolic proteins were also identified by mass spectrometry as 
glyceraldehyde-3-phosphate dehydrogenase, triosephosphate isomerase, 
phosphoglycerate mutase and phosphoglycerate kinase which are involved in the 
production of 1,3-bisphosphoglycerate and NADH, the reversible conversion of 
dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, the reversible 
conversion of 3-phosphoglycerate into 2-phosphoglycerate and the generation of ATP 
and 3-phosphoglycerate from ADP and 1,3-bisphosphoglycerate, respectively 
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(Ohlendieck, 2010). The increased expression in several glycolytic enzymes indicates a 
shift to more anaerobic metabolism.  
Interestingly, one of the chief regulatory enzymes for converting glycogen into glucose 
for utilisation in muscle, glycogen phosphorylase, was shown to be elevated in 
contractile mdx EDL tissue. Previous proteomic profiling of slow-twitching versus 
fast-twitching skeletal muscles has established that fast muscles reveal higher levels of 
enzymes involved in the glycolytic pathway and exhibit increase concentrations of 
glycogen phosphorylase (Gelfi et al., 2006). 
In addition, the increased expression of lactate dehydrogenase, an enzyme that 
catalyses the interconversion of the final product of glycolysis, pyruvate, and lactate 
supports the idea of a glycolytic shift in mdx EDL muscle. During periods of high intensity 
such as exercise, skeletal muscles adopt this anaerobic glycolysis (Wells et al., 2009), 
thus a sharp increase of glycolytic enzymes suggest an increased demand on the 
glycolytic pathway in the bioenergetics of dystrophin-deficient mdx EDL muscle.     
While in contrast to the mdx EDL muscle, the dystrophin-deficient mdx FDB muscle 
revealed a reduction in a crucial glycolytic enzyme. The skeletal muscle aldolase, an 
enzyme that catalyses the reversible biochemical breakdown of 
fructose-1,6-biphosphate into glyceraldehyde-3-phosphate and dihydroxyacetone 
phosphate (Ohlendieck, 2010). In the gluconeogenic pathway, muscle aldolase has 
been shown to form a supramolecular complex with alpha-actinin and 
fructose-1,6-biphosphatase on both sides of the Z-line in skeletal muscle fibers. It has 
been suggested that the tight association between aldolase and 
fructose-1,6-biphosphatase  might enable efficient substrate channeling between these 
proteins (Rakus et al., 2004). 
However, it is thought that many glycolytic enzymes have a multi-functional role in 
various cell types motility (Kim and Dang, 2005). Thus, alterations in these glycolytic 
enzymes may affect a number of biological systems other than the anaerobic breakdown 
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of glucose in skeletal muscles (Ohlendieck, 2010). For instance, enzymes with a key 
glycolytic function have also been shown to be involved in transcriptional regulation, 
metabolic integration, regulation of apoptosis and stimulation of cell motility (Kim and 
Dang, 2005). As a result it is difficult to determine from alterations in one key glycolytic 
enzyme whether this relates to distinct metabolic changes in mdx FDB or perhaps 
showing adaptations in a separate unrelated glycolysis biological system. Altered 
expression levels in tropomyosin and troponin and the cytosolic Ca2+-binding protein 
parvalbumin suggest abnormalities in the contractile apparatus and ion homeostasis, 
respectively. 
In comparison with the mdx SOL muscle, the apparent increased abundance of the 
molecular chaperone αB-crystallin in dystrophic FDB muscle agrees with the idea of an 
intensified cellular stress response in muscular dystrophy (Doran et al., 2006b). 
Interestingly, the cytoskeletal proteins desmin and vimentin were shown to be elevated in 
dystrophic mdx muscle suggesting a potential compensatory mechanism for the 
structural instabilities in the membrane cytoskeleton of the dystrophin-deficient fibers in 
the mdx FDB muscle.  
 
5.4 Conclusion  
In conclusion, the comparative proteomic analysis of 4 widely used skeletal muscles of 
the mdx mouse model of Duchenne muscular dystrophy, SOL, EDL, FDB and INT 
muscles, has revealed that high-resolution two-dimensional gel electrophoretic 
separation in combination with electrospray ionization mass spectrometry are highly 
suitable techniques for studying muscle subtype-specific changes in the mdx dystrophic 
skeletal muscle proteome. The variations in the number and degree of protein changes 
in the analysed mdx muscles suggest that the INT muscle is a protected phenotype, 
much less affected compared to that of the SOL, EDL and FDB muscles. These 
proteomic findings are in agreement with the lack of hypertrophy in FDB and INT 
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muscles and the lower levels of central nucleation compared with SOL and EDL muscle 
(Carberry et al., 2013b). Thus, the evaluation of experimental gene therapies for treating 
dystrophinopathy or future pharmacological studies should note that dystrophin-deficient 
skeletal muscle subtypes are not all affected in the same way. The individual 
physiological, biochemical and histological properties of specific muscles have to be 
taken into account when one wants to determine secondary abnormalities and 
adaptations in muscular dystrophy. 
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6 Comparative proteomic analysis of the contractile protein-
depleted fraction of the mdx mouse model of 
dystrophinopathy  
 
6.1 Introduction  
In recent years extensive proteomic surveys have highlighted various skeletal muscle 
extracts. However, since the main proteins of the actomyosin apparatus and its supporting 
sarcomeric components frequently negate weak signals from minor muscle protein species 
during proteomic analyses, we have employed a pre-fractionation step to remove certain 
parts of this analytical problem. In order to eliminate a large portion of highly abundant 
contractile proteins, differential centrifugation of the crude skeletal muscle extracts was 
performed to reduce the samples complexity. The subsequent protein fraction was then 
separated by two-dimensional gel electrophoresis and landmark proteins identified by mass 
spectrometry. In order to better comprehend the complex alterations that occur during X-
linked muscular  dystrophy,  this chapter  focused on analyse  of  contractile  protein-
depleted fractions  from  8-week-old normal  versus  dystrophic hind limb  muscle  
preparations. 
 
6.1.1 Duchenne muscular dystrophy and hind limb skeletal muscles  
Primary genetic abnormalities in the dystrophin gene result in the loss of a crucial 
427kDa cytoskeletal membrane protein located in the subsarcolemmal region of the 
muscle fibers (Dalkilic and Kunkel, 2003).  This loss causes secondary effects which lead 
to muscle weakness and damage due to sarcolemmal instability, disturbance of the 
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excitation-contraction coupling, metabolic pathways, alterations in ion homeostasis, and 
cellular signalling (Emery, 2002). As the dystrophin protein anchors large membrane 
glycoprotein complexes within the cell, membrane rupturing occurs due to its absence 
and results in the loss of membrane integrity. It is this reduction in the dystroglycan 
complex presence which is believed to be an important role in the degeneration of 
dystrophic muscles (Carlson and Makiejus, 1990; Williams and Bloch, 1999). 
 
6.1.2 Experimental design  
Comparative gel-based proteomic analysis of mdx hind limb muscles, subcellular 
fractionation was performed prior to gel electrophoretic separation of the contractile 
protein-depleted. Crude hind limb muscle extracts were separated by two-dimensional 
gel electrophoresis and labelled with the fluorescent dyes (RuBPs). This was followed 
by a detailed comparative DIGE analysis of subcellular hind limb fraction of 8-week-old 
dystrophin-deficient mice versus age-matched control mice across 3-11NL pH range. 
Then proteins with a significant change in their concentration were identified by mass 
spectrometry. Key proteomic findings were verified by immunoblot analysis. Proteomic 
profiling established a distinct change in abundance of 10 protein species in the 
dystrophic mdx hind limb muscles. Identified proteins were involved in various 
processes form the metabolite transport, ion handling and and the cellular stress 
response. 
 
6.2 Results  
6.2.1 Comparative proteomic analysis of mdx hind limb skeletal muscle 
In order to analyse the minor muscle protein species and the extent of secondary 
changes in the mdx hind limb skeletal subproteome due to absence in the 
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membrane cytoskeletal dystrophin protein, a pre-fractionation step to remove the 
actomyosin apparatus and its supporting sarcomeric components was employed. The 
urea-soluble protein complement from the 8-week-old wild type versus age-matched 
dystrophic hind limb muscle was then investigated. Following fluorescent labelling of 
wild type or mdx samples with the CyDyes Cy3, as well as fluor tagging of the 
pooled standard using the CyDye Cy5, high-resolution two-dimensional gel 
electrophoresis was carried out to separate the subproteome from dystrophic mdx 
hind limb muscle. A pH-range of 3-11NL in the first dimension was employed to 
establish a global proteomic pattern.  
Detailed densitometric analysis was carried out using a Typhoon Trio variable 
imager scanner and Samespot Progenesis 2-D analysis software was performed to 
establish differential expression patterns of the aged muscle. Figure 6-3 shows the 
2-D DIGE analysis of 8-week-old dystrophic mdx versus aged-matched normal hind 
limb skeletal muscle. An altered concentration was revealed for 10 protein species, 
with 8 proteins being increased and 2 proteins showing decreased expression in the 
mdx contractile protein-depleted fractions. Mass spectrometry was then used to 
identify these significant muscle-associated proteins of interest and listed in Table 
6-3. 
 
6.2.2 RuBPs analysis of landmark proteins in total extract of normal 
hind limb skeletal muscle  
Prior to the subcellular fractionation gel electrophoretic separation of the total crude 
extract were performed. A list of landmark 2D protein spots from the hind limb muscle 
are numbered 1 to 30 and marked by circles in the total muscle extract landmark 
master gel shown in Fig 6-1. The mass spectrometric identification of these 
unchanged landmark muscle proteins is listed in Table 6-1. This table contains the 
identified muscle-associated proteins names, international accession number, 
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relative molecular masses, pI-values, number of matched peptide sequences, 
Mascot scores, and percentage sequence coverage of major individual muscle 
protein species in dystrophic mdx hind limb muscles.  
Identified protein species ranged from a molecular mass of 12 kDa (parvalbumin) 
to 57 kDa (ATP synthase) and with a pI-range from 3.9 pI (calsequestrin) to 9.0 pI 
(troponin TnT). Spots 1 to 30 represent major muscle-associated protein species 
from ATP synthase (spot 1), enolase (spots 2 and 3), actin (spot 4), creatine kinase 
(spots 5,6, 13, 15 and 18) , fructose-bisphosphate aldolase A (spots 7 and 8), 
calsequestrin (spots 9 and 10), tropomyosin (spot 11), malate dehydrogenase (spot 
12), phosphate dehydrogenase (spot 14), myozenin-1 (spot 16), carbonic 
anhydrase (spot 17), various myosin light chains consisting of MLC1/3, MLC2 (spots 
19, 26-29), adenylate kinase (spot 20), triosephosphate (spot 21), troponin TnI (spot 
22), troponin TnT (spots 23-25) and parvalbumin (spot 30). A significant number of 
the landmark proteins identified are part of the contractile apparatus. 
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Figure 6-1 landmark 2D gel of total mouse skeletal muscle extracts 
Figure 6-1 Two-dimensional gel electrophoretic analysis of total muscle extracts. 
Shown is a RuBPs-stained gel representing major protein species from crude 8-
week-hind limb muscle extracts. Major protein spots are numbered 1 to 30 and 
marked by circles. See Table 6-1for the mass spectrometric identification of the 2D 
landmark proteins. The pH-values of the first dimension and molecular mass 
standards of the second dimension are shown on the top and on the left of the 
panels, respectively 
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Table 6.1 Mass spectrometry list of 2D-landmark proteins from crude tissue 
extracts 
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1 ATP synthase, Atp5b 
protein 
AAH37127 5.24 56632 34 67 834 
2 Enolase, beta NP_031959 6.73 47343 27 63 1249 
3 Enolase, beta NP_031959 6.73 47343 28 61 693 
4 Actin, beta CAA27396 5.78 39451 15 27 481 
5 Creatine kinase, M-
type 
NP_031736 6.58 43250 20 44 911 
6 Creatine kinase, M-
type 
NP_031736 6.58 43250 21 46 949 
7 Fructose-
bisphosphate aldolase 
A isoform 2 
NP_031464 8.31 39795 21 57 344 
8 Fructose-
bisphosphate aldolase 
A isoform 2 
NP_031464 8.31 39795 22 66 1063 
9 Calsequestrin, skeletal 
muscle 
AAC63616 3.93 45619 12 28 219 
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10 Calsequestrin, skeletal 
muscle 
AAC63616 3.93 45619 9 25 463 
11 Tropomyosin, beta 
chain isoform 1 
NP_033442 4.66 32933 12 30 232 
12 Malate 
dehydrogenase, 
mitochondrial 
NP_032643 8.93 36053 11 44 301 
13 Creatine kinase, M-
type 
NP_031736 6.58 43250 15 34 551 
14 Glyceraldehyde-3-
phosphate 
dehydrogenase 
AAH85315 7.59 36099 12 46 281 
15 Creatine kinase, M-
type 
NP_031736 6.58 43250 19 43 879 
16 Myozenin-1 NP_067483 8.57 31438 13 62 406 
17 Carbonic anhydrase, 
CA3 isoform 
NP_031632 6.89 29638 15 58 167 
18 Creatine kinase, M-
type 
NP_031736 6.58 43250 13 23 267 
19 Myosin light chain 
MLC1/3 muscle 
isoform 1f 
NP_067260 4.98 20697 17 78 792 
20 Adenylate kinase 
isoenzyme AK1 
NP_067490 5.7 23334 20 74 497 
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21 Triosephosphate 
isomerase 
AAB48543 5.62 22724 12 83 323 
22 Troponin TnI, fast 
skeletal muscle 
NP_033431 8.65 21518 12 31 191 
23 Troponin TnT, fast 
muscle isoform 
AAB39743 9.01 29358 6 13 237 
24 
Troponin TnT, fast 
muscle isoform 
AAL77612 5.08 36537 14 351 8 
25 Troponin TnT, fast 
muscle isoform 
AAB39743 9.01 29358 18 378 10 
26 Myosin light chain 
MLC2, skeletal muscle 
isoform 
NP_058034 4.82 19059 92 883 22 
27 Myosin light chain 
MLC2, skeletal muscle 
isoform 
NP_058034 4.82 19059 92 463 21 
28 Myosin light chain 
MLC2, skeletal muscle 
isoform 
NP_058034 4.82 19059 52 162 7 
29 Myosin light chain 
MLC1/3, muscle 
isoform 1f 
NP_067260 4.98 20697 39 313 11 
30 Parvalbumin, alpha NP_038673 5.02 11923 71 659 12 
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6.2.3 DIGE analysis of landmark proteins in the contractile protein- 
depleted fraction from mouse skeletal muscle  
A list of landmark 2D protein spots from the subcellular hind limb muscle fraction 
are numbered 1 to 39 and marked by circles in the subcellular fraction landmark 
master gel shown in Fig 6-2. The mass spectrometric identification of these 
landmark muscle proteins is listed in Table 6-2. This table contains the identified 
muscle-associated proteins names, international accession number, relative 
molecular masses, pI-values, number of matched peptide sequences, Mascot 
scores, and percentage sequence coverage of major individual muscle protein 
species in dystrophic mdx hind limb muscles.  
Identified protein species ranged from a molecular mass of 12 kDa (parvalbumin) 
to 86 kDa (phosphofructokinase) and with a pI-range from 4.7 pI (tropomyosin) to 8.7 
pI (phosphoglycerate mutase). Spots 1 to 39 represent most abundant 
subproteomic protein species from transferrin (spot 1), Phosphofructokinase (spot 
2), various heat shock protein Hsp70 isoforms (spots 3-6), Pgm2 protein (spot 7), 
pyruvate kinase (spots 8 and 9), ATP synthase (spot 10), hippocalcin-like protein 
(spot 11), enolase (spots 12-15 and 22), actin (spot 16), beta-actin-like protein (spot 
17), creatine kinase (spot 18), fructose-bisphosphate aldolase (spot 19), 
tropomyosin (spots 20 and 21), phosphate dehydrogenase (spot 23), malate 
dehydrogenase (spots 24 and 25), phosphoglycerate mutase (spots 27 and 28), DJ-
1 protein (spot 30), peroxide reductase (spot 31), manganese superoxide dismutase 
(spot 32), phosphatidylethanolamine binding protein (spot 33), adenylate kinase 
(spot 34), ferritin (spot 35), peptidyl-prolyl isomerase (spot 36), parvalbumin (spots 
37 and 38) and hemoglobin (spot 39). In contrast to the total extracts, a substantial 
number neutral-to-acidic protein species have been removed in the subcellular fraction 
with limited number of minor spots with contractile.  
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Figure 6-2 landmark 2D gel of the subcellular mouse muscle fraction 
Figure 6-2 Two-dimensional gel electrophoretic analysis of the subcellular mouse 
muscle fraction. Shown is a  DIGE-labelled gel representing major protein species from 
the contractile protein-depleted fraction. Major protein spots are numbered 1 to 39 and 
marked by circles. See Table 6-2 for the mass spectrometric identification of the 2D 
landmark proteins. The pH-values of the first dimension and molecular mass standards 
of the second dimension are shown on the top and on the left of the panels, respectively.  
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Table 6.2 Mass spectrometry list of 2D-landmark proteins from the subcellular 
fraction 
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1 Transferrin AAL34533 6.92 78832 4 6 41 
2 Phosphofructokinase, 
muscle 
GI:13529638 8.24 86119 8 10 53 
3 Heat shock protein 
Hsp70, inducible 
ABK96811 5.53 70378 5 11 136 
4 Heat shock protein 
Hsp70, mitochondrial 
BAA04493 5.91 73773 4 7 82 
5 Heat shock protein 
Hsp70, mortalin 
AAB28641 5.72 73403 4 6 99 
6 Heat shock protein 
Hsp70, mitochondrial 
BAA04493 5.91 73773 2 3 74 
7 Pgm2 protein, partial GI:33416468 6.02 63700 12 24 109 
8 Pyruvate kinase, 
muscle isoform M1 
GI:359807367 6.69 58470 11 22 182 
9 Pyruvate kinase, 
muscle isoform M1 
GI:359807367 6.69 58470 9 22 148 
 144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 ATP synthase Atp5b 
protein 
GI:23272966 5.24 56632 5 12 42 
11 Hippocalcin-like 
protein 1 
GI:407263738 5.54 22459 2 28 44 
12 Enolase, beta GI:6679651 6.73 47343 4 14 110 
13 Enolase, beta GI:6679651 6.73 47343 4 13 107 
14 Enolase, beta GI:6679651 6.73 47343 15 45 316 
15 Enolase, beta GI:6679651 6.73 47343 12 35 241 
16 Actin, alpha, skeletal 
muscle 
GI:4501881 5.23 42372 7 19 62 
17 Beta-actin-like protein 
2 
GI:30425250 5.3 42325 2 4 44 
18 Creatine kinase, M-
type 
GI:6671762 6.58 43250 6 22 181 
19 Fructose-
bisphosphate aldolase 
A isoform 2 
GI:6671539 8.31 39795 10 30 71 
20 Tropomyosin, beta 
chain 
GI:11875203 4.66 32933 2 9 42 
21 Tropomyosin, alpha-1 
chain isoform 3 
GI:31560030 4.71 32747 9 17 92 
22 Enolase, beta GI:6679651 6.73 47343 5 16 138 
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23 Glyceraldehyde-3- 
Phosphate 
dehydrogenase 
GI:6679937 8.44 36077 6 20 83 
24 Malate 
dehydrogenase, 
cytosolic 
GI:387129 6.16 36628 4 16 108 
25 Malate 
dehydrogenase, 
cytosolic 
GI:387129 6.16 36628 4 16 113 
26 Phosphoglycerate 
mutase 2 
GI:9256624 8.65 28980 7 22 93 
27 Triosephosphate 
isomerase 
GI:54855 6.9 27021 4 20 116 
28 Triosephosphate 
isomerase 
GI:54855 6.9 27021 8 55 125 
29 Phosphoglycerate 
mutase 2 
GI:9256624 8.65 28980 4 17 60 
30 DJ-1 protein GI:55741460 6.32 20236 3 12 42 
31 Thioredoxin-
dependent peroxide 
reductase, 
mitochondrial 
GI:6680690 7.15 28337 4 16 57 
32 Manganese 
superoxide dismutase 
GI:53450 8.8 24894 2 3 36 
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33 Phosphatidylethanol- 
amine binding protein 
GI:1517864 5.19 21018 3 18 93 
34 Adenylate kinase, 
isoenzyme AK1 
GI:10946936 5.7 23330 5 33 87 
35 Ferritin light chain 1 GI:120524 5.66 20847 4 32 81 
36 Peptidyl-prolyl cis-trans 
isomerase A 
NP_032933 7.74 18134 4 35 89 
37 Parvalbumin GI:53819 5.02 11937 3 26 80 
38 Parvalbumin GI:53819 5.02 11937 6 57 136 
39 Hemoglobin beta GI:229301 7.26 15767 5 40 98 
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6.2.4 Proteomic analysis of dystrophic skeletal muscle 
Following the optimisation and initial mass spectrometric identification of landmark 
muscle proteins in mouse skeletal muscle, comparative DIGE analysis was 
performed to determine potential differences protein expression patterns in mdx 
skeletal muscle subproteome.  4 biological replicates for each sample type were run 
using a two dye system. Each repeat contained a subcellular hind limb muscle 
fraction. Figure 6-3 shows the analytical 2-D gels  of  Cy3-labelled  normal  and  
dystrophic skeletal muscle  and  corresponding  Cy5-labelled  pooled  standards. 
The overall 2D  spot  patterns  of  normal  versus  dystrophic mouse skeletal  
muscle  were relatively comparable as a result a detailed denitometric analysis was 
performed in order to determine potential differences in individual protein species. 
Densitometric analysis was carried out using a Typhoon Trio variable imager 
scanner and Samespot Progenesis 2-D analysis software was performed to 
establish differential protein expression patterns. The detailed proteomic profiling of 
the contractile protein-depleted fraction revealed distinct changes in 10 muscle 
protein species in the mdx dystrophic muscle preparations. 
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Figure 6-3 Fluorescence 2D-DIGE analytical gel of normal versus mdx 
skeletal muscle fraction 
Figure 6-3 Two-dimensional gel electrophoretic analysis of the subcellular mouse 
muscle fraction. Shown are Cy3-labelled gels of the soluble fraction of contractile 
protein-depleted normal (A) and dystrophic mdx (C) skeletal muscle as well as Cy5-
labelled gels with all the samples combined to form a pooled standard (B) and (D).  
Analytical DIGE gels with electrophoretically separated proteins are displayed 
across 3-11 NL pH range. The pH-values of the first dimension gel system and 
molecular mass standards (in kDa) of the second dimension are indicated on the 
top and the left of the panels, respectively. 
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6.2.5 DIGE analysis of dystrophic muscle proteins 
The comparative proteomic analysis of normal vs dystrophic mdx hind limb 
muscle, performed with the contractile protein-depleted fraction, revealed altered 
expression patterns for 10 distinct protein spots. Proteins with significant changes 
are numbered 1 to 10 and marked by circles in the DIGE master gel Fig 6-4. The 
mass spectrometric identification of these altered muscle protein species are listed 
in Table 6-3. This table contains the identified muscle-associated proteins names, 
international accession number, relative molecular masses, pI-values, number of 
matched peptide sequences, Mascot scores, and percentage sequence coverage of 
major individual muscle protein species in dystrophic mdx hind limb muscles.  
Identified protein species ranged from a molecular mass of 18 kDa (peptidyl-prolyl 
cis-trans isomerase) to 79 kDa (transferrin) and with a pI-range from 5.5 pI (Hsp70) 
to 7.7 pI (peptidyl-prolyl cis-trans isomerase). Altered proteins were shown to be 
various isoforms of the molecular chaperone Hsp70 (spots 1-3 and 6), an unnamed 
protein BAC34145 (spots 4 and 5), ferritin light chain (spot 7), the transferrin protein 
(spot 8), peptidyl-prolyl cis-trans isomerase (spot 9) and Pgm2 protein (spot 10). 
While the 2 enzymes were revealed to be decreased in abundance, the heat shock 
proteins and iron-binding proteins expression levels showed an increased 
abundance (Table 6-3).  
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Figure 6-4 Fluorescence 2D-DIGE master gel of the subcellular mouse 
muscle fraction 
Figure 6-4 Two-dimensional gel electrophoretic analysis of the subcellular mouse 
muscle fraction. Shown is a  DIGE-labelled gel representing the analysis of 
dystrophin-deficient hind limb muscles from the mdx mouse animal model of 
Duchenne muscular dystrophy. Protein species with a significantly altered 
abundance are numbered 1 to 10 and marked by circles. See Table 6-3 for the 
mass spectrometric identification of the changed muscle proteins in muscular 
dystrophy. The pH-values of the first dimension and molecular mass standards of 
the second dimension are shown on the top and on the left of the panels, 
respectively.  
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Table 6.3 List of changed proteins in the subcellular fraction from mdx muscle as 
verified by fluorescent 2D-DIGE analysis 
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1 Heat shock protein 
Hsp70, mitochondrial 
BAA04493 5.91 73773 2 3 74 1.9 
2 Heat shock protein 
Hsp70, mortalin 
AAB28641 5.72 73403 4 6 99 1.9 
3 Heat shock protein 
Hsp70, mitochondrial 
BAA04493 5.91 73773 4 7 82 1.9 
4 Unnamed protein 
product 
BAC34145 5.75 70730 11 22 238 1.8 
5 Unnamed protein 
product 
BAC34145 5.75 70730 9 18 305 1.8 
6 Heat shock protein 
Hsp70, inducible 
ABK96811 5.53 70378 5 11 136 1.7 
7 Ferritin light chain 1 GI:120524 5.66 20847 4 32 81 1.6 
8 Transferrin AAL34533 6.92 78832 4 6 41 1.6 
9 Peptidyl-prolyl cis-
trans isomerase A 
NP_032933 7.74 18134 4 35 89 -1.4 
10 Pgm2 protein, partial GI:33416468 6.02 63700 12 24 109 -1.7 
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6.2.6 Immunoblot analysis of dystrophic hind limb muscle 
In order to further characterise the mdx hind limb muscle, comparative immunoblotting 
was carried out following the mass spectrometric identification of key changes in the 
mdx skeletal muscle subproteome. Immunoblotting was performed to verify the 
altered concentration in Hsp70, transferrin, and ferritin light chain protein in normal 
versus dystrophic muscle preparations (Figure 6-5E, F, H), respectively.  
Prior to investigating the novel candidates with distinct changes in expression in the 
mdx hind limb muscle, established biomarker proteins with unchanged concentration, 
increased expression and decreased expression were blotted. This included Immuno-
labelling of myosin MLC2, laminin and parvalbumin which exhibited comparable 
expression levels in normal versus mdx preparations (Figure 6-5A, B, G), respectively. In 
contrast, the dystrophin-associated glycoprotein β-dystroglycan and the extracellular 
matrix protein collagen revealed significantly altered concentrations in dystrophin-
deficient muscle (Figure 6-5C, D), respectively.  
Immunoblotting  of  the  novel  marker candidates  of  x-linked  muscular  dystrophy,  as  
shown  here  by  subcellular proteomics analysis,  clearly  confirmed  their  changed  
expression in  dystrophic mdx muscle. Immuno-labelled transferrin, Hsp70 and ferritin 
light chain blots revealed statistically significant reduced levels in mdx hind limb muscle 
(figure 6-5E, F, H), respectively. Immunoblots in Figure 6-5A-F were prepared with crude 
tissue extracts to establish changes in abundance on the global muscle protein level. 
However, immune decoration of ferritin light chain did not produce a sufficient signal. 
Thus ferritn analysis, in combination with the unchanged marker protein parvalbumin, 
was carried out with the contractile protein-depleted fraction (Figure 6-5G, H) 
respectively. 
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Figure 6-5A Immunoblotting analysis of unchanged MLC2  
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblots were labelled with the myosin MLC2 antibody. Lanes 1, 2 
represent normal wild type versus dystrophic muscle from total tissue extracts, 
respectively. The comparative  blotting  was  statistically  verified  using  an  unpaired  
Student’s  t-test (n=4 replicates).  
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Figure 6-5B Immunoblotting analysis of equally loaded extracellular matrix 
protein laminin  
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblots were labelled with the laminin antibody, an unchanged protein in 
dystrophic myofibres. Lanes 1, 2 represent normal wild type versus dystrophic muscle 
from total tissue extracts, respectively. The comparative  blotting  was  statistically  
verified  using  an  unpaired  Student’s  t-test (n=4 replicates).  
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Figure 6-5C Immunoblotting analysis of dystrophin-associated glycoprotein β-
dystroglycan 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblots were labelled with the β-dystroglycan Novocastra antibody. 
Lanes 1, 2 represent normal wild type versus dystrophic muscle from total tissue 
extracts, respectively. The comparative blotting was statistically verified using an unpaired 
Student’s t-test (n=4 replicates). Standard deviation represented by Error bars, 
(*p<0.05). 
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Figure 6-5D Immunoblotting analysis of extracellular matrix protein collagen  
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in hind limb muscle normal 
versus mdx. Immunoblots were labelled with the collagen antibody. Lanes 1, 2 represent 
normal wild type versus dystrophic muscle from total tissue extracts, respectively. The 
comparative  blotting  was  statistically  verified  using  an  unpaired  Student’s  t-test (n=4 
replicates). Standard deviation represented by Error bars, (**p<0.005). 
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Figure 6-5E Immunoblotting analysis of iron transporter protein transferrin  
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in hind limb muscle normal 
versus mdx. Immunoblots were labelled with the transferrin antibody. Lanes 1, 2 
represent normal wild type versus dystrophic muscle from total tissue extracts, 
respectively. The comparative  blotting  was  statistically  verified  using  an  unpaired  
Student’s  t-test (n=4 replicates). Standard deviation represented by Error bars, 
(*p<0.05). 
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Figure 6-5F Immunoblotting analysis of large heat shock protein 70 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in hind limb muscle normal 
versus mdx. Immunoblots were labelled with the Hsp70 antibody. Lanes 1, 2 represent 
normal wild type versus dystrophic muscle from total tissue extracts, respectively. The 
comparative  blotting  was  statistically  verified  using  an  unpaired  Student’s  t-test (n=4 
replicates). Standard deviation represented by Error bars, (***p<0.001). 
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Figure 6-5G Immunoblotting analysis of unchanged calcium-binding protein 
parvalbumin 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblots were labelled with the parvalbumin antibody. Lanes 1, 2 
represent normal wild type versus dystrophic muscle from the contractile protein-
depleted subcellular fraction, respectively. The comparative  blotting  was  statistically  
verified  using  an  unpaired  Student’s  t-test (n=4 replicates).  
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Figure 6-5H Immunoblotting analysis of iron storage protein ferritin 
Shown are representative blots with expanded views of immuno-decorated protein 
bands indicated by the arrowhead, with graphical presentation of the statistical 
evaluation. Immunoblot analysis of novel biomarker proteins in hind limb muscle normal 
versus mdx. Immunoblots were labelled with the ferritin light chain antibody. Lanes 1, 2 
represent normal wild type versus dystrophic muscle from the contractile protein-
depleted subcellular fraction, respectively. The comparative  blotting  was  statistically  
verified  using  an  unpaired  Student’s  t-test (n=4 replicates). Standard deviation 
represented by Error bars, (**p<0.005). 
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6.3 Discussion  
Duchenne muscular dystrophy is one of the most crippling childhood neuromuscular 
disorders, therefore meriting comprehensive large-scale studies into the establishment 
of detailed biomarker signatures of dystrophinopathy (Lewis et al., 2009; Griffin and 
Rosiers, 2009). Subproteomic surveys have clearly revealed that organelle proteomics 
is well suited for evaluating global alterations in distinct subcellular fractions from 
skeletal muscles during pathological or physiological adaptations (Ohlendieck, 2012). 
Although the primary defects causing X-linked muscular dystrophy are well-known and 
the resulting absence in the membrane cytoskeletal dystrophin protein is well 
documented, little is established about the complexity of secondary alterations leading 
to dystrophinopathy.  
In this chapter as outlined in Figure 6-6 below, an investigation into the suitability of 
introducing a simple subcellular fractionation step to swiftly eliminate a large part of the 
actomyosin apparatus from muscle homogenates was performed. Subsequently, 
allowing for the comparative analysis of low level protein species by MS-based 
subproteomics. The flowchart of Figure 6-6 clearly verifies the different protein 
expression patterns in the fluorescent 2-D gel images, with the separation of the 
abundant contractile protein fraction from the pellet representing less frequent muscle 
proteins.  
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Figure 6-6 Differential centrifugation of muscle homogenates to obtain a 
contractile protein-depleted fraction for comparative subproteomic analysis 
Shown is a flowchart of the subcellular fractionation protocol used to swiftly isolate low 
abundant protein fractions in normal versus dystrophic skeletal muscle homogenates (A). 
The separation of the abundant contractile protein fraction from the pellet representing 
less frequent muscle proteins is  shown  by  the considerably different protein expression 
patterns in the fluorescent 2-D gel images of  crude  tissue  extracts (B)  vs  the  protein  
pellet  following differential centrifugation (C). An open circle represents the contractile 
protein-containing area of 2D gels in the acidic-to-neutral pI range.  
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The drastic reduction in protein abundance in the acidic-to-neutral area of the gel 
image in Figure 6-6C, as compared to the crude extract shown in Figure 6-6B, suggests 
the successful elimination of a substantial portion of contractile elements, like the actins, 
troponins, myosins and tropomyosins (Holland and Ohlendieck  2013; Gannon  et al., 
2009). To confirm the depletion of the actomyosin apparatus, mass spectrometry 
analysis was performed on the 2-D gels before and after differential centrifugation to 
clearly identify abundant landmark protein spots.  
Table 6-1 lists their identity as actin (spot 4), tropomyosin (spot 11), myosin  
light chains MLC1f (spots 19, 29), MLC2 (spots 26-28), troponin I (spot 22) and troponin 
T (spots 23-25). In contrast, many of the contractile muscle proteins have subsequently 
been eliminated by differential centrifugation. Table 6-2 shows a limited number of 
proteins with contractile elements, like actin (spots 16, 17) and tropomyosin (spots 20, 
21). A number of the other 2D-landmark protein species in both the crude extracts and  
subcellular fraction of the  skeletal  muscle homogenates were identified as involved in 
various processes form the metabolite transport, ion handling and and the cellular stress 
response. 
 
6.3.1 Proteomic expression changes of skeletal muscle analysis  
Previous proteomic surveys have predominantly concentrated on total tissue extracts 
and as a result have identified mainly abundant muscle-associated proteins,  such  as  
components  involved  in various processes form metabolism, ion  handling, 
stabilization  of  the cytoskeleton and extracellular matrix, excitation-contraction 
coupling  and  the  cellular  stress  response (Lewis et al.,  2009; Guevel et al., 2011; 
Gardan-Salmon et al., 2011; Rayavarapu et al., 2013; Carberry et al., 2012a; Carberry et 
al., 2012b; Carberry et al., 2013b). 
In contrast, this chapter as shown that the depletion of the contractile apparatus by 
differential centrifugation, results in the comparative  proteomic  profiling  of  minor low 
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abundant  protein  species  in  normal  vs dystrophic   preparations. Changes in 
expression of these minor muscle-associated proteins were identified as various 
isoforms of the heat shock protein Hsp70, transferrin, ferritin light chain and the 
enzymes phosphoglucomutase and peptidyl-prolyl cis-trans isomerase in the mdx 
muscle. 
 
6.3.2 Increased expression of Iron handling proteins 
Transferrin (Szőke and Panteghini, 2012) and ferritin light chain (Crichton and 
Declercq, 2010) are essential iron-transporting proteins and key elements of iron 
metabolism (Wang and Pantopoulos, 2011). Elevated levels of transferrin and ferritin 
proteins in dystrophic muscle support recent findings from the proteomic profiling of the 
aged mdx heart (Holland et al., 2013a) and the aged mdx diaphragm, shown in chapter 
4. 
During the aging dystrophic diaphragm study which investigated 8-week to 22-month 
range (Carberry et al., 2012a), we also examined the 8-week to 12-month range and 
recorded a drastic increase in ferritin light chain levels in mdx muscle. Deficiency in 
dystrophin seems to impair iron homeostasis and the elevated iron transporter and 
binding-protein concentrations possibly suggest a compensatory mechanism to help 
prevent harmful iron overloading in muscle tissues. The 2-fold increase in 
concentration of transferrin indicates disruptions in iron absorption and 
consumption in muscular dystrophy, as circulating transferrin functions as an iron 
transporter providing iron requirements to tissue proteins (Wang and Pantopoulos, 
2011).  
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6.3.3 Perturbed stress response in mdx tissue   
Elevated levels of molecular chaperones are indicative of intensified cellular stress in 
dystrophic muscle tissue. One of these key molecular chaperones is Heat shock 
protein Hsp70 which exists as several different isoforms (Young, 2010). The various 
isoforms of Hsp70 play a main role in skeletal muscle stress in response to injury, 
oxidative conditions, reperfusion-induced ischemia, excessive exercise and 
neuromuscular disorders (Liu et al., 2006). In the aging dystrophic diaphragm study 
(Carberry et al., 2012a) which examined the 8-week to 12-month range also recorded a 
significant increase in heat shock protein Hsp70-cognate levels in mdx muscle. 
During periods of muscle stress molecular chaperone regulation has been shown to 
be crucial in protecting muscle from damage (Maglara et al., 2003). In general, stress 
proteins facilitate in protein-protein interactions by helping to stabilise misfolded 
proteins or peptide clusters as well as regulating there degradation and elimination in 
order to prevent harmful unwanted accumulation of non-functional protein  aggregates 
(Boluyt  et  al., 2006). Hence, the observed increase in expression of mitochondrial 
Hsp70 isoforms can be seen as a compensatory mechanism to protect dystrophic 
fibers from excessive oxidative stress and supporting previous reports on elevated 
levels of the small heat shock protein cvHsp in dystrophic skeletal muscle (Doran et al., 
2006a). 
 
6.3.4 Other proteins 
Besides the molecular chaperone Hsp70, two other protein spots were identified with 
an increased concentration displaying similar molecular mass and somewhat different 
isoelectric points. These protein spots relate to an unnamed protein (BAC34145 protein 
product, gi|26340966|) with unknown function. The reduction in expression of the 
enzymes phosphoglucomutase and peptidyl-prolyl-isomerase indicates abnormal 
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glycogen utilisation and impaired protein folding processes in mdx muscle, 
respectively. Phosphoglucomutase facilitates the interconversion of glucose-1-
phosphate and glucose 6-phosphate during glycogenesis and glycogenolysis, making it 
a key protein of glycogen and glucose metabolism in muscle (Ohlendieck, 2011).  
Reduced levels of this enzyme indicate impaired glucose utilisation in dystrophic 
muscle fibers. Peptidyl-prolyl-isomerase facilitates in protein folding by accelerating the 
process. In oligopeptides, this enzyme mediates the cis-trans isomerisation of proline 
imidic peptide bonds (Quintá et al., 2011). Therefore, its decreased concentration might 
reduce the capability of dystrophic muscles to correctly refold certain classes of muscle 
proteins.  
 
6.4 Conclusion  
In conclusion, the  systematic  depletion  of abundant  contractile  proteins  from  
muscle preparations before gel electrophoretic protein separation has resulted in 
improved  access  to  minor low level  protein  species  from  dystrophic  muscle. The 
comparative proteomic profiling of subcellular hind limb fraction of 8-week-old 
dystrophin-deficient mice versus age-matched control mice has revealed changes in 
expression levels in a number of interesting proteins and highlighted potential novel 
biomarker candidates for Duchenne muscular dystrophy. 
This chapter demonstrates that the employment of organelle proteomics can overcome 
particular technical limitations of whole tissue proteomics and should be used to 
complement these proteomic findings. Since skeletal muscle tissues are characterised 
by a mainly diverse range of minor low level protein species and a large dynamic range 
of protein expression patterns, the employment of pre-fractionation procedures 
significantly reduces sample complexity and thus enables for a more 
comprehensive coverage of complex muscle protein mixtures and the skeletal 
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proteome.  
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7 General Discussion  
 
X-linked Duchenne muscular dystrophy is an extremely progressive childhood 
neuromuscular disorder and can be characterised by primary genetic abnormalities in 
the dystrophin gene. Defects in the dystrophin gene result in the loss of a crucial 
427kDa cytoskeletal membrane protein (Dalkilic and Kunkel, 2003).  
The optimisation of animal models is a vital area in biomedical proteomics and 
proteomic biomarker discovery. The application of gel-based proteomics is routinely 
employed to establish muscle-associated biomarkers and in recent years been used 
with the mdx animal model of muscular dystrophy for the biochemical evaluation of 
novel experimental therapies, such as exon skipping for a potential treatment for DMD 
(Doran et al., 2009b).  
The overall goal of this report was to establish a detailed proteomic signature for the 
mdx animal model across various age groups and muscle types. It is important to 
stress that the muscles in mdx mouse exhibit varying degrees of degeneration. This 
report focused on moderately affected mdx hind limb muscles, the mildly affected 
phenotype of the mdx interossious muscle which was shown to be even less necrotic 
than the mdx soleus, extensor digitorum longus or tibialis anterior muscles. In 
contrast, the mdx diaphragm muscle was shown to be severely affected (Stedman et 
al., 1991) and aging of the diaphragm exacerbate the dystrophic phenotype (Carberry 
et al., 2012a). Thus, the aged mdx diaphragm muscle more closely resembles that of 
the neuromuscular pathology exhibited in Duchenne patients (Lefaucheur et al., 1995).  
Skeletal muscle proteomics is concerned with the global identification, comprehensive 
cataloguing and biochemical analysis of the entire protein complement of contractile 
fibers in normal and pathological specimens (Isfort, 2002). Previous proteomic reports 
have revealed that MS-based technologies are suitable for studying a representative 
proportion of muscle-associated proteins involved in regulation, contraction, structure, 
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metabolism and cellular stress response (Doran et al., 2008; O'Connell et al., 2008; 
Lewis et al., 2009). Figure 7-1 represents an overview of the past usage of MS-based 
proteomics employed to characterise the dystrophin-glycoprotein complex and 
secondary alterations in the dystrophic mdx mouse (Holland et al., 2013b). Figure 7-1 
includes the various age groups and muscle types evaluated by proteomics and also 
highlights the comparative proteomic approaches discussed in this report. 
Mass spectrometry in combination with fluorescence labelling techniques can  
detect several thousand muscle-associated proteins in high-resolution 2D gel 
electrophoresis (Doran et al., 2006b). However, there are limitations to this technique 
with respect to analysing the entire cellular proteome (Rabilloud et al., 2009). 
Membrane proteins, high molecular mass proteins and low-level abundance proteins 
can be challenging to detect in polyacrylamide  gels  due  to  the hydrophobic  nature,  
pore  size  and  dynamic  range, respectively. 
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Figure 7-1 MS-based proteomic profiling of the mdx mouse model of Duchenne 
muscular dystrophy 
Figure 7-1 represents the various types of muscle and age groups of the mdx mouse 
that have been analysed over the recent years to establish global changes in the 
dystrophic muscle proteome. All highlighted proteomic studies have been discussed in a 
detailed review of the proteomics of the dystrophin-glycoprotein complex and 
dystrophinopathy (Staunton et al., 2011). While, the blue circles represent the muscle 
types covered in this thesis. 
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Thus, since the main proteins of the actomyosin apparatus and its supporting sarcomeric 
components frequently negate weak signals from minor muscle protein species during 
proteomic analyses, we have employed a pre-fractionation step to remove certain parts of 
this analytical problem (Carberry et al., 2014). In order to eliminate a large portion of highly 
abundant contractile proteins, differential centrifugation of the crude skeletal muscle 
extracts were performed to reduce the samples complexity as shown in Chapter 6. 
In the mdx animal model of dystrophinopathy, different skeletal muscle subtypes are 
affected to varying degrees resulting from the same single base substitution of the 
dystrophin gene. Thus, to establish potential muscle subtype-specific alterations in 
secondary changes due to dystrophin-deficiency, we have performed a comparative 
proteomic survey of multiple mdx muscles. Highlighting alterations in naturally protected 
and moderately affected phenotypes as shown in Chapter 5.  
Furthermore, the established mdx mouse model of dystrophinopathy exhibits progressive 
muscle tissue deterioration with age and more closely resembles the human pathology as a 
result aged mdx muscle specimens were analysed on a large-scale survey of potential age-
related changes in the dystrophic phenotype as shown in Chapters 3 and 4. This 
established senescent mdx mouse diaphragm muscle as a more suitable dystrophic 
phenotype. Thus, we investigated this particular tissue further to determine the global 
changes in the protein complement during the natural aging process of the mdx muscle. 
 
Figure 7-2 illustrates an overview of the proteomic results from the senescent mdx 
mouse model survey for Duchenne muscular dystrophy. Global changes in structural 
proteins, extracellular proteins, contractile proteins, molecular chaperones, calcium-
binding proteins, glycolytic enzymes, mitochondrial enzymes and metabolite 
transporters suggest changes in the cytoskeletal complex and its indirect linkage to the 
extracellular matrix, reorganisations within the actomyosin apparatus, an intensified 
cellular stress response, compromised ion handling and metabolic disturbances.  
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Overall, this analysis revealed that protein expression patterns are severely changed 
in dystrophin-deficient mdx diaphragm muscle and that these pathobiochemical 
alterations are more intense compared to that of the different mdx skeletal muscles 
examined in this thesis (Rayavarapu  et al., 2013; Ge et al., 2003; Carberry et al., 
2012a; Carberry et al., 2013a). Additionally, it was revealed that isoforms of the same 
protein exhibit differential expression patterns suggesting possible post-translational 
modifications such as glycosylation demonstrating the complexity of the disease. 
These features display  the  benefits  of 2-D gel electrophoresis in  its  ability  to  
present  crude  soluble  protein complement of the muscle fibers.  
 
Elevated levels of dermatopontin and the resulting increase in collagen supports the 
progressive accumulation of connective tissue in the dystrophic mdx diaphragm (et al 
Carberry). ATP production appears severely disturbed in diaphragm tissue whereas 
we saw only moderate alterations in ATP production in the moderately affected hind limb 
muscles and the milder phenotype of the fingers and toes exhibited spared mitochondrial 
function. This bioenergetic dysfunction of mitochondria in the senescent mdx 
diaphragm indicates that aged mitochondria are incapable of meeting the ATP demand 
of the dystrophic muscle fibers. In addition, the proteomic findings of a decreased 
concentration of the vital and rate-limiting metabolite transporters for the utilisation of 
oxygen and fatty acids, intracellular oxygen transporter myoglobin and the fatty acid 
binging protein FABP3, suggest the idea of impaired mitochondrial metabolism. 
 
The contractile apparatus degeneration and/or remodeling of the skeletal muscles 
were indicated here with actin, troponins, tropomyosin and myosin light chains to 
varying degrees. All the muscle types exhibited an intensified cellular stress response 
with the up-regulation of various heat shock proteins due to the lack of dystrophin. 
Increased iron transporter and binding-protein concentrations indicate disruptions in 
iron absorption and consumption in muscular dystrophy, the elevated abundance 
suggests impaired iron homeostasis in the degenerating mdx diaphragm and hind limb 
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muscles. 
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Figure 7-2 Proteomic survey of the mdx animal model for Duchenne muscular 
dystrophy 
The diagram summarises the key classes of diaphragm proteins identified by the 
proteomic analysis of the aged and mdx dystrophin-deficient mouse model of X-
linked muscular dystrophy. The severely affected protein expression pattern of mdx 
dystrophic muscle includes extracellular matrix proteins, structural proteins, 
contractile proteins, molecular chaperones, calcium-binding proteins, mitochondrial 
enzymes, glycolytic enzymes and metabolite transporters. Thus, the absence of the 
dystrophin isoform Dp427 and resulting reduction in dystrophin-associated 
glycoproteins in the dystrophic sarcolemma seems to trigger a variety of secondary 
abnormalities in muscular dystrophy. 
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Sarcolemma disruption is high in mdx diaphragm tissue. As the dystrophin protein 
anchors large membrane glycoprotein complexes within the cell, membrane rupturing 
occurs due to its absence and results in the loss of membrane integrity. One of these 
glycoproteins, ß-dystroglycan is rescued in the finger and toe muscles of Chapter 5 
(Dowling et al., 2004). The rescue of ß-dystroglycan reduces the contraction-induced 
micro-rupturing normally observed in dystrophic tissue. The dystrophic diaphragm 
revealed progressive accumulation of connective tissue with elevated levels of 
dermatopontin and the resulting increase in collagen, while the fingers and toes appear 
naturally protected.   
Interestingly, the number of fibers containing central nuclei was lower in the fingers 
and toes compared to that of the mdx hind limb muscles (Fig 5-7). This is vital, since 
central nucleation is considered as a sign of recent muscle fiber regeneration. The 
fingers and toes also observed no increase in muscle mass, in contrast to the hind 
limb muscles. Both central nucleation and the level of hypertrophy of the finger and 
toe muscles are in line with a less severe impairment (Carberry et al., 2013b). 
From our studies we have demonstrated that the INT and FDB muscle are under less 
stress than the severely dystrophic diaphragm tissue. This is apparent from the stress 
response possible due to the rescue of the dystroglycan protein and evident from lack of 
central nucleation and hypertrophy. The smaller diameter of the muscle fibers may 
facilitate the replacement of utrophin and offer mechanical stability to the cell membrane. 
Over the last decade major advances have been made in both the understanding of the 
molecular genetics and pathogenesis of Duchenne muscular dystrophy. This has raised 
expectations of a curative treatment with gene theraphy.  Exon skipping therapy is a form 
of non-viral gene therapy, were it was hypothesized that one could change the serve DMD 
phenotype into a milder BMD phenotype, simply if one was able to change the splicing of 
the DMD gene to produce a smaller in-frame transcript. 
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A comparative proteomic analysis was performed to evaluate exon skipping as a 
potential therapeutic approach and revealed a restoration of key muscle-associated 
proteins after the dystrophin isoform was restored in the dystrophic diaphragm (Doran 
et al., 2009b). Reversal of differential proteins involved in dystroglycan complex, 
energy production and calcium handling were significantly expressed. Although this 
therapy appears promising one of the challenges is the need for personalised 
therapies. Skipping over a single exon in such a large size gene will only target a 
small number of suitable candidates to treat (Rando, 2007) (Lim and Rando, 2008) 
and offer a milder form of the disease and personalised therapies would prove costly at 
this initial stage of the development.  
While the large size and complexity of dystrophin is problematic, it does carry a 
silver lining as the vast majority of the gene remains unchanged (Menhart, 2003). 
Thus this major challenge of personalised therapy is partly obviated by the fact some 
deletions are very common in DMD and that a vast majority of DMD cases are 
represented by a relatively small number of deletions. This means, theoretically a 
limited number of antisense oligonucleotides will be effective in a majoriy of DMD 
patients (Aartsma-Rus et al., 2003). 
Over the years, many pharmacological interventions have been proposed as likely 
treatments for DMD/BMD. Glucocorticoids offer the only method of preserving muscle 
function. Though their mechcanism(s) of action is unknown, glucocorticoids such as 
prednisone and prednisone-derivative deflazacort are effective in slowing the progression 
of DMD. Side effects are associated with both drugs, which include excessive weight gain 
which can negatively impact muscle function (Biggar et al., 2006). Treatment of DMD boys 
carried out by using Deflazacort resulted in improved pulmonary function, suggested an 
improvement in the respiratory muscles (Biggar et al., 2001). There is universal agreement 
that boys with DMD benefit from corticosteroid treatment.  
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A number of neuromuscular disorders are characterised by this membrane-spanning  
complex that a detailed analysis is warranted into its assembly, interactions and 
maintenance in healthy fibers versus its dysfunction in dystrophic muscle tissue. The 
comprehensive proteomic study of the high-molecular mass proteins excluded 
from traditional 2D gels with subsequent MS identification may provide insight into the 
fate of protein species over the progression of muscular dystrophies. A detailed label-
free analysis into severely dystrophic aged diaphragm, mildly affected hind limb and 
spared extraocular and interosseus fibers may provide new insights into the 
compensatory mechanisms that counteract dystrophic abnormalities. Since the 
approximately 30,000 protein-coding genes in the human genome are predicted to 
produce several 100,000 protein species, it is assumed that the number of muscle-
associated protein isoforms far exceeds that of the skeletal muscle-specific genes. 
Therefore, future studies into the analysis of post-translational modifications and the 
classification of protein isoforms in healthy and diseased muscle is warranted.  
In recent years, comparative proteomic studies with mdx muscle tissue extracts 
have shown significant alterations in the enzyme adenylate kinase AK1 (Marouga 
et al., 2005; Ng et al., 2012; Theodoridis et al., 2012), the actin binding protein 
profilin, the fatty acid binding protein FABP3 (Okamoto and Fujiwara, 2006), the 
cytosolic Ca2+-binding protein parvalbumin (Stastna and van Eyk, 2012), the Ca2+-
binding protein calsequestrin CSQf (Cox and Mann 2011), the enzyme carbonic 
anhydrase CA3 (Carberry et al., 2012b), the molecular chaperone cvHsp/HspB7 
(Marouga et al., 2005; Kato et al., 2011), the oxygen carrier myoglobin (Stastna 
and van Eyk, 2012), different isoforms of annexin (Okamoto and Fujiwara, 2006), 
the ion transporter transferrin (Forbes et al., 1994; Graham et al., 2010), the 
mitochondrial enzyme isocitrate dehydrogenase (Kornegay et al., 2012; Stastna 
and van Eyk, 2012; Mallick and Kuster, 2010) and the extracellular matrix protein 
dermatopontin (Mouisel  et al., 2010). 
These proteomic profiles of the mdx mouse were performed with multiple muscle 
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subtypes, variety of tissue extracts or subcellular fractions, various protein 
separation techniques, opposing labelling methods and different mass 
spectrometric techniques. The proteomic results in this report has established that 
the abundance of annexin, carbonic anhydrase, cvHsp, profiling, transferrin and 
dermatopontin is severely increased and that the concentration of adenylate 
kinase, calsequestrin, isocitrate dehydrogenase, myoglobin, and parvalbumin is 
drastically reduced in dystrophic model of Duchenne muscular dystrophy. This 
makes these proteins suitable biomarker candidates of dystrophinopathy, which 
might be helpful to evaluate diagnostic, prognostic or therapeutic approaches. With 
a number of potential blood-based biomarkers present such as transferrin they 
could offer a simpler, cheaper and less invasive means for obtaining and analysing 
samples.  
In conclusion, the proteomic results presented here indicate that the aged mdx 
diaphragm, which shows severe respiratory impairment following fibrosis (Ishizaki 
et al., 2008), is a suitable model system to study the molecular pathogenesis of 
Duchenne muscular dystrophy. Although the cure for DMD remains elusive gene 
therapies such as exon skipping does provide hope. While supportive care remains 
vital until a curative treatment has been developed, with the use of corticosteroids, 
physiotherapy and orthoses shown to increase life expectancy and quality of life 
DMD patients considerably.  
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